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ABSTRACT 
Congenital lactase deficiency (CLD) (MIM 223000) is a rare autosomal recessive 
gastrointestinal disorder characterized by watery diarrhea in infants fed with breast 
milk or other lactose-containing formulas. The CLD locus was previously assigned 
by linkage and linkage disequilibrium analyses on 2q21 in 19 Finnish families. In 
this study, the molecular background of this disorder is reported. The CLD locus 
was refined in 32 CLD patients in 24 families by using microsatellite and single 
nucleotide polymorphism (SNP) haplotypes. Mutation analyses were performed by 
direct sequencing. We identified 5 distinct mutations in the lactase (LCT) gene, 
encoding the enzyme that hydrolyzes lactose in the intestinal lumen. Twenty-seven 
patients out of thirty-two (84%) were homozygous for a nonsense mutation, 
c.4170T→A (Y1390X, designated as Finmajor). In addition, four rare mutations were 
detected two of which, a four-nucleotide deletion (c.4998_5001delTGAG) and a 
two-nucleotide deletion (c.653_654delCT), predicted a frameshift and protein 
truncation at S1666fsX1722 and S218fsX224 of the 1927 amino acid polypeptide, 
respectively. Two point mutations, c.804G→C and c.4087G→A, would result in 
amino acid substitutions Q268H and G1363S, respectively. Five patients were 
compound heterozygous carrying the Finmajor mutation and one of the four minor 
mutations. These findings facilitate genetic testing of CLD in clinical practice and 
enable genetic counseling. The present data also provide the basis for detailed 
characterization of the molecular pathogenesis of this disorder. 
Adult-type hypolactasia (MIM 223100) (lactase non-persistence, lactose intolerance) 
is an autosomal recessive gastrointestinal condition that is a result of a decline in the 
activity of lactase in the intestinal lumen after weaning. Adult-type hypolactasia is 
considered to be a normal phenomenon among mammals and symptoms are 
remarkably milder than experienced in CLD. Recently, a variant C/T-13910 was 
shown to associate with the adult-type hypolactasia trait, locating 13.9 kb upstream 
of the LCT gene (Enattah et al. 2002). In this study, the functional significance of the 
C/T-13910 variant was determined by studying the LCT mRNA levels in intestinal 
biopsy samples in children and adults with different genotypes. Intestinal biopsy 
samples were taken from 15 children or adolescents and from 52 adults with 
abdominal complaints. The expression of LCT mRNA was demonstrated in patients 
  
heterozygous for the C/T-13910 variant and an informative expressed SNP located in 
the coding region of LCT. RT-PCR followed by solid-phase minisequencing was 
applied to determine the relative expression levels of the LCT alleles using an 
informative SNP located in exon 1. In children, the C-13910 allele was observed to be 
downregulated after five years of age in parallel with lactase enzyme activity. The 
expression of the LCT mRNA in the intestinal mucosa in individuals with the T-13910 
A-22018 alleles was 11.5 times higher than that found in individuals with the C-13910, 
G-22018 alleles. These findings suggest that the C/T-13910 associated with adult-type 
hypolactasia is associated with the transcriptional regulation of the LCT gene. The 
presence of the T-13910 A-22018 allele also showed significant elevation lactase 
activity.  
Galactose, the hydrolysing product of the milk sugar lactose, has been hypothesized 
to be poisonous to ovarian epithelial cells. Hence, consumption of dairy products 
and lactase persistence has been proposed to be a risk factor for ovarian carcinoma. 
To investigate whether lactase persistence is related to the risk of ovarian carcinoma 
the C/T-13910 genotype was determined in a cohort of 782 women with ovarian 
carcinoma. The C/T-13910 genotype was determined by the solid-phase 
minisequencing method from 327 Finnish, 303 Polish, 152 Swedish patients and 938 
Finnish, 296 Polish and 97 Swedish healthy subjects serving as controls. Lactase 
persistence did not associate significantly with the risk for ovarian carcinoma in the 
Finnish (OR 0.77, 95% CI, 0.57-1.05, p=0.097), in the Polish (OR 0.95, 95% CI, 
0.68-1.33, p=0.75), or in the Swedish populations (OR 1.63, 95% CI, 0.65-4.08, 
p=0.29). The findings do not support the hypothesis that lactase persistence 
increases the risk for ovarian carcinoma. 
 
 
 
Keywords: LCT, CLD, adult-type hypolactasia, lactase persistence/non-persistence, 
ovarian carcinoma, C/T-13910, single nucleotide polymorphism, solid-phase 
minisequencing 
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TIIVISTELMÄ 
Synnynnäinen laktaasin puutos (congenital lactase deficiency, CLD [MIM 223000]) 
on vakava peittyvästi periytyvä suolistosairaus. Potilailla on tyypillistä runsas 
vetinen ripuli, joka ilmenee maitoruokinnan alettua. Ripuli johtaa ravintoaineiden 
imeytymishäiriöön ja kasvun hidastumiseen. Potilaiden laktaasiaktiivisuus on 
havaittu ohutsuolessa hyvin alhaiseksi. Vaikea ripuli johtuu nimenomaan 
hydrolysoimattoman laktoosin kertymisestä suolistoon aiheuttaen osmoosin, vaikean 
kuivumistilan, asidoosin ja painon menetyksen syntymäpainon alapuolelle. 
Laktoositon ruokavalio poistaa oireet ja palauttaa kehityksen normaaliksi. CLD-
vauvoja syntyy Suomessa yksi vuodessa (1:60000). Se kuuluu yhdessä 36 muun 
harvinaisen Suomessa esiintyvän sairauden kanssa ns. suomalaiseen tautiperintöön. 
Tutkimuksen tarkoituksena oli tunnistaa CLD:lle altistavat geneettiset tekijät geenien 
kartoitus- ja sekvensointimenetelmien avulla. Tutkimuksessa analysoitiin 32 CLD-
potilasta 24 eri perheestä. Löysimme viisi CLD:lle altistavaa mutaatiota 
laktaasigeenistä (LCT), joista Y1390X-mutaation havaittiin olevan yleisin ns. Finmajor-
mutaatio. Löydökset mahdollistavat sairauden perinnöllisen testauksen ja neuvonnan. 
Lapsuuden jälkeen tai nuorella aikuisiällä havaittu primääri maitosokerin 
imeytymishäiriö (MIM 223100) (tunnettu myös laktoosi-intoleranssina) on yleinen 
laktaasin aktiivisuuden alenemisesta johtuva ilmiö. Laktaasiaktiivisuus alenee 
suolistossa 5-10% lapsuudesta havaitusta ja laktoosi ruokavaliossa aiheuttaa 
suolistoperäisiä oireita. Laktaasin puutos on nisäkkäille luonnollinen ilmiö, näin 
lapsi vierotetaan rinnasta käyttämään kiinteätä ravintoa. Kuitenkin joillain ihmisillä 
korkea laktaasiaktivisuus säilyy koko elinajan. Kyseiseen ilmiasuun on havaittu 
  
liittyvän yhden emäksen muutos C→T-13910 noin 14 kiloemästä laktaasigeenistä 
ylävirtaan. Muutos sijaitsee MCM6- (minichromosome maintenance deficient 6) 
geenin intronissa 13 kromosomissa 2q21. T-13910-muutoksen perineet henkilöt 
säilyttävät laktaasiaktiivisuuden ja kyvyn pilkkoa laktoosia.  
Tämän tutkimuksen tarkoituksena oli määrittää C/T-13910 emäsmuutoksen vaikutus 
laktaasigeenin ilmentymiseen lähetti-RNA tasolla lapsilla ja aikuisilla. 
Laktaasigeenin ilmentymistä tutkittiin geenispesifisellä 
minisekvensointimenetelmällä pohjukaissuolesta otetuista näytteistä. Havaitsimme, 
että laktaasia säädellään transkriptiotasolla, C-13910-muutos sallii laktaasigeenin 
lähetti-RNA:n laskun. Ilmiö oli havaittavissa lapsilla viiden ikävuoden jälkeen. 
Aikuisilla T-13910-emäsmuutos vastasi 92% havaitusta laktaasigeenin lähetti-RNA:n 
ilmentymisestä, joka näkyi myös korkeana laktaasiaktiivisuutena. 
Galaktoosi on glukoosin ohella laktoosin hajoamistuote. Galaktoosin on havaittu 
eläinkokeissa olevan myrkyllinen munasarjojen epiteelisoluille ja sen on epäilty 
aiheuttavan munasarjasyöpää. Tästä syystä korkean laktaasiaktiivisuuden ja 
maitotuotteiden runsaan nauttimisen on oletettu nostavan munasarjasyövän riskiä. 
Tässä tutkimuksessa määritettiin 782 suomalaisen, puolalaisen ja ruotsalaisen 
munasarjasyöpäpotilaan ja 1331 verrokkinäytteen C/T-13910-genotyyppi 
tutkiaksemme onko korkealla laktaasiaktiivisuudella yhteyttä syövän syntyyn. 
Genotyypillä ei havaittu olevan vaikutusta syöpäriskiin tutkituissa väestöryhmissä. 
Jatkotutkimuksella pyritään selvittämään maitotuotteiden kulutuksen merkitystä 
munasarjasyöpään eri C/T-13910 genotyypeillä. 
 
Avainsanat: synnynnäinen laktaasin puutos, geenikartoitus, suomalainen 
tautiperintö, laktoosin imeytymishäiriö, C/T-13910, minisekvensointi, 
munasarjasyöpä, galaktoosi 
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ABBREVIATIONS 
χ2 chi-square test 
λ proportion of excess of alleles in chromosomes carrying the disease 
allele 
θ recombination fraction 
Caco-2 cell  human intestinal adenocarcinoma cell 
cDNA complementary DNA 
Cdx caudal-related protein 
CEPH  Centre d’Etude du Polymorphisme Humain  
CLD congenital lactase deficiency  
cM centiMorgan 
cSNP coding single nucleotide polymorphism 
DARS aspartyl-tRNA synthetase 
DNA deoxyribonucleic acid 
dNTP deoxynucleosidetriphosphate 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum  
EST expressed sequence tag 
FISH fluorescence in situ hybridization 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
HNF hepatocyte nuclear factor 
HRR-LRT haplotype relative risk likelihood-ratio 
in situ on the spot 
in vitro in test tube 
L likelihood 
LCT lactase 
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LD linkage disequilibrium 
LOD, Z logarithm of odds 
L/S ratio of lactase to sucrase 
LTTE lactose tolerance test with ethanol 
MCM6 minichromosome maintenance deficient 6 
MIM Mendelian Inheritance in Man 
mRNA messenger RNA 
NMD Non-sense mediated mRNA decay 
Oct octamer-binding transcription factor  
OMIM Online Mendelian Inheritance in Man 
PCR polymerase chain reaction 
PTH  parathyroid hormone 
q long arm of chromosome 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
RT reverse transcriptase 
SCCA squamous cell carcinoma antigen 
SNP single nucleotide polymorphism 
STR short tandem repeat 
tRNA transfer RNA 
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1 INTRODUCTION 
Congenital lactase deficiency (CLD) is a severe gastrointestinal disorder in 
newborns. It is characterized by watery diarrhea during the first days of life in 
infants who are fed lactose-containing milk. Diarrhea is caused by diminished 
lactase activity in the intestinal mucosa. CLD is a rare autosomal recessively 
inherited disorder and belongs to the group of 36 rare diseases found in Finland 
(Norio et al. 1973; Savilahti et al. 1983; Norio 2000; Norio 2003c). Holzel and 
colleagues (1959) discovered the first patients in 1959. Adult-type hypolactasia (also 
known as lactase non-persistence, primary lactose malabsorption) is a common 
gastrointestinal condition whose recessive inheritance was shown in 1973 (Sahi et 
al. 1973). It is caused by developmental downregulation of lactase (LCT) resulting in 
unhydrolysed lactose in the intestinal mucosa. Clinical symptoms (lactose 
intolerance) such as diarrhea are mainly due to osmosis (Auricchio et al. 1963; 
Dahlqvist et al. 1963). Adult-type hypolactasia represents a normal physiological 
condition after weaning (Simoons 1970). However, the majority of northern 
Europeans and some nomadic population in Africa and Arabia have the ability to 
maintain lactase activity and digest lactose throughout life (lactase persistence) 
(Swallow and Hollox 2000). Adult-type hypolactasia has shown to associate with 
the C/T-13910 variant, which is located 13.9 kilobases (kb) upstream of the LCT gene. 
The C/C-13910 genotype is associated with lactase non-persistence whereas C/T-13910 
and T/T-13910 genotypes are associated with lactase persistence. 
Galactose, the hydrolyzing product of the milk sugar lactose, has been hypothesized 
to be toxic to ovarian epithelial cells and consumption of dairy products with lactase 
persistence has been suggested to be a risk factor for ovarian carcinoma. Ovarian 
carcinoma is the fourth most common cause of cancer death in women. The cause 
and pathogenesis of this disease has remained obscure. 
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In this thesis, linkage disequilibrium (LD) and haplotype mapping was applied to 
refine the CLD locus and direct sequencing to identify mutations underlying CLD. 
In addition, the functional effect of the variant C/T-13910 was studied on the mRNA 
level of the LCT gene in children and adults using the solid-phase minisequencing 
method. In order to assess whether lactase persistence is a risk factor for ovarian 
carcinoma we have determined the C/T-13910 variant in Finnish, Polish and Swedish 
women with ovarian carcinoma and defined its relation to their corresponding 
control populations. 
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2 REVIEW OF THE LITERATURE 
2.1 The Finnish disease heritage 
The exceptional pattern of rare hereditary disorders in Finland, the Finnish disease 
heritage, was introduced by Doctors Norio, Nevanlinna and Perheentupa in 1973 
(Norio et al. 1973). The very first of these distinctive disorders the Finnish type 
congenital nephrotic syndrome was described in 1956 (Hallman et al. 1956). Its 
mode of inheritance was traced back ten years later from the very carefully 
maintained records of church books reaching back to the 16th century (Norio 1966). 
Records of church books and land tax registers have been the keys to exploring 
Finnish hereditary disorders. There are 36 disorders which belong to the Finnish 
disease heritage, 32 of which are autosomal recessive, two X-chromosomal and two 
dominantly inherited (Table 1). The incidence of these disorders is in the range of 
1:10000-1:100000. The higher prevalence of certain disorders in Finland and on the 
other hand the lack of disorders that are prevalent elsewhere in the world have 
inspired researchers to investigate the origin of Finns and their genes (Markkanen et 
al. 1987; Norio 2000; Norio 2003a). Disorders of the Finnish disease heritage are 
introduced in Table 1. 
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Table 1. Disorders of the Finnish disease heritage and their defective proteins 
or loci in alphabetical order 
Disease [OMIM number] Defective gene/protein or 
locus 
Reference 
Amyloidosis V [105120] 
(dominant) 
Gelsonin (GSN) Levy et al. 1990, Maury 
et al. 1990 
Aspartylglucosaminuria (AGU) 
[208400] 
Aspartylglucosaminidase 
(AGA) 
Ikonen at al. 1991 
Autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy 
(APECED) [240300] 
Autoimmune regulator 
(AIRE) 
Nagamine et al. 1997, 
The Finnish-German 
APECED Consortium 
1997 
Batten disease [204200] 
CLN3 The International Batten 
Disease Consortium 1995 
Cartilage-hair hypoplasia (CHH)    
[250250] 
RNA component of Rnase 
MRP (RMRP) 
Ridanpää et al. 2001 
Choroidemia (CHM) [303100]  
(X-linked) 
Rab escort protein 1 (REP1) Sankila et al. 1992 
Cohen syndrome (COH1)        
[216550] 
COH1 Kolehmainen et al. 2003 
Congenital chloride diarrhea 
(CCD) [214700] 
Solute carrier family 26, 
member 3 (SLC26A3) 
Höglund et al. 1996 
Congenital lactase deficiency  
(CLD) [223000] 
LCT Study I 
Congenital nephrosis (CNF)    
[256300] 
Nephrin Kestilä et al. 1998 
Cornea plana congenita (CNA2) 
[217300] 
Keratocan (KERA) Pellegata et al. 2000 
Diastrophic dysplasia (DTD)   
[222600] 
Solute carrier family 26, 
member 2 (SLC26A2) 
Hästbacka et al. 1994 
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Free sialic acid storage disease 
(Salla disease) [604369] 
Solute carrier family 17, 
member 5 (SLC17A5) 
Verheijen et al. 1999 
Growth retardation,  
aminoaciduria, cholestasis, iron 
overload lactacidosis and early 
death (GRACILE) [603358] 
BCS1-like (BCS1L) Visapää et al. 200 
Gyrate atropy (GA) [258870] Ornithine aminotransferase 
(OAT) 
Mitchell et al. 1989 
Hydrolethalus syndrome (HLS) 
[236680] 
HYLS 1 Mee et al. 2005 
Hypergonadotrophic ovarian 
dysgenesis (ODG1) [233300] 
FSH receptor (FSHR) Aittomäki et al. 1995 
Infantile neuronal ceroid-
lipofuscinosis (INCL) [256730] 
Palmitoyl protein  
thioesterase 1 
Vesa et al. 1995 
Infantile onset spinocerebellar 
ataxia (IOSCA) [271245] 
Twinkle and Twinky Nikali et al. 2005 
Lethal arthrogyposis with anterior 
horn cell disease 
unknown Clinical characterization 
by Vuopala et al. 1995 
Lethal congenital contracture 
syndrome (LCCS) [253310] 
9q34 Mäkelä-Bengs et al. 1998 
Lysinuric protein intolerance (LPI) 
[222700] 
Solute carrier family 7, 
member 7 (SLC7A7) 
Borsani et al. 1999, 
Torrents et al. 1999 
Meckel syndrome (MKS1)      
[249000] 
MKS1 Kyttälä et al. 2006 
Megaloblastic anemia 1 
[261100] 
Cubilin (CUBN) Aminoff et al. 1999 
Mulibrey nanism [253250] TRIM37 Avela et al. 2000 
Muscle-eye-brain disease (MEB) 
[253280] 
POMGnT1 Diesen et al. 2004 
Nonketotic hyperglycinemia 
(NKH) [605899] 
Glycine decarboxylase 
(GLDC) 
Kure et al. 1992 
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Polycystic lipomembranous 
osteodysplasia with sclerosing 
leukoencephalopathy (PLO-SL) 
[221770] 
TYRO protein tyrosine 
kinase-binding protein 
(TYROBP) and TREM2 
Paloneva et al. 2000, 
Paloneva et al. 2002 
Progressive encephalopathy with 
edema, hypsarrhythmia and optic 
atrophy (PEHO syndrome)      
[260565] 
unknown Clinical characterization 
by Salonen et al. 1991 
Progressive epilepsy with mental 
retardation (EPMR) [600143] 
CLN8 Ranta et al. 1999 
Progressive myoclonus epilepsy 
(EPM1) [254800] 
Cystatin B (CSTB) Pennacchio et al. 1996; 
Virtaneva et al. 1997 
RAPADILINO syndrome        
[266280] 
RECQL4 Siitonen et al. 2003 
Retinoschisis [312700]              
(X-linked) 
Retinoschisin The Retinoschisis 
Consortium 1998 
Tibial muscle dystrophy (TMD)     
[600334] (dominant) 
Titin (TTN) Hackman et al. 2002 
Usher syndrome type III          
[276902] 
USH3A Joensuu et al. 2001 
Variant late infantile neuronal 
ceroid-lipofuscinosis (vLINCL) 
[256731] 
CLN5 Savukoski et al. 1998 
Thirty-two disorders are recessively inherited, two are dominantly inherited and two 
are X-linked traits (in bold text). The table is based on Norio (2000) and Norio 
(2003c). 
 
2.1.1 Causes of the unique gene pool 
2 . 1 . 1 . 1  T h e  s e t t l e m e n t  h i s t o r y  o f  F i n l a n d  
The predominant hypothesis is that Finland has been inhabited continuously from 
the last glacial period approximately 10000 years ago (Nunez 1987; Norio 2003b). 
The oldest archaeological discovery from southern Finland is circa 9000 years old 
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whereas the first signs of settlement date from 8000 years ago (Huurre 1992; 
Jutikkala and Pirinen 1996). It cannot be known for sure who the first settlers were. 
They could have been inhabitants, despite the arctic circumstances, living on the 
coast of Scandinavia from the glacial period or/and immigrants who returned from 
the south as the ice melted. However, some of these first settlers are probably the 
ancestors of the Saami and some of them adopted agriculture and merged with the 
growing southern settler groups. In prehistoric Scandinavia times the warm Gulf 
stream offered bearable living conditions for a small population whose source of 
livelihood was based on hunting, fishing, and gathering (Norio 2000; Norio 2003b). 
Nowadays, there are only 60000 Saami living in the northern regions of Finland, 
Sweden, Norway and the Russian Kola Peninsula of these 6000 individuals live in 
Finland. The climate and source of livelihood were not conducive to expansion of 
population, the size has been estimated to have been constant throughout history 
(Lehtivirta and Seurujärvi-Kari 1991). Still warming climate forced the Saami to 
retreat gradually to the north away from growing settlers groups who had adopted 
agriculture (Eriksson 1973; Lehtivirta and Seurujärvi-Kari 1991). These settler 
groups carried the genes of today’s Finns. Where did the farmers come from? The 
dual theory of Finland’s inhabitation by Eriksson (1973) and Norio (1981) suggests 
there was an early migration of eastern Uralic speakers ~4000 years ago and a later 
migration from the south ~2000 years ago (Figure 1). Kittles and his colleagues’s 
(1998) Y chromosome haplotype study supported this theory as they observed two 
different male lineages. Mitochondrial and nuclear DNA analyses show that the 
majority of Finnish genes are of central European origin (Cavalli-Sforza and Piazza 
1993; Sajantila et al. 1995; Sajantila and Pääbo 1995; Lahermo et al. 1996; Laan and 
Pääbo 1997; Torroni et al. 1998). The Saami and other Europeans including Finns 
have been suggested to have a divergent population history (Cavalli-Sforza and 
Piazza 1993; Sajantila et al. 1995; Sajantila and Pääbo 1995; Lahermo et al. 1996). 
A recent mitochondrial and Y chromosomal study suggests that most likely the 
Saami have European origin after all. The large genetic difference between the 
 22 
Saami and other Europeans is explained by the Saami representing a narrow subset 
of Europeans (Tambets et al. 2004). Since the last glacial period all migrations from 
south, east and also small ones from west shaped the Finnish population genetically, 
linguistically and culturally but kept as a relatively small founder population. 
 
Figure 1. The main two migration waves came to the area of Finland from 
south and east. Adapted from Varilo (1999). 
 
2 . 1 . 1 . 2  T h e  i n t e r n a l  m i g r a t i o n  i n  t h e  1 6 t h  c e n t u r y  
In the 16th century the Finnish population had grown to 250 000 and inhabitation 
who were focused in the coastal regions (Figure 2). Sweden acquired Denmark after 
the Liberation War in 1521-1523 and Gustavus of Vasa (1523-1560) was crowned 
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monarch of a new independent state Sweden-Finland. King Gustavus of Vasa was 
interested in his kingdom and made administrative reforms, which included 
increasing taxation and district court sessions. The superpower politics of King 
Gustavus of Vasa favoured the inhabitation of wildernesses to enlarge the country’s 
borders. Farming were encouraged by lower taxation for farmers; also the growth of 
the population led to pressure to cultivate more land. The majority of inhabitants 
originated from the area of southeastern Finland called South Savo (Figure 2). 
Within two centuries nearly the whole area of Finland was inhabited and the 
population had increased to 400000. There was a great famine in 1696-1698 which 
decreased the population to 250000 but from the 1700s the Finnish population has 
grown pretty quickly to its present figure of 5300000 e.g. (Jokipii 1992; Jokipii and 
Rikkinen 1992; Jutikkala and Pirinen 1996; Varilo 1999; Norio 2003a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The internal migration movement led to regional subisolates in the 
Finland area in the 16th century. The map is modified from Varilo (1999). 
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 24 
The small number of original ancestors both due to genetic drift and regional 
subisolates, a rapid increase in population and linguistic and geographical isolation 
have strongly shaped the Finnish population and created our unique gene pool. Our 
carefully maintained church books, land registers and history books have given us 
tools to study our origin and rare diseases (Norio et al. 1973; Norio 2000). 
 
2.2 Lactase 
Lactase (LCT), also known as lactase-phlorizin hydrolase, belongs to the β-
galactosidase family having both lactase (EC 3.2.1.108) and phlorizin hydrolase 
activity (EC 3.2.1.62). LCT is exclusively expressed in the small intestine and it is 
responsible for hydrolysing lactose (Figure 3) to glucose and galactose. Lactose is a 
major disaccharide found in milk synthesized by lactose synthetase in the mammary 
gland. Human milk has the highest lactose content (7%) e.g. cow milk contains 
4.8% of lactose. Phlorizin hydrolase is responsible for hydrolysing aryl- and alkyl-β-
glycosides such as phlorizin and galactosyl- and glycosyl-β-ceramides (Sahi 1994b). 
Lactase activity is delimited in mammals whereas phlorizin hydrolase activity has 
been detected in vertebrates. The natural substrate of phlorizin hydrolase has been 
thought to be glycosyl ceramides that inhere in the diet of most vertebrates and are 
also found in milk (Leese and Semenza 1973; Skovbjerg et al. 1981). Both catalytic 
activities are located on a single polypeptide chain (Wacker et al. 1992). 
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Figure 3. Lactose the milk sugar. In lactose, a glucose unit and a galactose unit are 
joined by an β-1, 4 glycosidic linkage. 
 
2.2.1 Structure 
The LCT gene reaches a genomic size of 50 kb and it is composed of 17 exons. 
There is one kb promotor region preceding LCT (Boll et al. 1991). The size of 
messenger RNA (mRNA) is 6274 bases and the primary translation product (pre-
pro-LCT) is 1927 amino acids (Figure 3). Pre-pro-LCT consists of an N-terminal 
signal sequence, pre-domain (19 amino acids), a pro-domain size of 849 amino 
acids, an extracellular domain of 1014 amino acids, a hydrophobic transmembrane 
anchor domain (19 amino acids), and a short C-terminal cytosolic domain of 26 
amino acids. Pro-LCT contains four internal repeats of which the pro-domain 
includes repeats I-II and an extracellular domain includes repeats III-IV (Figure 4). 
Phlorizin hydrolase activity locates in repeat III and lactase activity locates in repeat 
IV (Neele et al. 1995; Zecca et al. 1998; Arribas et al. 2000). These four repeats 
contain 38-55% identical amino acids. Mantei and colleagues (1988) suggest that 
repeats III-IV are results of duplication of the I-II repeats of one ancestor gene. 
Sequence similarities of the I-IV regions to β-glycosidases of archaebacteria, 
eubacteria, and fungi support this hypothesis and thus, lactase belongs to the β-
glucosidase and β-galactosidase superfamily (Naim 2001). 
O
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2.2.2 Biosynthesis 
Mature lactase is anchored to the intestinal membrane by a hydrophobic region near 
its carboxy terminus and the catalytic sites of the enzyme are located in the lumen of 
the intestine (Mantei et al. 1988). How is a lactase polypeptide processed to its 
active form? Intestinal epithelial cells synthesize lactase as a single chain pre-pro-
LCT precursor polypeptide that is translocated over the endoplasmic reticulum (ER) 
guided by a signal sequence (Figure 4). The signal sequence is removed during the 
process resulting in pro-LCT with a molecular weight of 215 kiloDalton (kDa) 
(Naim and Naim 1996). Even if the pro-region of LCT (LCTα) does not have 
enzymatic activity (Naim 1995) it is has been shown to function as an 
intramolecular chaperone essential for the folding of pro-LCT (Oberholzer et al. 
1993; Naim et al. 1994; Jacob et al. 2002). In ER, pro-LCT is glycosylated by 
mannose rich N-linked oligosaccharides. Glycosylated pro-LCT forms a homodimer 
that is further transferred to the Golgi apparatus. The transmembrane anchor domain 
and the cytosolic domain participate directly in the dimerization and apical sorting 
of lactase. The O-linked sugars of the pro-LCT dimer are glycosylated and N-linked 
sugars are further processed in cis-Golgi resulting in a glycoprotein with a molecular 
weight of 230 kDa. Glycosylation and dimerization of pro-LCT is required for 
efficient intracellular transport and enzyme activity (Naim et al. 1991; Naim and 
Lentze 1992; Naim 1994; Naim and Naim 1996; Panzer et al. 1998; Jacob et al. 
2000). Pro-LCT undergoes two proteolytic cleavage steps before it finally becomes 
mature lactase. The first cleavage takes place intracellulary and removes the large 
LCTα at R734/L735 resulting in a membrane bound LCTβinitial (L735-Y1927). 
LCTβinitial is targeted to the intestine brush border membrane where it is cleaved by 
trypsin at R868/A869 leading to a 160 kDa mature lactase, LCTβfinal (Figure 4) 
(Jacob et al. 1996; Wüthrich et al. 1996). 
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Figure 4. The structure and biosynthesis of lactase. Lactase is synthesized as a 
pre-pro-LCT precursor. The pre-pro-LCT contains a cleavable signal sequence that 
translocates the polypeptide over the endoplasmic reticulum (ER) (von Heijne 1986; 
Mantei et al. 1988). The pro-lactase region consists of four homologous repeats (I-
IV). Repeats I and II are located in the pro-domain while repeats III-IV are found in 
mature lactase (Mantei et al. 1988). Later in the ER, the signal sequence is cut off 
yielding pro-LCT that is N-glycosylated and forms homodimers (Naim et al. 1991; 
Naim and Lentze 1992; Naim 1994; Naim and Naim 1996; Panzer et al. 1998; Jacob 
et al. 2000). The region involved in apical sorting and dimerization is indicated. The 
pro-region, LCTα, is shown to function as an intramolecular chaperone for folding 
of pro-LCT (Oberholzer et al. 1993; Naim et al. 1994; Jacob et al. 2002). The pro-
LCT is transferred to the Golgi apparatus and O-glycosylated. The pro-LCT is 
further processed by two proteolytic cleavages: an intracellular cleavage that occurs 
between R734 and L735 produces LCTβinitial and a cleavage in the intestinal lumen 
between R868-A869 generates LCTβfinal the mature enzyme (Jacob et al. 1996; 
Wüthrich et al. 1996). The figure is based on Naim (2001) and Troelsen (2005). 
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2.2.3 Regulation 
Milk is the major nutrient consumed by newborn mammals. As lactose is the main 
carbohydrate and the most important source of energy in milk, it is necessary for 
mammals to be able to hydrolyse lactose after birth. LCT is expressed only by small 
intestinal enterocytes located at the crypt-villus junction and on the villus. Although, 
lactase activity is required from birth in mammals the timing of high LCT expression 
differs between rodents and humans. Humans have high LCT expression from birth 
whereas in mouse lactase expression reaches its maximum level 3 days after birth. 
This has been thought to be due to the intestinal immaturity of rodents. Fully 
developed crypts are not detected until 2-3 days after birth in mice. This finding has 
made LCT an ideal marker for fully differentiated enterocytes (Klein 1989; Freeman 
et al. 1993; Freund et al. 1995; Troelsen 2005). 
 
2 . 2 . 3 . 1  P r o x i m a l  L C T  p r o m o t e r  
The proximal LCT promoter, a 150-basepair fragment upstream of the transcription 
initiation site (-150), is conserved in mouse, rat, rabbit, pig and human. Promoter 
analyses have revealed three transcription factor binding sites (CE1a, CE2c and 
GATA-site) so called cis-elements in this fragment (Figure 5) (Troelsen et al. 1992; 
Fitzgerald et al. 1998; Spodsberg et al. 1999). The functional role of transcription 
factors in these binding sites has been studied in transfection studies of promoter-
reporter gene constructs and in DNA-protein and protein-protein interaction 
analyses using human intestinal adenocarcinoma (Caco-2) cells. 
It has been shown that the caudal-related homeobox protein (Cdx-2) and the 
homeobox protein HOXC11 bind to CE1a (Troelsen et al. 1997; Mitchelmore et al. 
1998; van Wering et al. 2002b). Cdx-2 is a significant factor for intestinal 
transcription and maintenance (Chawengsaksophak et al. 1997; Freund et al. 1998) 
and it is capable of activating pig (Troelsen et al. 1997) rat (Fang et al. 2000; 
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Krasinski et al. 2001) and human LCT promoters (Krasinski et al. 2001). Cdx-2 was 
also detected to bind to a site overlapping the LCT TATA-box. However, it 
remained unknown whether Cdx-2 binds directly to the site or through protein-
protein interactions with a transcription initiation complex (van Wering et al. 
2002b). The significance of this observation is to be clarified. HOXC11 is expressed 
in human fetal intestines but it could not be detected after birth suggesting a role in 
early intestinal development (Mitchelmore et al. 1998). Additionally, there are 
unidentified factors which repress LCT expression through the CE1a-site (Troelsen 
et al. 1997; van Wering et al. 2002b). Repression of LCT transcription by those 
factors was suggested to take place in cells that do not express Cdx-2 (van Wering et 
al. 2002b). This would indicate a tissue-specific LCT promoter activation by Cdx-2.  
CE2c has been shown to be crucial for the LCT promoter activity. Mutations of the 
CE2c-site remarkably decrease the LCT promoter activity in pigs (Spodsberg et al. 
1999) and in human (van Wering et al. 2002a). Hepatocyte nuclear factor-1α (HNF-
1α) has been shown to bind to the CE2c-site (Mitchelmore et al. 1998; Spodsberg et 
al. 1999; Mitchelmore et al. 2000; Krasinski et al. 2001; van Wering et al. 2002a). 
HNF-1α has been shown to activate pig (Spodsberg et al. 1999) rat and human LCT 
promoters (Krasinski et al. 2001). Furthermore, HNF-1α and Cdx-2 has been shown 
to physically interact with and cooperatively activate pig (Mitchelmore et al. 2000) 
and human LCT promoters (Krasinski et al. 2001). HNF-1α was shown to be 
essential for LCT expression in vivo. LCT mRNA was reduced 95% in HNF-1α(-/-) 
mice compared with wild types (Bosse et al. 2006). HNF-1 transcription factors are 
expressed in a number of tissues such as intestine, liver, kidney, pancreas, stomach 
(Ott et al. 1991; Cereghini et al. 1992) and they have been shown to be involved in 
the activation of a number of intestinal genes (Bosse et al. 2006), genes of 
developmental appearance and embryonic regulation, as reviewed in Weber et al. 
(1996), and regulating the expression of genes that are expressed in the liver, kidney, 
and pancreas, reviewed in Pontoglio (2000).  
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GATA-4, -5 and -6 zinc finger transcription factor has been demonstrated to be capable 
of binding and activating individually the human (Fitzgerald et al. 1998; Krasinski et al. 
2001), rat (Fang et al. 2001; Krasinski et al. 2001) LCT promoters. A study showed that 
GATA-4 is the key GATA-factor regulating lactase expression in mice (van Wering et 
al. 2004). GATA-4/HNF-1α and GATA-5/HNF-1α has been shown to physically 
interact with and synergistically activate mouse, rat and human LCT promoters 
(Krasinski et al. 2001; van Wering et al. 2002a; van Wering et al. 2004). GATA factors 
are expressed in a number of tissues. A subfamily of GATA-1, -2, and -3 is expressed in 
hematopoietic stem cells regulating differentiation-specific gene expression in T-
lymphocytes, erythroid cells, and megakaryocytes, reviewed in Orkin (1998). A 
subfamily of GATA-4, -5, and -6 are expressed in a variety of mesoderm- and 
endoderm-derived tissues such as heart, liver, lung, gonad and intestine where they 
regulate tissue-specific gene expression, reviewed in Molkentin (2000).  
The pancreatic duodenal homeobox-1 protein (Pdx-1) has been demonstrated to 
repress endogenous LCT promoter activity when Pdx-1 was overexpressed in Caco-
2 cells. Pdx-1 is expressed the anterior duodenal region of the intestine (Guz et al. 
1995) where LCT expression is repressed in adult mammals. A Pdx-1 candidate 
binding site TAAT was identified in the rat promoter but mutation analysis of the 
binding site failed to recover LCT expression suggesting a more complex regulation 
pattern (Wang et al. 2004). Pdx-1 binding sites have not been identified in human or 
pig LCT promoters (Troelsen 2005). 
 
2 . 2 . 3 . 2  D i s t a l  r e g u l a t o r y  e l e m e n t s  
Even though, there is no doubt of the importance of the proximal LCT promoter in 
the regulation of the LCT gene it has a relatively weak effect on transcription in 
Caco-2 cells (Troelsen et al. 1992). There is evidence that distal regulatory elements, 
enhancers, are needed to complete the proximal promoter in order to obtain full LCT 
expression (Figure 5). This type of enhancer sequences was identified in the pig 
 31 
locating around -850 of the lactase gene, this was necessary for high expression in 
Caco-2 cells (Spodsberg et al. 1999; Troelsen et al. 2003a). This enhancer region 
includes three binding sites CE2a, nt20 and CE2b of which CE2a is known to bind 
HNF-1α, the other two in binding factors are unidentified (Simon et al. 1995; 
Spodsberg et al. 1999; Troelsen et al. 2003a). The enhancer element is not conserved 
in human nor rat. Furthermore, a negative regulatory region CE3 has been identified 
in the pig and human promoter (Spodsberg et al. 1999). The Forkhead box (Fox) 
factors FREAC-2 and -3 have been shown to bind to this element in the pig, 
(Spodsberg et al. 1999) in human the same element binds intestinal nuclear factors 
(Hollox et al. 1999). 
Experiments in transgenic mice have shown that distal regulatory sequences located 
at -2038-(+15) of the rat LCT promoter are important for tissue specificity, correct 
spatial and developmental expression (Krasinski et al. 1997; Lee et al. 2002; Wang 
et al. 2006). DNAse footprint analyses have revealed several Fox and a leucine 
zipper factor C/EBP in the rat LCT promoter (Figure 5). HNF-3 has been shown to 
activate the promoter whereas a negative regulatory region similar to the pig and 
human promoter repress the activity (Verhave et al. 2004). Even if distal regulatory 
regions are not conserved in pig, rat and human the same type of pattern does exist. 
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Figure 5. Proximal and distal regulatory elements of pig, rat and human LCT 
promoters. Arrows with + or – indicate the regulatory effect of cis-elements via 
proximal promoter on LCT transcription in vitro. Cis-elements are named as follows: 
CE (cis-element), HS (hypersensitive site) and FP (footprint). Transcription factors 
that bind the cis-elements are shown, question marks indicate unknown factors. The 
Figure is based on studies referred to on pages 26-29 and Troelsen (2005). 
 
2.3 Congenital lactase deficiency 
Congenital lactase deficiency (CLD [MIM 223000]) is an autosomal recessively 
inherited severe gastrointestinal disorder. Holzel et al. (1959) described the first 
patients in 1959. Launiala, Kuitunen, and Visakorpi (1966) discovered the absence 
of lactase activity in duodenal specimens of infants with explosive diarrhea after 
breastfeeding. In a clinical study on 16 patients Savilahti and colleagues (1983) gave 
the first evidence for a recessive mode of inheritance for CLD. So far, 50 patients in 
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42 families have been diagnosed in Finland (Savilahti et al. 1983; Study I) and 
several cases have been reported elsewhere in the world (Holzel 1967). CLD has an 
incidence of 1:60000 in the Finnish population (Savilahti E personal 
communication). The birthplaces of great-grandparents of 31 Finnish CLD families 
demonstrate that CLD mutation is emphasized in central Finland (Figure 6) (Järvelä 
et al. 1998). CLD is one of the 36 rare monogenic disorders enriched in Finland 
(Norio et al. 1973; Norio 2000; Norio 2003c). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The birthplaces of the great-grandparents of 31 CLD families in 
Finland. The figure is adapted from Järvelä et al. (1998). 
 
2.3.1 Clinical features 
CLD is characterized by a pure watery diarrhea that is due to osmosis developed by 
unhydrolysed lactose. Feces are acidic (pH 4.5-5.5) and contain large quantities of 
lactose as a result of undeveloped bacterial flora. Later, at the age of 1.7 years or 
older lactose is absent, probably fermented by colonic bacterial flora creating 
flatulence and abdominal pains. The severe diarrhea followed by dehydration, 
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metabolic acidosis, and weight loss is usually diagnosed during the first weeks or 
months of life (Savilahti et al. 1983). Some patients have hypercalcemia and 
medullar nephrocalcinosis (Saarela et al. 1995). Serum cholesterol is reduced but the 
levels of triglycerides are normal. Regardless of the symptoms, CLD infants are 
lively and they have a good appetite (Savilahti et al. 1983). Lactase activity 
determined in duodenal biopsy specimen is very low (0-10 U/g protein). The 
morphology of duodenum and sucrase, maltase and isomaltase activities are 
observed to be normal. Normal psychomotor development and growth is achieved 
and the symptoms disappear when the patients are put on a lactose-free diet 
(Savilahti et al. 1983). 
 
2.3.2 Assignment of the locus to 2q21 
As lactase is responsible for the hydrolysis of lactose into galactose and glucose in 
the intestinal lumen it was an obvious candidate for CLD. LCT was localized to 
chromosome 2q and subsequently 2q21 by Kruse et al. (1988) and Harvey et al. 
(1993), respectively (Figure 7). Using this information Järvelä and colleagues (1998) 
found linkage for CLD on 2q21 in the close proximity of the LCT gene in 19 Finnish 
families. However, extended haplotype analysis by seven polymorphic microsatellite 
markers seemed to refine the CLD locus in the 350 kb area between D2S314 and 
D2S2385 from two centiMorgans (cM) telomeric from LCT (Figure 7). These 
microsatellites gave the highest LD in the disease alleles. This finding supported the 
hypothesis of one major mutation in most CLD patients in Finland. Based on strong 
LD spanning an area of ~8 cM at the CLD locus, the mutation was estimated to have 
been enriched by approximately 30 generations in the Finnish population (Järvelä et 
al. 1998). Sequence analysis of LCT and its promoter region failed to reveal disease-
causing mutations in a Finnish CLD patient (Poggi and Sebastio 1991). This finding 
and the haplotype analyses of Finnish CLD patients encouraged the authors to 
suggest that there is a novel gene underlying CLD (Järvelä et al. 1998).  
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Figure 7. Physical map of the CLD region. According Järvelä et al. (1998) the 
critical CLD region located 2 cM telomeric from the LCT gene. 
 
2.4 Adult-type hypolactasia 
Adult-type hypolactasia (MIM 223100) (lactase non-persistence, lactose intolerance) 
is an autosomal recessive gastrointestinal condition that is the result of a decline in 
the activity of lactase in the intestinal lumen after weaning. Downregulation of 
lactase is considered as a normal phenomenon among mammals, and symptoms are 
remarkably milder than experienced in CLD. Milk intolerance was described in 
1901 when carbohydrate ingestion was noted to be linked with pathogenesis of 
diarrhea (Montgomery et al. 1991). Röhmann and Nagano (1903) demonstrated the 
pathophysiologic mechanism of this condition in dogs as early as 1903 when they 
observed unhydrolysed lactose molecules in the intestinal lumen, reviewed in Sahi 
(1994a). The lactase activity was detected in the duodenum but the activity was 
highest in the jejunum and decreased towards the ileum. Absorption was observed in 
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the jejunum (Borgström et al. 1957). In 1963, Auricchio et al. (1963) and Dahlqvist 
et al. (1963) reported a decrease in lactase activity from birth in humans. 
Interestingly, some humans have the ability to maintain lactase activity and digest 
lactose throughout their lives (lactase persistence). The reasons for these phenomena 
have been speculated on for a quite some time. It was noted that lactase activity 
could not be induced by intake of lactose (Keusch et al. 1969b). Genetic factors 
were observed to play a role when evidence for the autosomal recessive inheritance 
was published in 1973 (Sahi et al. 1973). These fascinating characteristics have 
inspired researchers to study the molecular background of the lactase non-
persistence and persistence phenotypes. 
 
2.4.1 Diagnosis 
Diagnosis of adult-type hypolactasia is commonly assessed by the lactose tolerance 
test (LTT). The method is indirect and is based on a serial of measurements of 
glucose in blood after oral lactose ingestion (50 g). A small rise in blood glucose 
concentration (<1.1 mmol/l) after a 20, 40, 60 and 90 minutes of lactose load 
indicate hypolactasia. A rise in blood glucose of more than 1.7 mmol/l indicates 
lactase persistence. In addition, clinical symptoms, such as possible stomach pains, 
distension, cramps, flatulence, nausea and diarrhea are registered (Sahi and Launiala 
1978; Arola 1994). Lactose tolerance test with ethanol (LTTE) was a successful step 
towards a more specific test. Galactose in blood is measured instead of glucose and 
ethanol is used to inhibit the conversion of galactose to glucose in the liver (Jussila 
1969; Isokoski et al. 1972; Arola 1994). One measurement at 40 min after lactose 
and ethanol ingestion is sufficient for a diagnosis. Blood galactose concentrations 
less than 0.3 mmol/l indicate hypolactasia (Isokoski et al. 1972). In addition, there 
are some applications of LTTE, which rely on urinary galactose determinations, 
reviewed in detail in Arola (1994). Tolerance tests for glucose and galactose are 
needed for exclusion of secondary malabsorption (Jussila 1969). Diagnosis by the 
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breath hydrogen test (BHT) after lactose ingestion is based on the definition of 
hydrogen from exhaled air. Hydrogen concentration is measured by gas 
chromatography from a set of samples taken for 2 to 6 hours. Usually hydrogen 
concentration >20 ppm indicates hypolactasia (Metz et al. 1975; Metz et al. 1976; 
Arola 1994). However, a definitive diagnosis of adult-type hypolactasia can be made 
by measuring lactase together with sucrase and maltase activities directly from 
intestinal biopsy specimen and exploring the histology of the mucosa (Dahlqvist 
1984). Lactase activity less than 10 U/g protein and a ratio of lactase to sucrase 
activities less than 0.30 indicate hypolactasia (Jussila 1969; Dahlqvist 1984). 
Histological evaluations are important to study possible secondary reasons for a low 
lactase activity. Infections and inflammations have been found to decrease activities 
of several intestinal enzymes (Phillips et al. 1988). The comparison of indirect LTT, 
different LTTEs and BHT with direct mucosal disaccharidases shows that their 
sensitivities and specificities vary between 69 to 100% (Isokoski et al. 1972).  
 
2.4.2 Onset and prevalence 
In a number of populations lactase activity starts to decline a few years after 
weaning. The age at downregulation varies between populations. For example in 
Thais downregulation takes place between 1-2 years of age (Keusch et al. 1969a). In 
African children, the first signs of decline of lactase activity was detected at 3 years 
of age but in Finnish children somewhat later at 5-12 years of age (Rasinperä et al. 
2004). A British study of different ethnic groups demonstrated that downregulation 
of LCT expression was detected from the second year of life, although the extent and 
onset was not constant (Wang et al. 1998b). The reasons for these timing variations 
are unknown. 
The prevalence of adult-type hypolactasia varies between populations. The 
prevalence of adult-type hypolactasia is highest in Asia, for example 90-100% of 
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Thais, Chinese, and Japanese suffer from a decline of lactase activity (Flatz and 
Saengudom 1969). A total of 81-91% of the blacks of Africa cannot digest lactose 
(Cook and Kajubi 1966; Olatunbosun and Kwaku Adadevoh 1971). Lactase non-
persistence is a frequent phenotype among native population of Australia and 
America reviewed in Swallow and Hollox (2000). In contrast, a low prevalence of 
hypolactasia 1-9.6% have been observed in Sweden and Denmark (Gudmand-Höyer 
et al. 1969; Dahlqvist and Lindquist 1971; Nilsson TK personal communication). 
Also, some nomadic populations in Africa and Arabia such as the Beja, Beduin, 
Fulbe and Tuareg can tolerate lactose efficiently, only 0-24% of them develop 
hypolactasia, reviewed in Swallow and Hollox (2000). Among the Finns the 
prevalence is about 17-18% while the prevalence in Finnish Swedish-speaking 
population is only 8% (Jussila et al. 1970; Sahi 1974; Enattah et al. 2002).  
 
2.4.3 Genetics 
2 . 4 . 3 . 1  E v o l u t i o n a r y  f a v o u r  o f  l a c t a s e  p e r s i s t e n c e  
Lactase non-persistence is considered to be the ancestral phenotype, lactase 
persistence has been regarded to be evolutionary advantageous when milk from 
domestic cows became available as a source of nutrition (Hollox 2005). It has been 
rationalized that this gene-culture coevolution created selective pressure for 
individuals who could efficiently use milk for nutrition in adulthood. This has been 
supported by observations as dairy farming and lactase persistence coincide, by the 
epidemiologic data as there are a wide distribution of the prevalence in lactase 
persistence between populations and by the fact that lactase persistence is 
genetically determined (Simoons 1969; McCracken 1970; Simoons 1970; 
McCracken 1971; Sahi et al. 1973; Sahi 1994a; Enattah et al. 2002). The gene-
culture coevolution hypothesis was strongly supported when a high diversity in 
cattle milk protein genes and lactase persistence was demonstrated to coincide in 
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Europe (Beja-Pereira et al. 2003). Furthermore, convincing lines of evidence for the 
selective pressure of lactase persistence were obtained when genetic data nearby 
LCT was evaluated in northern European or derived populations. The lactase 
persistence locus was observed to contain an exceptionally long haplotype, LD was 
detected up to 1 Mb (Hollox et al. 2001; Enattah et al. 2002; Poulter et al. 2003; 
Bersaglieri et al. 2004) which was demonstrated to be longer and more common 
(77% of northern Europeans) than expected only by chance (Bersaglieri et al. 2004). 
The strong selection was estimated to have been taken place during past the 10000 
years, 400 generations coinciding with a dairy culture (Bersaglieri et al. 2004; 
Coelho et al. 2005; Myles et al. 2005; Enattah et al. unpublished). The selection 
power was calculated to be 1.4-15% which is in agreement with previous 
estimations of 1-7% (Cavalli-Sforza 1973; Heston and Gottesman 1973; Flatz and 
Rotthauwe 1977; Aoki 1986; Flatz 1987). These findings indicate that lactase 
persistence has undergone the strongest positive selection seen in the human genome 
(Bersaglieri et al. 2004). Indeed, genetic, cultural and epidemiologic signs indicate 
that the ability to use milk efficiently for nutrition improved the survival 
opportunities of early farmers. 
 
2 . 4 . 3 . 2  M e c h a n i s m  o f  d o w n r e g u l a t i o n  
Mutation analysis of LCT and its one kb sized promoter area have not shown the 
sequence variation associated with adult-type hypolactasia (Boll et al. 1991; Lloyd 
et al. 1992). In addition, a number of single nucleotide polymorphisms (SNPs) have 
been identified in one Mb fragment of LD at LCT but none of them could explain 
the lactase persistence phenotype (Harvey et al. 1995; Harvey et al. 1998; Hollox et 
al. 2001; Poulter et al. 2003). Many studies have been conducted at the cellular level 
to explain the phenotype differences and as a result several factors have been 
reported to influence the decline of lactase after childhood. At first, 
posttranscriptional regulation was suggested when LCT mRNA levels could not be 
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seen to correlate with lactase activity (Sebastio et al. 1989). Both slow processing of 
the lactase protein or/and reduction of pro-LCT synthesis were observed in metabolic 
labelling studies in lactase non-persistent individuals (Sterchi et al. 1990; Witte et al. 
1990; Lloyd et al. 1992). Biosynthesis of pro-LCT has been detected to correlate with 
LCT mRNA levels but not lactase activity. A comparison of LCT mRNA levels and 
lactase activity/LCT mRNA level ratios indicated a heterogeneous pattern of 
regulation in both hypolactasic and lactase persistent individuals (Rossi et al. 1997). 
Even, mosaic regulation of lactase was observed from individuals with adult-type 
hypolactasia (Maiuri et al. 1994). However in the majority of cases, the LCT mRNA 
level have been shown to correlate with lactase activity or the ratio of lactase to 
sucrase (L/S) activities indicating that the decline of lactase activity is regulated at the 
transcriptional level (Escher et al. 1992; Lloyd et al. 1992; Fajardo et al. 1994). 
Analogous results have been observed in studies on animals (Krasinski et al. 1994; 
Lacey et al. 1994). Later, the lactase persistence/non-persistence was demonstrated to 
be controlled by a cis-acting element (Wang et al. 1995). In that study, LCT steady 
state mRNA levels were studied utilizing SNPs in the coding region of LCT. Certain 
types of lactase persistent were detected to have asymmetric allelic mRNA expression 
suggesting that expression of the LCT alleles could be independently regulated. 
Authors concluded that a developmentally regulated trans-acting DNA-binding protein 
could bind to only one kind of lactase allele and influence transcription and/or mRNA 
stability (Wang et al. 1995; Wang et al. 1998b). 
 
2 . 4 . 3 . 3  D i s c o v e r y  o f  t h e  r e s p o n s i b l e  v a r i a n t  
Enattah and colleagues (2002) used the candidate gene approach and restricted the 
locus of adult-type hypolactasia to a 47 kb area at the 5’-end of the LCT gene on 
2q21 using LD and haplotype analysis of nine extended Finnish families. Diagnoses 
for adult-type hypolactasia were assessed by LTTE. Sequence analysis of the 47 kb 
region exposed two SNPs C/T-13910 (rs4988235) and G/A-22018 (rs182549), 14 kb and 
 41 
22 kb upstream from the initiation codon of LCT, respectively. The SNPs C/T-13910 
and G/A-22018 are located in introns 13 and 9 of the minichromosome maintenance 
deficient 6 (MCM6) gene, respectively (Figure 8). These SNPs cosegregated 
completely with the adult-type hypolactasia trait in Finnish families. All 
hypolactasic individuals showed homozygosity for C-13910 and G-22018. Furthermore, 
in an independent sample set of 236 individuals, with biochemically verified 
disaccharidase activities from intestinal biopsy specimens from four different 
populations, the C/T-13910 SNP was completely found to be associated with the trait 
and the SNP G/A-22018 associated in 229 of 236 cases (Enattah et al. 2002). The 
frequency of the C/C-13910 in a sample set of 1047 individuals was in agreement with 
the reported prevalence of adult-type hypolactasia in Finnish, French, African 
American and South Korean populations and North American Caucasians (Sahi 
1974; Simoons 1978; Cuddenec et al. 1982). As early as this time, the lactase 
persistence allele, T-13910, was anticipated to be very old as it was found in distally 
related populations (Enattah et al. 2002). 
 
 
 
 
 
 
 
 
 
Figure 8. The physical map of the adult-type hypolactasia locus. The adult-type 
hypolactasia locus is located between markers D2S3013 and D2S3014. The horizontal 
arrows indicate the positions of lactase (LCT), minichromosome maintenance deficient 
6 (MCM6) and aspartyl-tRNA synthetase (DARS). SNPs C/T-13910 (rs4988235) and 
G/A-22018 (rs182549) are located in intron 13 and 9 of the MCM6 gene, 14 and 22 kb 
from LCT, respectively. Modified from Enattah et al (2002). 
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2 . 4 . 3 . 3 . 1   F u n c t i o n a l  e v i d e n c e  
Both the SNPs, C/T-13910 and G/A-22018, were found in introns of MCM6, which are 
located in close proximity of, only 2.5 kb upstream, LCT. MCM6 is a mammalian 
homologue of mis5 of yeast, it functions as a cell cycle factor (Takahashi et al. 
1994) and its mammalian version was initially identified in intestinal crypt cells of 
the rat (Sykes and Weiser 1995). MCM6 is expressed in various human tissues 
including intestine during development. However, intestinal expressions of MCM6 
and LCT were not observed to match with lactase persistence or non-persistence 
individuals suggesting that these genes are independently regulated (Harvey et al. 
1996). Thus, it seems that the influence of the MCM6 gene on adult-type 
hypolactasia is only structural. The next evident step was to define the significance 
of C/T-13910 and G/A-22018 on the regulation of lactase activity. The answer for the 
dilemma was sought in the present study (III, see discussion) but later also by others 
using human (Troelsen et al. 2003b) and rat (Olds and Sibley 2003) LCT promoter-
reporter gene construct analyses in Caco-2 cells. Both C-13910 and T-13910 variants 
were observed to enhance LCT promoter activity. The region containing T-13910 was 
demonstrated to increase 25%-75% LCT promoter activity compared to the results 
with the region cloned with C-13910 in undifferentiated Caco-2 (Olds and Sibley 
2003; Troelsen et al. 2003b). Interestingly, the enhancer activity of C-13910 and T-
13910 was detected to be several times higher in differentiated Caco-2 cells. The 
differentiated Caco-2 cells are commonly considered as a better model as they 
endogenously express LCT. Also, the difference of enhancer activities between C-
13910 and T-13910 was found to be clearer, the T-13910 variant had a 3-6-fold increase in 
transcription compared with the C-13910 variant. Furthermore, electrophoretic 
mobility shift assays (EMSAs) showed a strong interaction between the T-13910 
variant and a nuclear factor in nuclear extracts of HeLa and differentiated Caco-2 
cells. On the contrary, the C-13910 variant had a weak interaction suggesting that the 
observed difference of LCT promoter activities are due to the binding capacity of C-
13910 and T-13910 of a nuclear factor (Troelsen et al. 2003b). Analogous analyses of 
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the G/A-22018 variant with human and rat LCT promoters did not reveal any 
significant functional role for phenotype differences of adult-type hypolactasia (Olds 
and Sibley 2003; Troelsen et al. 2003b). The G/A-22018 variants were detected to 
possess a modest silencer effect on the C/T-13910 enhancer activity but there were no 
differences where one of the variants G22018 or A-22018 were present (Troelsen et al. 
2003b). These results suggest that only C/T-13910 has a functional significance for 
enhancing LCT in vitro (Olds and Sibley 2003; Troelsen et al. 2003b). Although, 
G/A-22018 was observed to closely associate with the adult-type hypolactasia trait 
(Enattah et al. 2002) it probably is in LD locating only 8 kb from C/T-13910.  
The hunt for the nuclear factor, which binds to the C/T-13910 enhancer, was started 
from nuclear extracts of HeLa and CaCo-2 cells. DNA affinity purification analyses 
using the DNA region containing the T-13910 variant demonstrated co-purification of 
Octamer-binding transcription factor-1 (Oct-1) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Super shift assays showed that Oct-1 binds directly to the 
T-13910 variant. Furthermore, the binding was detected to be stronger to the T-13910 
variant than the C-13910 variant (Lewinsky et al. 2005). Earlier, GAPDH has been 
shown to directly interact with Oct-1 (Zheng et al. 2003) which could explain its 
observed co-purification with Oct-1 (Lewinsky et al. 2005). In addition, DNase 
footprint and supershift analyses identified binding motifs for Cdx-2, GATA-6, Fox 
and HNF-4α nearby C/T-13910 (Figure 9). Mutation analyses of the Oct-1 binding site 
of T-13910 enhancer led a 5-fold decrease of expression using LCT promoter-reporter 
gene construct in Caco-2 cells. Also, mutation analyses of GATA, Fox and HNF-4α 
sites remarkably diminished the T-13910 enhancer activity suggesting they are 
important factors belonging to the enhancer structure; in contrast mutations in the 
Cdx-2 site had no significant effect on enhancer activity. Co-transfection analyses of 
Oct-1, GATA-6, HNF-4α, Cdx-2 and HNF-1α and HNF-1β with the T-13910 
enhancer uncovered the fact that Oct-1 triggers reporter gene expression (133-fold) 
only with HNF-1α. The HNF-1α motif has not been found within the C/T-13910 
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enhancer but it probably acts via a proximal promoter, which has a fine-
characterized HNF-1α binding site. Co-transfection of Oct-1 and HNF-1α using the 
C-13910 enhancer led to a 112-fold increase in enhancer activity. Over-expression of 
Oct-1 could not alone initiate the T-13910 enhancer suggesting Oct-1 is not the 
limiting factor in Caco-2 cells. Over-expression of HNF-1α, GATA-6, HNF-4α and 
Cdx-2 was observed to induce the C/T-13910 enhancer activity but only HNF-1α was 
observed to maintain the difference in activity between the T-13910 and C-13910 
enhancers. In addition, the C/T-13910 enhancer had no influence on MCM6 promoter 
activity. The results suggest that the C/T-13910 variant locates in the middle of a 
sophisticated enhancer structure consisting of at least Oct-1, GATA, Fox and HNF-
4α binding sites (Figure 9). Oct-1 with C/T-13910 directs specifically the LCT 
promoter activity and enhances reporter gene expression with the T-13910 variant 
significantly over the C-13910 variant. These in vitro observations offer a convincing 
model for T-13910-induced lactase persistence in humans (Lewinsky et al. 2005). 
 
 
 
 
 
Figure 9. Structure of the C/T-13910 enhancer and the proximal promoter. Analysis 
of region of the C/T-13910 enhancer revealed the binding sites for Cdx-2, GATA-6, Oct-1, 
Fox and HNF-4α from 14045-13825 bp upstream of the LCT gene. Oct-1 interacts 
directly with the C/T-13910 site and has a stronger affinity to the T-13910 than the C-13910 
variant. Oct-1 was observed to interact with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) that possibly functions as a co-activator for Oct-1. Mutation analyses of the 
binding sites demonstrated that the GATA-6, Fox and HNF-4α sites belong to the 
enhancer structure together with the Oct-1 site eliminating the enhancer activity. Disrupt 
of the Cdx-2 binding site had no effect on the enhancer activity. In expression studies of 
the C/T-13910 enhancer and the proximal LCT promoter construct, Oct-1 was observed to 
enhance reporter gene expression only when co-expressed with HNF-1α. This is 
assumed to occur through interactions with Oct-1 and HNF-1α that is bound to the CE2c 
site at the proximal promoter (Lewinsky et al. 2005). 
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2 . 4 . 3 . 4  T - 1 3 9 1 0 ,  t h e  o n l y  v a r i a n t  r u l i n g  l a c t a s e  
p e r s i s t e n c e  f o r  h u m a n i t y ?  
Originally, the T-13910 variant was cloned in the Finnish population, which is a 
population that has been proven to be invaluable for tracing mutations underlying 
rare monogenic diseases (Enattah et al. 2002). Interestingly, the variant has also 
been found in other European Caucasians or their descendants. The prevalence of 
the T-13910 allele has been observed to be in agreement with the epidemiological 
observations of lactase persistence in Austria, (Obermayer-Pietsch et al. 2004; 
Bodlaj et al. 2006) Germany, (Büning et al. 2003) France, US, (Enattah et al. 2002) 
UK, (Rasinperä et al. 2005) Ireland (Mulcare et al. 2004) Poland and Sweden (Study 
IV). C/T-13910 has also been shown to match, with few exceptions, with sets of 
individuals whose ability to hydrolyse lactose was determined by duodenal enzyme 
assays in the UK (Poulter et al. 2003) and by LTT in Sweden (Nilsson and 
Johansson 2004; Ridefelt and Håkansson 2005). In Austria, BHT diagnosed lactase 
status correlated with the C/C-13910 genotype, however the test indicated lactase 
deficiency in 14% of individuals with C/T-13910 and T/T-13910 (Hogenauer et al. 
2005). The results are acceptable if it is taken into account that the accuracy of BHT 
is not very high (Arola 1994). Outside of Europe the T-13910 allele was strongly 
represented in Pakistan and Algeria, lower frequencies were observed in Middle 
Eastern populations (Bersaglieri et al. 2004). In Pakistan, five out of eight 
population groups had the T-13910 allele frequency ≥0.30 (Bersaglieri et al. 2004) that 
is in scale with the phenotyped data (0.20-0.33) in this region (Abbas and Ahmad 
1983; Ahmad and Flatz 1984). There is no published data of lactase persistence 
available for Algerians. The T-13910 allele was suggested to have been spread 
between populations along dairy farming thus, increasing traces of T-13910 is seen in 
neighbouring European populations (Bersaglieri et al. 2004). There are certain 
nomadic populations with known pastoralism and high lactase persistence in Africa 
and the Arabian Peninsula. To shed some light on lactase persistence in Africans, 
different populations were analysed for the T-13910 variant. Statistically, T-13910 could 
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not match with five out of seven population groups with the published lactase 
persistence incidences. Four of those five populations came from Sudan one came 
from Senegal. On the contrary, in two population groups from Cameroon T-13910 
associated with the epidemiological observations. Based on these results, these five 
groups may have a divergent genetic background for lactase persistence. A variant 
that could explain lactase persistence in these groups was not identified (Mulcare et 
al. 2004). The study has its limitations including the small number of analysed 
subjects and carefully characterized phenotypes are required to confirm the results. 
As there may be other variants apart from the T-13910 one influencing lactase 
persistence, at least in Africans, it will be interesting to see whether any new variant 
found shares the same enhancer element or if its mechanism of up-regulation is 
more complex. Also, it is to be determined what variant nomadic populations of 
Arabia possess to allow lactase expression in adulthood. Be that as it may, the case 
is not closed yet. There is still work to be done to uncover causes or to confirm the 
present one for lactase persistence globally. Thus far, the T-13910 variant is the only 
one that has been published to be causative for the lactase persistence phenotype.  
There have been discussions of the diagnostic value of the C/T-13910 variant for 
adult-type hypolactasia (Swallow 2006). Based on studies in children (Rasinperä et 
al. 2004) and the population and functional studies reviewed here, C/T-13910 can be 
regarded as a suitable first-stage screening test for adult-type hypolactasia in adults 
of European ancestry. 
 
2.5 Lactase persistence, non-persistence and dairy consumption 
risk factors for other diseases? 
Milk contains a large quantity of calcium, lactose and many other components such 
as vitamin D and various vitamins of B. Milk is a versatile nutrient, and its 
consumption and effects on health have been studied with a passion. Obviously high 
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lactase activity facilitates the use of milk as nutrition and this has been noted as an 
increasing milk consumption in western countries (Obermayer-Pietsch et al. 2004; 
Rasinperä et al. 2004; Rasinperä et al. 2006). Hence, lactase persistence or non-
persistence has been suggested to influence indirectly the pathogenesis of certain 
diseases. Perhaps one of the most studied is the link between the milk consumption 
and the development of osteoporosis. Calcium is the main mineral involved in bone 
formation and it is needed throughout life. The recommended daily intake of 
calcium is about 900 mg/day for adults, 1200 mg/day for adolescents and the elderly 
(National Nutrition Council 1999). As milk is an excellent source of bioavailable 
calcium, it has a positive effect on calcium balance and therefore on bone formation. 
Especially, the consumption of dairy products in childhood and adolescence is seen 
as an increasing bone density in adulthood and an ability to protect women against 
osteoporosis (Gueguen and Pointillart 2000). In addition, the C/C-13910 genotype 
defining lactase non-persistence associated with bone fractures in elderly people in 
Austria and Finland (Obermayer-Pietsch et al. 2004; Enattah et al. 2005b) but in 
young Finnish men the genotype had no effect (Enattah et al. 2004a). With this 
background lactase persistence could help maintain the milk drinking habit from 
childhood to adolescence and hence decrease the risk of osteoporosis. However, 
studies focussed on this issue are controversial and there is not consensus among 
researchers. Even, a case control study using genetically defined lactase status by the 
C/T-13910 variant could not find any link between lactase non-persistence and 
osteoporosis in Finnish postmenopausal women (Enattah et al. 2005a). Lactose has 
also been suggested to enhance calcium absorption in the intestine but studies on 
subjects with lactase persistence and non-persistence have shown no real proof of 
this. In general, it has been rationalized that diminished calcium availability in non-
persistence subjects might explain the more efficient calcium absorption, reviewed 
in Gueguen and Pointillart (2000), Prentice (2004). Osteoporosis is a complex 
disease, which is caused by genetic and environmental factors. It seems that dietary 
calcium for its part during the peak of bone formation reduces bone fracture risk and 
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osteoporosis in adulthood. Yet, the effect of lactase non-persistence is more arguable 
(Gueguen and Pointillart 2000; Prentice 2004). The composition of Finnish 1.5% 
milk is represented in Table 2 (Fineli, National Public Health Institute, Finland). 
 
 
 
 
 
 
 
 
 
Milk consumption has been proposed to have a modest protective effect against 
colorectal cancer (World Cancer Research Fund 1997). Primarily, the protective 
effect has been suggested to be mediated by calcium and vitamin D. However, only 
large cohort studies have been able to confirm the relation, most case control studies 
have failed to find supportive evidences for the hypothesis (Norat and Riboli 2003). 
Lactase persistence variant, T-13910, was found to have a modest protective effect 
against colorectal cancer in the Finnish population. However, there was no 
significant risk effect observed in the British or Spanish populations (Rasinperä et 
al. 2005). This might be related to the fact that Finnish milk consumption is the 
highest in the world (The World Dairy Situation 2003). The findings require more 
detailed studies concerning the possible mechanism between components of milk 
and colorectal carcinogenesis. Therefore, another association study would not seem 
to be the most reasonable alternative.  
Table 2. Milk (1.5%) content
Milk component Quantity Milk component Quantity
Energy 191 kJ Iodine 16.0 µg
Fat 1.5 g Selenium 2.8 µg
Protein 3.0 g Vitamine A 12.9 µg
Lactose 4.8 g Vitamine D 0.5 µg
Cholesterol 6.4 mg Vitamine E <0.1 mg
Sodium 41.0 mg Vitamine K 0.33 µg
NaCl 104.5 mg Vitamine C 1.1 mg
Potassium 150.0 mg Folate 4.2 µg
Magnesium 11.0 mg Niasine 0.8 mg
Calcium 120.0 mg Vitamine B2 0.19 mg
Phosphorus 90.0 mg Vitamine B1 0.04 mg
Iron < 0.1 mg Vitamine B12 0.4 µg
Zinc 0.4 mg Carotenoid 8.7 µg
 49 
Lactase non-persistence has been suggested to associate also with Crohn’s disease 
(Mishkin et al. 1997; von Tirpitz et al. 2002) and lactase persistence with type I and II 
diabetes (Meloni et al. 2001). Association analysis of C/T-13910 with patients with 
Crohn’s disease (Büning et al. 2003) and type I and II diabetes (Enattah et al. 2004b) did 
not support those earlier findings. These and other’s findings (Park et al. 1990) suggest 
that the hypotheses might be closer to a myth than a real cause and effect relation. 
 
2.5.1 Ovarian carcinoma 
Ovarian cancer is the sixth most common cause of cancer among women but it is 
one of the deathliest disease of the female genital tract in the world (Parkin et al. 
2001; Schulz et al. 2004). Ovarian cancer occurrence rates are observed to be 
highest in Europe and North America and lowest in Asia (World Cancer Research 
Fund 1997). Epithelial ovarian cancer (ovarian carcinoma) consists of 90% of 
ovarian cancers; germ cell and stromal cell ovarian cancers are responsible for 10% 
of cases. Ovarian carcinoma can be divided into four major histological subtypes: 
serous, endometrioid, mucinous and clear cells tumours of which the serous subtype 
is the most common one consisting of about 40% of ovarian carcinoma tumours. 
Papillary serous, Brenner cell, undifferentiated adenocarcinomas and sarcomas 
represent a minority of the histological subtypes. The majority of ovarian cancer 
patients are postmenopausal women in their late 50’s, reviewed by Schulz et al. 
(2004). About 90% of the cases of all types of ovarian cancers are sporadic and 
hereditary factors are proposed to describe 5-10% of cases (Runnebaum and 
Stickeler 2001; Schulz et al. 2004). The aetiology of ovarian carcinoma is poorly 
known but both genetic and environmental factors are involved. For example, in 
sporadic ovarian carcinomas inactivation of the p53 tumour suppressor gene has 
been observed (Wen et al. 1999; Christie and Oehler 2006). The BRCA1 and BRCA2 
genes are occasionally mutated in hereditary ovarian carcinomas (Menkiszak et al. 
 50 
2003; Christie and Oehler 2006). Numerous “incessant” ovulation and hormonal 
factors have also been hypothesized to be involved in its pathogenesis (Risch 1998). 
Thus, factors that reduce ovulation cycles such as multiparity, lactation, tubal 
ligation and hysterectomy or use of oral contraceptives are associated with a 
decreased risk of ovarian carcinoma (Whittemore et al. 1992; Hankinson et al. 
1993). Also, nutritional features have been suggested as contributory factors 
(Haenszel and Kurihara 1968; Schulz et al. 2004). 
 
2 . 5 . 1 . 1  D a i r y  c o n s u m p t i o n  a n d  o v a r i a n  c a r c i n o m a  r i s k  
Dairy products have been hypothesized to play a role in the tumour genesis of 
ovarian carcinoma. Milk, as known, has a high content of lactose and it is further 
metabolized by lactase to glucose and galactose. Galactose is converted to glucose 
in the liver by the Leloir pathway (Xu et al. 1989; Reichardt and Woo 1991). The 
hypothesis was born in the 1980’s when animal studies showed that high quantities 
of dietary galactose is poisonous to oocytes (Chen et al. 1981; Schwartz and 
Storozuk 1988). In addition, young women with galactosemia were observed to 
develop ovarian failure (Kaufman et al. 1981). Galactosemia is an autosomal 
recessive disorder with an almost total absence of galactose-1-phosphate 
uridyltransferase (GALT) activity leading metabolites of galactose to accumulate in 
the ovary and other tissues (Xu et al. 1989; Reichardt and Woo 1991). Hence, the 
premature ovarian failure was suggested to be due to the direct toxicity of galactose, 
its metabolites or elevated gonadotropin levels (Cramer and Welch 1983; Harlow et 
al. 1991; Leslie 2003). The hypothesis truly got off the ground when milk 
consumption and lactase persistence were observed to correlate with ovarian 
carcinoma incidence (Cramer 1989). Since, then a number of studies have been 
conducted to define the significance of milk or its components and/or lactase 
persistence/non-persistence to ovarian carcinogenesis. Once again the results are 
controversial. Lactase persistence and lactose consumption were shown to associate 
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with increased ovarian carcinoma risk in Sardinia, Italy (Meloni et al. 1999) and 
lactose intolerance was suggested to indicate a protective effect against ovarian 
carcinoma at an early age in eastern U.S. (Cramer et al. 2000) but in studies with 
subjects from Canada (Risch et al. 1994) and with Caucasian from the U.S. 
(Herrinton et al. 1995) no such association was found. Diagnosis of lactase 
phenotypes has been often obtained using LTTs and self-reports of clinical 
symptoms that naturally increase the distribution. In multiple studies, milk or lactose 
consumption was found to have a protective effect on ovarian carcinoma (Goodman 
et al. 2002a; Goodman et al. 2002b; Salazar-Martinez et al. 2002; Yen et al. 2003). 
Two cohort studies from the U.S. (Kushi et al. 1999; Fairfield et al. 2004) and one 
from Sweden (Larsson et al. 2004) found a correlation between lactose consumption 
and increased ovarian carcinoma risk, especially that of serous subtype (Fairfield et 
al. 2004; Larsson et al. 2004). In contrast, cohorts from the Netherlands (Mommers 
et al. 2006) and another from the U.S. (Kiani et al. 2006) did not show any 
association whatsoever. Several case control studies have failed to find a clear 
relation of milk or lactose consumption to ovarian tumour genesis (Mettlin and Piver 
1990; Engle et al. 1991; Risch et al. 1994; Herrinton et al. 1995; Webb et al. 1998; 
Britton et al. 2000; Bertone et al. 2001; Pan et al. 2004; Parazzini et al. 2004). Meta-
analyses showed that only cohort studies found a link between milk/dairy/lactose 
consumption and an increased risk for ovarian carcinogenesis, but not case control 
studies (Larsson et al. 2006), nor the studies combined (Qin et al. 2005; Larsson et 
al. 2006). However, a recent pooled analysis of 12 cohort studies showed no 
statistically significant association between lactose consumption and the risk of 
ovarian carcinoma (Genkinger et al. 2006). Dietary vitamin D has been shown to 
protect from the development of ovarian carcinoma (Bidoli et al. 2001; Salazar-
Martinez et al. 2002). In addition, calcium consumption has been observed to 
decrease ovarian carcinoma risk (Bidoli et al. 2001; Goodman et al. 2002b). 
Calcium, dietary vitamin D and endogenous vitamin D formation has been shown to 
downregulate the synthesis of parathyroid hormone (PTH) (Takeuchi et al. 1995; 
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Malabanan et al. 1998). PTH is involved in dietary calcium absorption increasing 
1,25 dihydroxyvitamin D synthesis. It has been suggested that PTH is involved in 
cancer stimulating IGF-1 formation or acting as a co-mitogen in preneoplastic lesion 
expressing PTH receptors (McCarty 2000). However, all studies have not supported 
the potential protective effect of vitamin D and/or calcium (Tzonou et al. 1993; 
Kushi et al. 1999; Goodman et al. 2002b; Salazar-Martinez et al. 2002; Pan et al. 
2004). The results about the dairy consumption as a risk factor for ovarian 
carcinogenesis are contentious. Milk consists of a huge number of various 
components and there is no clear consensus of the effect of any of them. However, it 
must be taken into account and they are difficult analyse individually. 
The influence of GALT activity as directly involving the galactose hypothesis has 
been studied in the development of ovarian carcinoma. Some studies have used the 
N314D polymorphism of GALT as a molecular marker as it has been shown to 
diminish the GALT activity to 74-43% from normal (Elsas et al. 1994; Langley et al. 
1997). Decreased activity of GALT together with lactose consumption was detected 
to associate with ovarian carcinoma (Cramer et al. 1989). However, later studies 
could not find any significant difference in GALT activity (Herrinton et al. 1995; 
Webb et al. 1998; Cramer et al. 2000; Goodman et al. 2002a) or in the frequency of 
N314D (Goodman et al. 2002a) between ovarian carcinoma patients and controls. 
The frequency of N314D was found to be higher in women with serous ovarian 
carcinoma but not endometroid or clear cell subtypes (Morland et al. 1998). On the 
contrary, another study found that N314D associated with endometroid and clear 
cell ovarian carcinomas but not with the serous subtype (Cramer et al. 2000). In 
addition, the N314D polymorphism and lactose consumption associated with 
borderline ovarian carcinoma (Cozen et al. 2002). 
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2.6 Identification of disease genes 
2.6.1 The Human Genome Project 
The Human Genome Project (HGP) had the ambitious goal to determine the 
structure of the human DNA sequence. The HGP was initiated in various National 
Institutes of Health and the U.S. Department of Energy in the United States in 1990. 
In 1998 a private company, Celera Genomics, announced a three-year project aimed 
at revealing the human genome nucleotide sequence. In February 2001 they and the 
public International Human Genome Sequencing Consortium published a nearly 
complete sequence of the euchromatic portion of the human genome (Lander et al. 
2001; Venter et al. 2001). 
 
2.6.2 The Human Genome 
The genetic map length of the human genome (unit of Morgan) between two loci 
defines the average number of genetic recombinations (crossing-over) occurring in a 
gamete during meiosis. The recombination frequency fluctuates with chromosomal 
regions and it is different for males and females. The genetic length of the whole 
genome is 4301 cM in females and 2849 cM in males (Collins et al. 1996). One 
centiMorgan is estimated to be roughly equal to a physical length of 1 Mb (Ott 
1999).  
The physical length of the euchromatic portion of the haploid human genome is 
~2.91 billion bp. Sequence analysis showed circa 24500-26000 protein encoding 
transcripts and 6500-12000 additional genes obtained by gene prediction programs 
with weak similarities to other species. Exons cover only 1.1-1.5% of the genome, 
24-33% is covered by introns, and 66-75% of the genome consists of intragenic 
DNA without any known function. The organization of the human genome primary 
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structure provides scientists with a tool to understand human biology (Lander et al. 
2001; Venter et al. 2001). 
 
2.6.3 Positional cloning 
In positional cloning a disease gene is isolated based on its chromosomal location 
without any knowledge of its function or pathogenesis. A chromosomal location is 
defined by genetic mapping using family material adequate for linkage analyses. 
Locus can be further refined by LD and haplotype mapping (Collins 1992; Collins 
1995). Today in the post genomic era, genes of interest are listed in databases, thus 
regional candidate genes can be carefully chosen and/or systematically screened for 
mutation. 
 
2.6.4 Genetic mapping 
Genetic mapping requires family material with a precisely diagnosed inherited disease. 
Only reliable diagnosis by experienced clinician(s) can lead to useful results using the 
genetic mapping approach. For linkage analysis two or more affected individuals are 
required. The collected family material is analysed with polymorphic microsatellite 
markers positioned at about 4-10 cM intervals throughout the genome. Until linkage is 
reached, the study can be further carried on by fine mapping with more frequent 
microsatellite maps to get as close as possible to the mutation responsible for the 
disease. Botstein et al. (1980) introduced the principles of genetic mapping with DNA 
markers in 1980 and Gusella et al. (1983) were the first to identify a human disease 
gene locus (Huntington disease) using this approach in 1983.  
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2 . 6 . 4 . 1  G e n e t i c  m a r k e r s  
There are a large number of sequence variations in the human genome between 
individuals. Most of them are located in the non-coding regions but such harmless 
alterations in the coding regions are not unusual. The segregation of these variations 
to offspring within families is the foundation for genetic mapping. The sequence 
variations are called polymorphisms when its most common allele has a population 
frequency of less than 95-99% (Botstein et al. 1980; Ott 1999). The usefulness of a 
marker for linkage analysis depends on the number of alleles and their gene 
frequencies (degrees of polymorphism). Short tandem repeats (STR) are highly 
polymorphic usually consisting of 10-50 copies of di-, tri-, tetra-, or pentanucleotide 
repeat elements. The most common repeat (CA)n is distributed approximately in 30 
kb intervals in the human genome (Hearne et al. 1992). Today, thousands of 
microsatellite markers and several genetic maps are available in public databases 
(e.g. Marshfield Medical Genetic Foundation, Genome Database). High-resolution 
recombination maps have also been created and they are available as a 
supplementary file (Kong et al. 2002). The use of single nucleotide polymorphisms 
(SNPs) as biallelic markers have led to seriously new opportunities again not seen 
since the times of biallelic restriction fragment length polymorphism (RFLPs) 
detection. SNPs are observed about once in every kilobase, they are also found in 
the coding regions of the genes (cSNP). They are more stable than STRs but at the 
same time carry less information (Li and Sadler 1991; Wang et al. 1998a). SNPs can 
be easily and automatically identified using primer extension techniques and 
detected by scintillation, fluorometry or mass spectrometry based methods. They are 
suitable for genetic mapping and gene expression studies using cSNP as a marker 
(Syvänen et al. 1990; Syvänen et al. 1993; Lander 1996; Pastinen et al. 1996; Braun 
et al. 1997; Haff and Smirnov 1997; Pastinen et al. 1997; Ross et al. 1998; Syvänen 
1998; Tang et al. 1999). Wang DG and colleagues (1998) published the first genetic 
SNP map in 1998. 
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2 . 6 . 4 . 2  L i n k a g e  a n a l y s i s  
The purpose of linkage analysis is to assign a disease locus its specific chromosomal 
region. It is based on comparing the inheritance of alleles of polymorphic markers 
with the disease phenotype. If a polymorphic marker is so close to a disease locus 
that they cannot be separated by recombination (or it is extremely rare) they are said 
to be genetically linked. The techniques of the statistical significance of linkage 
testing are based on maximum likelihood estimation and likelihood ratio testing. The 
most used approach is the logarithm of odds (LOD) score method. The likelihood 
(L) that two loci, e.g. a marker and a disease locus, are linked with a recombination 
fraction (θ) is compared the likelihood that they are not linked (θ=½). The LOD 
score Z(θ) is obtained when the ratio of these likelihoods are converted into log10, 
 
Z(θ) = log10 ⎥⎦
⎤⎢⎣
⎡
L(½)
 )L(θ . 
 
A LOD score value ≥3, which means that two loci are 1000 times more likely to be 
linked than not linked, is considered to be significant evidence for linkage. On the 
other hand, a LOD score value ≤-2 is evidence against linkage (probably a 100 times 
likely not to be linked) (Morton 1955; Ott 1999). Linkage analyses are performed by 
comparing a disease locus with each marker locus as a two-point linkage analysis 
and analysis of numerous linked loci, multipoint analysis. Multipoint analysis uses 
the information of adjacent marker loci thus, the order of loci matters. 
 
2 . 6 . 4 . 3  L i n k a g e  d i s e q u i l i b r i u m  
Linkage disequilibrium is a phenomenon of non-random association of alleles at 
linked loci. The association can be statistically measured by the traditional chi-
square (χ2) test, the Fisher’s exact test, (Armitage and Berry 1987) r2, (Ardlie et al. 
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2002) and the likelihood based lambda (λ) test (Terwilliger 1995). The chi-square 
and a Fisher’s exact tests evaluate independence of a 2x2 table. The chi-square test 
is adjusted for large sample sets. 
 
χ2 = ∑
=
R
1i
∑
=
C
1j ij
ijij
E
)E - (O
, 
 
where Oij is the observed frequency of the ith row and the jth column, E is the 
expected frequency of the ith row and the jth column, R is a number of rows and C 
is a number of columns (Armitage and Berry 1987). Lambda informs about the 
proportion of excess of a certain allele in disease chromosomes, relative to its 
population frequency. 
 
λi = α(1-θ)n , 
 
Where λi is proportion of excess of allele i in chromosomes carrying the disease 
allele, αi is proportion of disease alleles originally in association with allele i, θ is 
recombination fraction, n is number of generation since introduction of the founder 
disease allele into the population (Terwilliger 1995). 
LD is used for fine mapping of disease genes and it is powerful in situations where 
chromosomes are carrying a mutation originating from one common ancestor. An 
efficient LD mapping also requires a low number of the original settlers, rapid 
expansion of the population without major immigration like the Finns or an ancient 
small population which has been stable for a long time like the Saami, and a large 
enough number of patients (Edwards 1980; de la Chapelle 1993; de la Chapelle and 
Wright 1998; Terwilliger et al. 1998; Peltonen et al. 1999). The power of LD 
mapping was showed in a rare Finnish monogenic disease infantile-onset 
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spinocerebellar ataxia (IOSCA) where initial gene localization was obtained using 
four affected individuals from two consanguineous pedigrees (Nikali et al. 1995). 
LD mapping has also been successfully used in narrowing the disease locus in other 
rare Finnish diseases such as diastrophic dysplasia (DTD) (Hästbacka et al. 1992) or 
autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED) 
(Aaltonen et al. 1994). The length of LD can be utilized to estimate the age of 
mutations. Meiotic recombinations which may have occurred over time decrease the 
length of the observed LD generation after generation thus, indicating the older 
mutation (Varilo 1999). Figure 10 represents the principle used for LD mapping. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The basis of linkage disequilibrium (LD) mapping. The conserved 
region of a founder chromosome, exposed to disease mutation, shorten after 
generations due to recombinations in meiosis. In the course of time, only a short 
chromosomal segment is preserved from the founder chromosome. This event is 
detected as LD and can be used in a similar manner in haplotype analyses and for 
evaluating the age of mutation (de la Chapelle et al. 1994; Ott 1999; Varilo 1999; 
Norio 2000). 
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2 . 6 . 4 . 4  H a p l o t y p e  a n a l y s i s  
Haplotype analysis, like LD mapping, is used for further restriction of disease locus 
in the isolated populations. Haplotype analysis is the identification of shared 
ancestral disease alleles of informative marker loci in a critical region. 
Recombinations events can dramatically reduce the shared region. Haplotype 
analysis extends beyond recombinations events by revealing old recombinations and 
thus further restricts the critical region needed to identify a disease gene, 
exemplified in many Finnish diseases such as progressive myoclonus epilepsy 
(EPM1) from about 7 cM to 0.30 cM (Lehesjoki et al. 1993). 
 
2 . 6 . 4 . 5  T o w a r d s  c a u s a t i v e  m u t a t i o n s  
When a disease locus has been defined to a certain chromosomal region by genetic 
mapping, the virtually completed human genome project gives a possibility to use 
bioinformatics to locate ESTs, protein homologies, known genes or predicted genes. 
Also, genome projects of other organisms help to identify conserved gene structures and 
regulatory elements. Modern capillary techniques enable a fast mutation screening by 
cycle sequencing. The validation of found sequence variations can be performed by 
carrier screening, functional analyses in vitro and in vivo, and model organisms. 
 
2.7 Gene expression studies 
A fundamental part of disease gene characterization, as well as the basic gene 
studies, is to examine gene expression. Gene expression can be studied by a number 
of techniques for example, histochemically and immunohistochemically evaluations 
at the protein level. Cell specific gene expression can be detected using in situ 
hybridization at the mRNA level (Bleeker et al. 2000; Ropponen et al. 2001; van 
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Noorden 2002). Furthermore, more accurate sensitive expression detection 
techniques have been developed. 
 
2.7.1 Techniques for mRNA detection 
The monitoring of mRNAs has been found to be an important approach to studying 
gene function. Alwine et al. (1977) modified the southern blot technique (Southern 
1975) and created the specific northern blot hybridization assay for the detection of 
mRNA. Northern blotting requires electrophoretic separation of total RNA or 
mRNA on an agarose gel, transferring to a nitrocellulose sheet, and hybridization 
with a 32P-labeled DNA probe. The results are visualized by autoradiography.  
Since Mullis et al’s (1986) development of the PCR method, RT-PCR has been 
utilized efficiently to study the expression of genes. RT-PCR is a sensitive technique 
that enables the quantitative monitoring of changes of mRNA expression at the 
cellular level. Real-time PCR offers the opportunity to follow the accumulation of 
PCR products during amplification. It is based on specific hybridization of the 
fluorescent probes. Quantitation can be obtained using internal standard 
competitively during amplification and detection is based on decrease in fluorescein 
quenching by rhodamine after Taq DNA polymerase’s exonuclease cleavage of 
dual-labelled probes during the exponential phase of amplification (Livak et al. 
1995), see also (Holland et al. 1991). Alternatively, fluorescence can be monitored 
by the resonance energy transfer of fluorescein to Cy5 between adjacently 
hybridized probes (Wittwer et al. 1997). 
A number of competitive endpoint RT-PCR based techniques have been developed. 
The quantitation is achieved by coamplification of in vitro-generated internal 
standard RNA with target mRNA. For example, in the early quantitation methods 
the PCR products of the internal standard and target mRNA had to differ in length 
(Wang et al. 1989) or the size difference were generated by restriction endonuclease 
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digestion (Becker-Andre and Hahlbrock 1989). The detection needed electrophoretic 
separation followed by northern blot hybridisation. The initial copy number of the 
target mRNA is estimated from the ratio to the internal standard. However, more 
sensitive methods of endpoint quantitation have been introduced. The versatile 
enzyme-linked immunosorbent (ELISA) PCR assay relies on the hybridization of a 
solid-support captured amplification product with a digoxigenin-labeled internal 
oligonucleotide probe. Detection is performed by optical reading after an anti-
digoxigenin alkaline phosphatase coupled antibody treatment (Alard et al. 1993). 
Solid-phase minisequencing enables quantitation of highly homologous sequences 
that differ from each other only by one single nucleotide (Figure 11). It utilizes 
DNA polymerase to a single nucleotide primer extension. PCR is performed by a 
biotinylated primer which is immobilized to a streptavidine coated solid support and 
denaturated. A detection primer is designed to anneal adjacent to the single 
nucleotide polymorphism and minisequencing is performed separately with the 
expected 3H-labeled dNTPs. The ratio of two incorporated labels as a measure of the 
two sequences is determined by a liquid scintillation counter (Syvänen et al. 1990; 
Syvänen et al. 1992a; Syvänen et al. 1992b). Solid-phase minisequencing has been 
used for quantitation of rare transcripts (Ikonen et al. 1991) and e.g. the detection 
method using fluorescent labels in multiplex analyses (Pastinen et al. 1996; Pastinen 
et al. 1997). Furthermore, solid-phase minisequencing was used for accurate 
determination of the relative mRNA levels of two closely related mRNAs 
(squamous cell carcinoma antigen; SCCA1 and 2). Quantitation was based on the 
ratio of the SCCA2 to SCCA1 genes in the same cell as internal standard for each 
other (Stenman et al. 1999), see also (Karttunen et al. 1996). Multiple genes or 
whole genomes can be simultaneously studied by the complementary DNA 
microarray technology. DNA microarray expression analysis involves reverse 
transcription (RT) of isolated mRNA with fluorescently labelled dNTPs. A mixture 
of equivalent amounts of both labelled cDNA sample are hybridized to the 
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microarray and the ratio of labels are measured by laser confocal fluorescent 
scanning (Schena et al. 1995; Lockhart et al. 1996; Brown and Botstein 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The principle of the solid-phase minisequencing. The initiation step is 
PCR or RT-PCR with a biotinylated primer. 2. Then dividing the reaction into two 
samples and immobilizing streptavidine-coated microplates. 3. Denaturation of the 
complementary strand. 4. A primer-guided tritium labelled nucleotide incorporation 
assay. As a result, the ratios of two nucleotides as a measure of two alleles are 
calculated (Syvänen et al. 1990; Syvänen et al. 1992a; Syvänen et al. 1992b). The 
Figure is modified from Study III. 
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3 AIMS OF THE STUDY 
Aims of the present study were: 
 
1. To identify causative mutations for congenital lactase deficiency (I). 
2. To determine the functional consequences of the C/T-13910 variant associated with 
adult-type hypolactasia both in children (II) and in adults (III). 
4. To study a potential relationship between lactase persistence and ovarian 
carcinoma (IV). 
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4 MATERIALS AND METHODS 
4.1 Study subjects 
4.1.1 Finnish CLD families and controls (I) 
Initially, family material consisted of 19 Finnish families, 27 patients and 64 healthy 
family members (Järvelä et al. 1998) at the end of the study a total number of 32 
patients, 76 healthy family members from 24 families were included. The CLD 
diagnoses were based on clinical symptoms as described elsewhere (Savilahti et al. 
1983). The carrier frequencies of the CLD mutations were determined from 556 
anonymous blood donors obtained from the Finnish Red Cross Blood Transfusion 
Service. 
 
4.1.2 LCT mRNA study in children (II) 
Fifteen Finnish children and adolescents aged 10 months to 23 years from the 
Hospital for Children and Adolescents were included in the study.  
 
4.1.3 LCT mRNA study in adults (III) 
A total of 52 patients having unspecific abdominal complaints from Herttoniemi 
Hospital participated in the study. The diagnosis for adult-type hypolactasia was 
based on lactase and sucrase activities. An L/S ratio <0.30 indicated hypolactasia. 
Lactase, sucrase and maltase activities were determined from a duodenal biopsy 
specimen based on (Dahlqvist 1984). To exclude secondary lactase deficiencies all 
biopsies underwent histological examinations. Enzyme activities were determined at 
the Laboratory of the Hospital for Children and Adolescents.  
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4.1.4 Lactase persistence and ovarian carcinoma (IV) 
The Finnish sample set consisted of 327 patients with ovarian carcinoma treated at 
the Department of Obstetrics and Gynaecology, Helsinki University Central 
Hospital throughout the years 1989-1998. The clinical diagnosis of ovarian 
carcinoma in the Finnish patients was made at the mean age of 56 years ± 14. The 
analysis of the Finnish control material was reported earlier (Enattah et al. 2002). 
Polish samples consisted of 303 patients with ovarian carcinoma treated at the 
Department of Chemotherapy, Regional oncology Centre, Szczecin, during the years 
2001-2004. The mean age of diagnosis was 54 (range 21-80) years. Control material 
consisted of 296 unselected adults. 
The 152 Swedish samples were obtained from the southern Swedish health care 
region and were diagnosed with ovarian carcinoma during 1998-2000. The mean age 
of diagnosis was 59 (range 22-82) years. This patient material has previously been 
examined for germline mutations in BRCA1 and BRCA2. The control samples were 
obtained from healthy individuals and from patients without known malignancy 
operated on at the Department of Orthopedics at the University Hospital in Lund. 
 
4.1.5 Ethical considerations 
The Ethics Committee of Helsinki University Hospital approved the lactase studies 
with a decision numbered 523/E7/2001. Written informed consent was obtained 
from the patients and controls. The ovarian carcinoma project has been approved by 
the Ethics Committee of the Department of Obstetrics and Gynecology, HUCH 
(040/95) and National Authority for Medicolegal Affairs (1129/32/300/03). As 
regards fresh tissue and blood samples informed consent has been obtained from 
each patient. The study was done in accordance with the Helsinki declaration. 
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Methods used in this study have been described in the original articles below and 
listed in Table 3. 
 
Table 3. Methods used in the study. 
    
Methods 
Original 
publication 
Bioinformatics used I 
DNA extraction with a strip method III 
RNA extraction III 
Polymerase chain reaction III 
Genotyping by Solid-phase 
minisequencing IV 
Quantitation by Solid-phase 
minisequencing III 
RT-PCR III 
Electrophoresis:   
Agarose gel electrophoresis  III 
ABI377 III 
 
4.1.6 Methods not described in the publications 
4 . 1 . 6 . 1  S e q u e n c i n g  
The PCR products (~5 μl) were cycle sequenced in a total volume of 10 μl on both 
strands with 4 μl BigDye™ Terminator RR mix, (Applied Biosystems, Perkin Elmer, 
Foster City, CA, USA) and 3.5 pmol of primers. The sequencing reaction included a 
30-second denaturation step at +96°C, a 15-second primer-annealing step at +55°C 
and a 4-minute extension step at +60°C. The sequencing reactions were cycled 25 
times and stored at +4°C. Sequenced products were electrophoresed on an ABI377 
or ABI3730 DNA Sequencher (Perkin Elmer). 
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4 . 1 . 6 . 2  M i c r o s a t e l l i t e  g e n o t y p i n g  
One of the two PCR primers of each reaction included a fluorescent label (6-FAM, 
TET, HEX) at its 5’ end. PCR products were pooled and electrophoresed with 
TAMRA 500 size marker (Applera Corporation, Norwalk, CT, USA) on an ABI 377 
(Applied Biosystems) using a 6% polyacrylamide gel. The GENESCAN 3.0 
program together with GENOTYPER 2.0 (Applera Corporation) was used for 
determining the genotypes. The genotypes were validated by two individuals, and 
organized using LINKBASE 0.952 (Suomalainen 1998 unpublished). The pedigree 
inconsistencies were checked by PEDCHECK 1.1 (O'Connell and Weeks 1998). 
 
4 . 1 . 6 . 3  S t a t i s t i c a l  a n a l y s e s  
Parametric two-point linkage analyses were performed with the recessive mode of 
inheritance assuming complete penetrance and 0.001 disease allele frequency. The 
analyses were carried out with the MLINK program of the linkage package (Lathrop 
and Lalouel 1984; Lathrop et al. 1984) using the ANALYZE 2.1 program 
(Hiekkalinna et al. 2005). Association analyses were carried out using the haplotype 
relative risk likelihood-ratio algorithm based test (HRR-LRT). In addition, LD was 
measured by a likelihood based lambda (λ) test which gives information about the 
proportion excess of a certain allele in disease chromosomes, relative to its 
population frequency (Terwilliger 1995). Haplotypes were constructed using the 
GENEHUNTER 2.1 program (Kruglyak et al. 1996) and the CLD founder haplotype 
was generated assuming that there were a minimum number of recombinations.  
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5 RESULTS AND DISCUSSION 
5.1 Results of congenital lactase deficiency (I) 
Previously, the CLD locus was assigned by linkage analysis on 2q21. LD and 
haplotype analysis appeared to restrict the critical locus between microsatellites 
D2S314 and D2S2385 (Järvelä et al. 1998). Hence, the locus excluded LCT as a 
causative gene. The observation was supported by the sequence analysis of the 
coding region of LCT that not succeeded in finding disease mutations in a Finnish 
CLD patient (Poggi and Sebastio 1991). However, sequence analyses of transcripts 
between D2S314 and D2S2385 could not identify disease-causing mutations (data 
not shown). In this study, the CLD locus was further analysed using a denser 
microsatellite map. In addition, five novel CLD families were included in the 
analyses.  
5.1.1 Linkage, linkage disequilibrium and haplotype analyses 
Fifteen microsatellite markers and C/T-13910 were genotyped covering 5.88 cM on 
2q21-2q22 in 24 families with a total of 32 affected children. Twenty-one different 
haplotypes were detected in 48 disease chromosomes (Figure 12 a). The highest 
parametric two-point LOD score of 7.24, with a θ value of 0, was achieved with 
marker D2S2385. Strong evidence for linkage with LOD scores ≥2.95 was obtained 
with all the included markers. LD was evaluated by calculation of the allelic 
association using HRR-LRT and lambda (λ) methods. The HRR-method gave 
statistically the most significant p-values of 1x10-10 and 9x10-10 with markers 
D2S314 and D2S2385, respectively. A significant LD was observed with all 
markers except D2S1334 and D2S2288, of which p-values were higher than 0.01. In 
contrast, a λ-value 0.84 gave the strongest evidence for LD with marker D2S3026 
between the previous markers, decreasing to the lowest value of 0.30 at marker 
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D2S1334. The founder haplotype, cen-5-T-13910-7-5-12-9-6-11-4-15-12-9-7-5-4-4-
tel, was present in 18 disease chromosomes from which 15 of the remaining 20 
different haplotypes have been derived (Figure 12 b). Five disease chromosomes 
each of which had a diverged haplotype and could not linked to the major haplotype. 
Haplotypes was detected to share a region that includes LCT and we carried on to 
perform sequence analysis of this gene. The haplotype and transcript map of the 
critical DNA region for CLD is shown in Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. a) Haplotypes of 24 Finnish CLD families on 2q21. Haplotypes were 
constructed using 15 microsatellites and C/T-13910. Haplotypes derived from one 
major haplotypes are highlighted. 
b) Transcript map of the critical DNA region for CLD. Lactase (LCT), 
minichromosome maintenance deficient 6 (MCM6), aspartyl-tRNA synthetase 
(DARS), chemokine receptor type 4 (CXCR4) and KIAA1679 are the known genes 
in the region (indicated by horizontal arrows). The centromere is on the left. 
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5.1.2 CLD mutations in LCT 
The LCT gene was sequenced in all 32 CLD patients in 24 families and a total of 
five different mutations were identified. Twenty-seven patients out of thirty-two 
were homozygous for a substitution of T→A at c.4170 that was designated as the 
Finmajor mutation (Table 4, Figure 13). All their parents analysed (five were not 
available) and five patients were c.4170T→A heterozygotes. The c.4170T→A 
mutation was predicted to result in a premature stop codon Y1390X in exon nine, 
thus leading to a truncation of the eight remaining LCT exons. Two patients out of 
those five Finmajor heterozygotes had a paternally transmitted deletion of four 
nucleotides, c.4998_5001delTGAG, in their other disease allele in exon 14. This 
mutation was anticipated to end in a frameshift and an early stop codon after 55 
changed amino acids (S1666fsX1722). One of those five patients had a deletion of 
two nucleotides c.653_654delCT in exon two predicting a frameshift and truncation 
at S218fsX224. The patient’s father carried the mutation. The last two mutations, 
each of which was found in a different patient, were substitutions of c.804G→C and 
c.4087G→A. They are expected to result in amino acid substitutions of histidine for 
glutamine at Q268H and serine for glycine at G1363S in exon 3 and 14, 
respectively. Two patients were heterozygous for Q268H or G1363S and Finmajor. 
Both mutations were detected to be as a maternal origin. In addition, the 
c.4087G→A mutation was carried by a healthy sibling in the family. The CLD 
mutations and corresponding lactase activities of duodenal biopsy specimens are 
shown in Table 4. 
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Table 4. Identified CLD mutations in the LCT gene and detected lactase 
activities of duodenal biopsy specimens. 
   
Mutation 
Consequence in 
protein Exon
Mean lactase 
activities  
U/g protein (range) 
c.4170T→A  Y1390X 9 2.4 (0-7) 
c.4998_5001delTGAG S1666fsX1722 14 5 (3-7) 
c.653_654delCT  S218fsX224 2 2 
c.804G→C  Q268H 3 5 
c.4087G→A  G1363S 9 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. CLD mutations in the LCT gene. DNA sequence chromatograms of 
five identified CLD mutations, a-e. Mutation Y1390X (a) is homozygote, whereas 
the rest of mutations are heterozygotes. The first row shows affected and the second 
row wild type sequences. 
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5 . 1 . 2 . 1  T h e  i m p a c t  o f  F i n m a j o r  o n  L C T  t r a n s c r i p t i o n  
To explore the consequence of the Finmajor mutation at the mRNA level, LCT 
transcripts were analyzed using total RNA extracted from duodenal biopsies of a 
five-year old patient and five control subjects aged 6.7-17 years (Table 1, Study II). 
The patient was heterozygous for Finmajor and C/T-13910 that defines the lactase non-
persistence/persistence phenotype. The patient’s duodenal lactase activity was 6 U/g 
of protein and the L/S ratio was 0.08. All control subjects had the C/T-13910 genotype 
and lactase activity (determined from four subjects) ranged between 21-29 U/g of 
protein and L/S ratio between 0.28-0.62. RT-PCR followed by solid-phase 
minisequencing was employed to quantitate mRNA levels using an informative SNP 
G/A+593 in LCT. The T-13910 allele of the control subjects was expressed about five 
times higher than the downregulated C-13910 allele. On the contrary, the T-13910 allele 
carrying the Finmajor was not able to maintain the LCT expression. The phenomenon 
is probably due to nonsense-mediated mRNA decay (NMD). This mechanism is 
harnessed to eliminate the production of potentially harmful truncated proteins 
degrading the nascent mRNA (Maquat 2005). 
 
5.1.3 Genealogy and carrier frequencies of the CLD mutations in 
Finland 
On the basis of the genealogical studies Finmajor and S1666fsX1722 mutations were 
tracked to central and northern Finland, respectively. Mutations S218fsX224, 
Q268H and G1363S were traced in eastern Finland. The carrier frequency for the 
CLD mutations was determined among 556 anonymous donors representing both the 
early and the late settlement regions of Finland (Figure 14). Carriers of the Finmajor 
were found in all towns analyzed locating in later settlement regions. The highest 
carrier frequency of was found in Nilsiä 1:35 (4/140) predicting an incidence of 
~1:4800 for CLD in this particular region. In this region, a cluster of the ancestors 
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was also trailed using church book records (Järvelä et al. 1998). No carriers for the 
four more rare CLD mutations were observed in any subpopulation screened. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Carrier frequency of the Y1390X mutation in four subpopulations of 
Finland. Modified from Study I. 
 
5.2 Discussion of congenital lactase deficiency 
CLD patients suffer from deficiency of lactase activity in the intestinal lumen. Thus, 
infants, fed breast or other lactose containing milks, are exposed to substantial 
watery diarrhea that risks normal growth and development. Breast milk is, 
indisputably, an essential source of nutrition postnatally. For example, antibodies of 
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mother’s milk stimulate infants’ immune systems to protect them from fatal 
infections. The importance of lactose is indicated by the fact that breast milk 
contains 6.5% of lactose that represents 37% of its energy resource (Fineli, National 
Public Health Institute, Finland). Furthermore, acidic lactose facilitates the 
development of the valuable colonic bacterial floor of newborns.  
It took nearly a half of the century to unravel the molecular background of CLD as 
the very first patients were described already in 1959 (Holzel et al. 1959). In this 
study, five distinctive mutations in the LCT gene underlying this disease are finally 
reported. The mutation Y1390X was found to be the prevailing one as 90% (43/48) 
of disease chromosomes carried the mutation. The observation is considered to 
reflect the founder effect of the Finnish population. The rest of the mutations were 
rare being specific to one or two families only. 
As described in chapter 2.2.3 lactase is synthesized as a precursor of 1927 amino 
acids. The lactase precursor includes a pro-domain (repeats I and II) and an active 
domain (repeats III and IV), which possesses the catalytically active sites for 
phlorizin hydrolase and lactase (Figure 15). The pro-domain functions as an 
intermolecular chaperone assisting in the formation of the functional enzyme 
complex. It is cleaved off in the Golgi complex yielding the mature enzyme. 
Mutations G1363S, Y1390X (Finmajor) and S1666fsX1722 hit directly in the active 
domain while S218fsX224 and Q268H were found in the pro-domain. Finmajor and 
S1666fsX1722 truncate lactase polypeptide at repeat IV and S218fsX224 at repeat I. 
Finmajor was observed not be able to retain LCT expression probably affecting the 
stability of LCT mRNA directing the mutated transcript to NMD. NMD is across 
eukaryotes a conserved mRNA surveillance mechanism that verifies that mRNA has 
the appropriate quality for translation. NMD prevents the production of potentially 
fatal truncated proteins created by premature termination codons (Wagner and 
Lykke-Andersen 2002; Maquat 2005). However, premature termination codons 
closer than 50 nucleotides upstream of the last intron escape from NMD. This allows 
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accumulation of mutant protein resulting in a dominant negative effect as observed 
in dominant forms of β-thalassemia and Marfan syndrome (Baserga and Benz 1988; 
Frischmeyer and Dietz 1999). Although, NMD has been observed to link with 
nonsense mutations they hardly had enough evolutionary pressure to maintain the 
mechanism. Indeed, NMD has been observed to regulate normal cellular processes 
and mute genomic noise (Carter et al. 1995; Mendell et al. 2004). Lactase activity 
and its mobility on polyacrylamide gels were studied in duodenal biopsies of three 
of our CLD patients with Finmajor. In this preliminary study, brush-border lactase 
protein and activity was barely detectable, which supports undisputedly the NMD 
hypothesis (Freiburghaus et al. 1976). Alleles with frameshift mutations, 
S218fsX224 and S1666fsX1722, resulting eventually in stop codons may also be 
guided to NMD. Q268H substitutes the alcaline histidine for an uncharged 
glutamine and was found in LCTα the intramolecular chaperone. Q268H may affect 
the structure of LCTα disturbing the maturation process of lactase polypeptide. 
G1363S substitutes a small glycine for a reactive serine. The mutation locates close 
to catalytically active sites possibly changing the three-dimensional structure of the 
LCT polypeptide hence, inactivating the enzyme. The importance of the Q268 and 
G1363 residues are indicated by the fact that they are conserved across the species. 
The schematic structure of lactase polypeptide and the location of the five CLD 
mutations are illustrated in Figure 15. 
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Figure 15. Structure of the translated lactase polypeptide and the location of 
the identified CLD mutations. The primary translation product (pre-pro-LCT) 
contains 1927 amino acids. The pro-LCT consists of four homologous repeats (I-
IV). Repeats I and II are located in the pro-domain while repeats III-IV are found in 
the mature lactase (Mantei et al. 1988). Mutations S218fsX224 and Q268H were 
identified in LCTα that functions as an intramolecular chaperone. Mutations 
G1363S, Y1390X and S1666fsX1722 were found in mature lactase. 
 
Regional clusters of CLD in the late settlement region of Finland, the rareness of 
disease, and the detected ~6 cM interval for LD indicate a fairly late introduction of 
the disease alleles into the population. The timing is expected to coincidence with 
many of the diseases in the Finnish disease heritage like IOSCA whose disease 
alleles were estimated to have been introduced before the major internal population 
movement to the inland in the 1500s some 30 generations, 750 years ago (Varilo et 
al. 1996). 
Contrary to the rare CLD, lactase non-persistence is a common enzyme deficiency 
worldwide. Lactase activity in adult-type hypolactasia declines to a mean value of 
5.9 U/g protein (Study III) differing significantly from the CLD patients’ mean 
value of 2.4 U/g protein [t(36) = 5.0; p = 0.0001]. Interestingly, the CLD Finmajor 
mutation was found in the background of the lactase persistent allele, T-13910, in 
Finns. As showed in this study, some Finmajor carriers with the C/T-13910 genotype 
may suffer from lactose-related symptoms after downregulation of the C-13910 allele.  
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5.3 Results of LCT mRNA studies 
5.3.1  LCT expression and quantitation in children (II) 
Fifteen subjects of forty-five (33%) were observed to be heterozygous for the 
A/G+593 polymorphism residing in exon 1 of the LCT gene and, thus their intestinal 
biopsies could be used for further analyses. Twelve of them were heterozygous for 
the lactase persistent C/T-13910 and three were homozygous for the lactase non-
persistent C/C-13910 genotype (Table 5). The subjects with the C/T-13910 genotype 
(age range: 10 months to 17 years) had high lactase activity, ranging from 21 to 113 
U/g of protein. 
 
Table 5. Lactase activities, L/S and allelic ratios in children. 
 
 
 
 
 
 
 
 
 
 
 
ND not determined 
 
1.1 C/C 52 ND ND
5.0 C/C 51 24 0.28
22.8 C/C 49 6 0.08
0.8 C/T 48 85 1.11
1.1 C/T 52 113 1.02
4.0 C/T 48 31 0.49
4.3 C/T 42 53 0.48
4.7 C/T 40 40 0.62
4.9 C/T 42 ND ND
6.7 C/T 18 22 0.28
7.6 C/T 16 ND ND
11.1 C/T 13 29 0.54
14.9 C/T 17 21 0.40
17.0 C/T 24 29 0.62
L/S ratioAge (years) Genotype 
(C/T-13910)
C-13910 expressed 
(%)
Lactase activity 
(U/g protein)
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A standard curve was prepared for the G/A+593 of the LCT gene. An equal level of 
lactase mRNA was transcribed from both C-13910 and T-13910 allele in children 
younger than 5 years. In those aged between 4 and 5, a decline in the lactase mRNA 
transcribed from the C-13910 allele started to appear. In the children aged four to five 
years, the relative expression from the C-allele was 48% in two cases and, 40-42% 
in another three. In children aged six and seven years relative LCT mRNA 
expression was reduced to 18% and 16%. In children >6 years of age the relative 
expression was reduced to 13-24 % of the expression from that of the T-13910-allele 
(see Figure 16, and Table 5). In contrast, in children with the C/C-13910 genotype the 
relative expression from both alleles was equal as expected.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Relative proportion of LCT expressed by the C-13910 allele. 
5.3.2 LCT expression in adults (III) 
Relative allelic expression of LCT transcripts was studied using 52 patients. Eleven 
of the 52 patients (21%) were observed to be hypolactasic with lactase activities (4-9 
U/g), L/S ratios (0.05-0.18), and genotypes C/C-13910 and G/G-22018. Twenty-three 
(44%) patients’ lactase activities ranged between 13-49 U/g, their L/S ratios from 
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0.35 to 0.69 and they were heterozygous for C/T-13910 and G/A-22018. Eighteen of the 
52 (35%) patients were homozygous for T/T-13910 and A/A-22018 and their lactase 
activities ranged from 18 to 87 U/g and their L/S ratios from 0.49-1.05 (Figure 17). 
Using Fisher’s exact test, the statistically significant difference between each 
genotype and their corresponding L/S ratios was found to have a p-value <0.0001. 
 
 
 
 
 
 
 
 
 
 
Figure 17. Correlation of LCT genotypes with L/S ratios. The effect of the T-13910 
variant was observed as elevation of L/S ratio, (p<0.0001). 
 
5 . 3 . 2 . 1  Q u a n t i t a t i o n  o f  L C T  m R N A  l e v e l s  
The most informative single nucleotide polymorphisms (cSNPs) in the coding 
region of the LCT gene are located in exon 1 (c.593G→A) and exon 17 
(c.5578C→T) in the Finnish families. These cSNPs were primarily chosen to 
quantify the relative mRNA levels. Twenty-two of fifty-two (42%) were found to be 
heterozygous for one or both of these cSNPs. Novel single nucleotide 
polymorphisms were searched for in the 30 uninformative patients by direct 
sequencing of exons 2, 6, 10, and/or 13. Six patients were found to be informative at 
least for one of the sites. Seventeen of the remaining 24 patients, were homozygous 
for T/T-13910, A/A-22018, 7 of those 24 were heterozygous for C/T-13910, G/A-22018. 
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Thus, 11 hypolactasic patients, 16 lactase persistent heterozygous and one lactase 
persistent homozygous could be further analysed for relative allelic expression. 
To relate the actual difference in the expression of the LCT alleles in the 
minisequencing assay a standard curve was prepared for the G/A+593 cSNP in exon 
1. The relative quantitation of the LCT alleles showed that the persistent allele 
represented 92% +/- 6% (mean +/- standard error of mean, range 78-99%, n=14) of 
the total LCT mRNA quantity. A clear increase in the R-value, suggesting allelic 
asymmetry of LCT mRNA expression, was also seen independently when 
quantitation was performed for any of the cSNPs located in exons 1, 2, 6, 10, 13, or 
17 (Table 6). Hypolactasic patients with the C/C-13910 and G/G-22018 genotypes had 
equal expression of both alleles (47% +/-1%, n=7). Only one subject homozygous 
for lactase persistent T-13910, A-22018 had an informative SNP of the coding region of 
the LCT gene. This individual equally expressed both LCT alleles (Table 6).  
 
Table 6. The genotypes of each patient and their expressed allelic ratio of the 
LCT gene. 
 
5.4 Discussion of LCT mRNA studies (II, III) 
The decline of lactase activity after childhood, adult-type hypolactasia, is probably 
the best-known enzyme deficiency in humans. Hence, it has inspired scientists to 
study its occurrence for a century. The development and creation of methods in the 
  Genotype Cpm ratio of the cSNPs of the LCT gene 
Diagnosis N C/T-13910/ G/A-22018 
Exon1  
A/G 
Exon6  
G/T 
Exon10 
G/A 
Exon13 
C/T 
Exon17 
C/T 
Hypolactasic 11/11 CC/GG 0.58-0.70 - 1.1 1.3-1.4 1.5-4.7 
Lactase 
persistent  16/23 CT/GA 3.3-37 - 5.5-7.6 - 13-64 
Lactase 
persistent  1/18 TT/AA - 1.6 - - - 
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natural science over the last two decades has provided opportunities to approach this 
dilemma at the molecular level. As discussed in section 2.4.3.2 ‘Mechanism of 
downregulation’, the downregulation of lactase activity has been suggested to 
operate at the transcriptional and/or posttranscriptional level. This enigma climaxed 
in Enattah and his colleagues’ (2002) linkage disequilibrium and haplotype studies 
in Finnish families, which exposed two variants associated with adult-type 
hypolactasia supporting the transcriptional regulation theory.  
In this study, those variants affecting the developmental changes in LCT expression 
was evaluated in biopsy specimens by determining the biological activities of lactase 
and sucrase and quantitating the mRNA levels by solid-phase minisequencing in 
Finnish children and adults. In children the C-13910 allele, determining lactase non-
persistence, declined by the age of six years (Figure 18). In children aged six years 
or more the C-13910 allele contributed only 13-24% to the produced LCT mRNA. The 
age of LCT mRNA was observed to decline is pretty well to scale with that of the 
age of downregulation of lactase activity in Finnish children (Sahi 1994a; Rasinperä 
et al. 2004). However, the age when downregulation takes place varies between 
populations. In Thai children the downregulation event was observed between one 
and two years of age (Keusch et al. 1969a). In African children, the decline of 
lactase activity was detected from three years of age (Rasinperä et al. 2004). A 
British study of different ethnic groups demonstrated that the decline of LCT mRNA 
expression was detected from the second year of life (Wang et al. 1998b). The 
spatial and temporal gene regulation involved in the timing of LCT decline is so far 
unsolved. Timing variables should be taken into account when the usefulness of the 
genetic testing of C/T-13910 for adult-type hypolactasia is estimated. Tests before the 
age of downregulation occurs can lead to diminished milk consumption too early. 
Thus, positive effects of milk may be remained unexploited. The determination of 
C/T-13910 after 8-12 of years is considered to reflect the lactase phenotypes reliably 
(Rasinperä et al. 2004). In adults, the effect of a persistent allele T-13910 A-22018 was 
seen in elevation of lactase activity that was furthermore observed in significant 
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correlations in lactase activities between all the three genotypes C/C-13910 G/G-22018, 
C/T-13910 G/A-22018, and T/T-13910 A/A-22018. The quantitation of relative LCT mRNA 
levels showed a clear difference between patients with lactase persistent and non-
persistent genotypes. The lactase persistent allele, T-13910 A-22018, had an average 
11.5-fold higher expression than the non-persistent allele, C-13910 G-22018 (Figure 18). 
Lactase non-persistence patients having the C/C-13910 G/G-22018 genotype, and 
patients homozygous for lactase persistent with the T/T-13910 A/A-22018 genotype 
evenly expressed both alleles. These observations unambiguously show that the 
variants C/T-13910, G/A-22018, associated with adult-type hypolactasia, are also 
associated with the transcriptional regulation of the LCT gene. These results agree 
with previous findings that indicated that the decline of lactase activity is regulated 
at the transcriptional level (Escher et al. 1992; Lloyd et al. 1992; Fajardo et al. 1994) 
operating by a cis-acting element (Wang et al. 1995; Wang et al. 1998b). 
Both the SNPs, C/T-13910 and G/A-22018, are located in introns of MCM6, which 
locate at 5’-end of LCT. MCM6 is a mammalian homologue of mis5 of yeast, it 
functions as a cell cycle factor (Takahashi et al. 1994). MCM6 is expressed in a 
variety of human tissues including intestine. Intestinal expressions of MCM6 and 
LCT were not observed to correlate with subjects of lactase persistence or non-
persistence suggesting that these genes are independently regulated (Harvey et al. 
1996). So, obviously the influence of the MCM6 gene on adult-type hypolactasia is 
only structural. The observation was confirmed later when the C/T-13910 construct 
was not able to activate the MCM6 promoter (Lewinsky et al. 2005). 
Recently, studies have been focussed to clarify the functional role of the C/T-13910 
G/A-22018 variants. Two studies using human (Troelsen et al. 2003b) and rat (Olds 
and Sibley 2003) LCT promoter-reporter gene construct analyses with C/T-13910 
region in Caco-2 cells demonstrated independently differential regulation of LCT 
promoter activity. Furthermore, EMSA showed that the observed difference was a 
consequence of the binding capacity of the nuclear factors for the C-13910 and T-13910 
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allele constructs (Troelsen et al. 2003b). The T-13910 variant had a stronger 
interaction than C-13910 suggesting a model for the T-13910 as a strong transcriptional 
enhancer. Similar analyses of the G/A-22018 variant did not reveal any significant 
functional role for phenotype differences of lactase persistence/non-persistence 
(Olds and Sibley 2003; Troelsen et al. 2003b).  Later, DNA affinity purification 
analyses showed that Oct-1 binds directly to the C/T-13910 variant co-purifying with 
GAPDH and furthermore, the binding was detected to be stronger to the T-13910 
variant than the C-13910 variant. DNase footprint and supershift analyses identified 
binding motifs for Cdx-2, GATA-6, Fox and HNF-4α in the close proximity of C/T-
13910. In mutation analyses, GATA-6, Fox and HNF-4α motifs were detected to be 
necessary for the pursuit of the C/T-13910 enhancer. Co-transfection analyses with 
C/T-13910 demonstrated that Oct-1 was able to activate LCT promoter only with 
HNF-1α. Interestingly, a HNF-1α site has not been found within the C/T-13910 
enhancer but it probably is acting via a proximal promoter, which has a HNF-1α 
binding site. The results are convincing. The C/T-13910 variant seems to locate in the 
heart of an enhancer structure consisting of Oct-1, GATA, Fox and HNF-4α binding 
sites (Figure 18). Oct-1 with the C/T-13910 sequence directs specifically the LCT 
promoter activity and enhances reporter gene expression with the T-13910 variant 
significantly over the C-13910 variant. These discoveries offer a plausible model for 
the T-13910-induced lactase persistence phenotype in humans (Lewinsky et al. 2005). 
Although, we have learned a great deal about the molecular background of the 
lactase persistence phenotype the virtual cascade that leads to activation of the LCT 
gene is still obscure. Interestingly, Oct-1 has been reported to recruit co-factors for 
chromatin structure enhancing or silencing genes depending on the tissue type or 
promoter structure (Zabel et al. 2002; Remenyi et al. 2004). A similar mechanism 
was also considered as a potential one for the lactase persistence phenotype 
(Lewinsky et al. 2005). The T-13910 allele has been demonstrated to match the 
functional, phenotypic and epidemiological data of European and European derived 
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populations (reviewed in section 2.4.3 ‘Genetics’). It has been reported that 
statistically the T-13910 allele could not explain the lactase persistence incidence in 
some African populations (Mulcare et al. 2004). If carefully characterized 
phenotypes can confirm the results, there are still unidentified variants to be found, 
which probably will provide their own interesting characteristics to explain the 
lactase persistence mechanism. 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Regulation of the LCT gene – an overview. Regardless of the genotype 
of the C/T-13910 enhancer, LCT is fully expressed up to five years of age. The C-13910 
variant has weaker interaction with Oct-1 than the T-13910 variant (Lewinsky et al. 
2005), hence yet unknown mechanism allows the downregulation of the C-13910 
allele at the age of six (Study II). In contrast, the T-13910 allele maintains LCT 
expression and is responsible for an average 92% of expressed LCT mRNA (Study 
III). 
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5.5 Results of lactase persistence and ovarian carcinoma (IV) 
Lactase persistence had no statistically significant effect on the development of 
ovarian carcinoma in the Finnish, Polish or Swedish populations. Combined analysis 
of all three populations showed no significant risk for ovarian cancer (Figure 19). In 
addition, dissecting ovarian carcinoma tumours by histological subtypes for analyses 
did not affect the outcome (Table 1, Study IV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Molecularly defined lactase persistence and its risk to ovarian 
carcinoma pathogenesis in the Finnish, Polish and Swedish populations. 
*Mantel-Haenszel common odds ratio estimates, (CI) confidence interval. 
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The frequency of the C/C-13910 genotype was detected as 33.1% in the Polish 
controls. This was a bit lower than the earlier reported incidence of lactase non-
persistence (37.5%) diagnosed by BHT in the Polish population (Socha et al. 1984) 
In Swedish controls, the C/C-13910 frequency was observed to be 10.3% which is in 
concordance with the recently observed occurrence of C/C-13910 (9.6%) in the 
Swedish population (Nilsson TK personal communication). 
 
5.6 Discussion of lactase persistence and ovarian carcinoma 
Ovarian cancer is a deadly disease among women with a high incidence in western 
industrialized countries (World Cancer Research Fund 1997). Epithelial ovarian 
cancer (ovarian carcinoma) is the major cancer type explaining 90% of ovarian 
cancer cases. The aetiology is still for the most part unravelled but both genetic and 
environmental factors affect the pathogenesis. The pathogenesis has been studied 
intensively tracing frequent ovulation cycles and hormonal issues as contributory 
factors to the disease. Dietary factors particularly a high consumption of milk 
(lactose) and lactase persistence which is closely related its consumption have been 
put forward as risk factors for ovarian tumour genesis (Cramer 1989). Galactose, the 
hydrolysing product of lactose, was observed to be toxic to oocytes in animals 
studies (Chen et al. 1981; Schwartz and Storozuk 1988). Thus, galactose has been 
hypothesized to promote the development of ovarian carcinoma. In order to test the 
hypothesis, the C/T-13910 variant that specifies lactase phenotypes, was defined in 
ovarian carcinoma patients and compared with healthy controls in the Finnish, 
Polish and Swedish populations. We observed that lactase persistence had a modest 
reduced effect (OR 0.77) on ovarian carcinoma risk but the trend was not 
statistically significant. Lactase persistence did not associate with the ovarian 
carcinoma risk either in the Polish or Swedish populations. The results might be 
related to the fact that Finnish milk consumption is the highest in the world (The 
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World Dairy Situation 2003). Lactase persistence facilitate milk’s use as a nutrition 
which has been noted as an increasing milk consumption (Obermayer-Pietsch et al. 
2004; Rasinperä et al. 2004; Rasinperä et al. 2006). However, these observations 
cannot replace the dairy consumption data of subjects of this study. As reviewed in 
chapter 2.5.1.1 ‘Dairy consumption and ovarian carcinoma risk’ many studies have 
tried to shed light on the risks or benefits of milk and its components for ovarian 
tumour genesis. But there is not been any breakthroughs concerning the issue. Meta-
analyses have shown that only large prospective cohort studies show a modest 
increased risk between high milk consumption and ovarian carcinoma (Genkinger et 
al. 2006; Larsson et al. 2006). Interestingly, the same trend was observed in a meta-
analysis between milk consumption and colorectal cancer (Norat and Riboli 2003). 
Thus, large sample sizes probably play a role in these kinds of studies. 
Milk is a versatile nutrient and an important source of calcium and many other traces 
and vitamins (Table 2). For example, dietary calcium has been observed to decrease 
bone fracture risk and to prevent osteoporosis in adulthood (Gueguen and Pointillart 
2000; Prentice 2004). Milk has also been regarded as benefit for early farmers since 
the lactase persistence mutation arouse 5000-10000 years ago. The selection power 
of lactase persistence is the strongest seen in the human genome (Cavalli-Sforza 
1973; Heston and Gottesman 1973; Flatz and Rotthauwe 1977; Aoki 1986; Flatz 
1987; Bersaglieri et al. 2004). Perhaps, an abstemious consumption brings the best 
out of milk also today. The results of our study do not support the hypothesis that 
lactase persistence promotes the development of ovarian carcinoma. 
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6 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
There are two different types of lactase deficiencies in humans; a rare recessively 
inherited CLD and a common so-called adult-type hypolactasia with milder features. 
CLD belongs to the Finnish disease heritage and is caused by mutations detected in 
the translated region of lactase, which is responsible for hydrolysing lactose in the 
intestine. In this study, five unique mutations were found in 32 patients in 24 
families. They all were expected to inactivate mucosal lactase activities. Mutation 
Y1390X, Finmajor, is anticipated to direct LCT transcripts to NMD that is typically 
the consequence of premature stop codons. A detailed analysis of impact of other 
four mutations on the development of CLD should be conducted in the future. 
Especially, Q268H and G1363S mutations can bring new insights for the mechanism 
of lactase maturation and for crucial sites of activities of lactase and phlorizin 
hydrolase. From the clinical viewpoint, this study has created a direct DNA-based 
diagnosis and a carrier identification of CLD that has thus far been relied on clinical 
symptoms completed by lactase activity analysis from duodenal biopsy specimens. 
The development of adult-type hypolactasia, lactase non-persistence, is dependent 
on a variant C/T-13910 locating 13.9 kb upstream from LCT (Enattah et al. 2002). In 
this study, the C-13910 allele was detected to allow the transcriptional downregulation 
of LCT. The timing of the downregulation was detected at the age of six. In adults, 
the T-13910 allele represented a mean 92% of the expressed LCT mRNA when 
compared with the C-13910 allele. The C/T-13910 variant locates in the middle of 
enhancer element consisting of Oct-1, GATA, Fox and HNF-4α binding sites. Oct-1 
was demonstrated to bind directly to the C/T-13910 site. It has been speculated that 
Oct-1 may induce chromatin changes and activate LCT (Lewinsky et al. 2005). The 
major goal of future functional studies will be to clarify which genes are directly 
involved in transcriptional downregulation of LCT. For example, evidence of 
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activated or inactivated genes can be traced from duodenal biopsies by an 
Affymetrix array. It remains also unknown which variants and/or mechanisms are at 
the background of lactase persistence in some African and Arabia nomads.  
Milk is a significant part of the Northern European and American diet. Milk’s 
lactose has been suggested to be a risk factor for the development of ovarian 
carcinomas. As lactase persistence is associated with increased milk consumption, 
C/T-13910 was tested in ovarian carcinoma patients and in the Finnish, Polish and 
Swedish populations. Lactase persistence did not associate with ovarian carcinoma 
risk in any of the populations tested. Multiple studies have been conducted in an 
attempt to shed light on dietary milk and its components in relation to ovarian 
tumour genesis (section 2.5.1.1). However, the results have remained controversial 
possibly reflecting the fact that milk has no cancer promoting effect on the ovary. 
On the other hand, components of milk are hard to dissect in this type of studies. 
Cell line studies are a more exact approach to study promoting or inhibiting factors 
of tumour growth. For example, high concentrations of 1,25 dihydroxyvitamin D has 
been detected to inhibit human ovarian cancer cell lines (Ahonen et al. 2000; 
Miettinen et al. 2004). However, only two case-control studies have shown that 
dietary vitamin D diminish ovarian carcinoma risk (Bidoli et al. 2001; Salazar-
Martinez et al. 2002). Ovarian cancer is a deadly disease, about 110000 women per 
year perishes from the disease in the world (Parkin et al. 2001). Even if some genes 
have found to be causal for the disease, the background of the most of cases has 
remained obscure. It is probable that eventually efforts will recompense those 
involved in the research and their findings pave the way for risk factors and 
mechanisms underlying ovarian carcinoma. It is hoped that new diagnostic markers 
would permit more accurate and specific diagnosis and offer new tools for drug 
development for this lethal cancer. 
 
 
 90 
7 ACKNOWLEDGEMENTS 
This research was carried out in the Department of Molecular Medicine at the 
National Public Health Institute in Helsinki and in the Department of Medical 
Genetics at the University of Helsinki. I want to thank the former and the present 
heads of the National Public Health Institute Jussi Huttunen and Pekka Puska for 
providing excellent research facilities. 
The pride and joy of our laboratory my supervisor Docent Irma Järvelä is thanked 
for giving me the opportunity to work in this project. I am grateful to her for 
introducing me the world of molecular genetics. I want to thank her for educative, 
endless and amusing scientific and non-scientific talks during my time here. I wish 
to thank Academy Professor Leena Peltonen-Palotie for her interest toward my work 
and for supporting me with her great knowledge in science. I want to thank her for 
the educative, exciting and inspiring discussions that have given me a drive for my 
scientific career.  
I would like to thank Professor Helena Kääriäinen for accepting the role as 
Opponent in my thesis defence. 
Professor Mikko Hallman and Docent Johanna Schleutker are thanked for reviewing my 
thesis. Their constructive comments cannot be praised enough. Bachelor of Science 
M.A. Donald J.M. Smart is acknowledged for language revision of this thesis. 
I wish to thank excellent clinicians Professor Erkki Savilahti, Docent Jorma 
Kokkonen, Aino Oksanen MD, PhD and Docents Ralf Bützow and Kaija-Leena 
Kolho. Their contributions to my work have been priceless and discussions fruitful. 
Docent Arto Orpana is thanked for the brilliant guidance of the mRNA quantitation 
and for pieces of advice concerning research in general. I would like to thank Docent 
Teppo Varilo for the genealogical studies of CLD and for his cheerful company in 
the laboratory.  
 91 
I wish to thank Docent Marjo Kestilä for her many, many helpful discussions and 
guidance and interest toward my research. You always had a time for me! Senior 
Docents Ismo Ulmanen and Anu Jalanko are warmly thanked help in various matters 
in the lab. Iski is also thanked for organizing numerous unforgettable excursions. 
I would like to thank Professor Jan Lubinski, and Doctors Krzysztof Medrek, Susanne 
Malander and Mef Nilbert for the collaboration in the ovarian carcinoma study (IV).  
I wish to thank the members of the lactase group Nabil Enattah and Heli Rasinperä 
for the help in the lab and for interesting discussions during these years. Especially, 
issues concerning the right colour of stockings and the lost of a missile in the desert 
have been memorable.  
Tero Ylisaukko-oja is thanked for his friendship, support, brilliant and not so 
brilliant (if possible) conversations with a wide perspective. I think we have shared a 
few laughs and theories. Knowing you has been a pleasure. Thanks also for 
badminton and tennis matches but do not worry as Niklas stated in his thesis “se 
kasvattaa luonnetta”. 
Hanna Komu is acknowledged for her skilful handling of lab tasks. Karola 
Rehnström is thanked for her cheery personality, beautiful smile and introducing the 
blond perspective in the lab. Elli Kempas is thanked for the help and guidance of 
various methods. The newcomer of the lactase group Suvi Torniainen and former 
and present lab members of Irma: Anne Koivisto, Susanna Lemmelä, Ilona 
Nummela, Sanna Seitsonen, Ulla Sundström, Hanna Nurmi, Sini Penttilä, Kristiina 
Pulli, Selina Mäkinen and Mari Rossi are acknowledged for their joyful company. 
I would like to thank Teemu Perheentupa and Jari Raikko for solving computer-
related problems and good conversations. Teemu is thanked for introducing me 
crisis meetings on Fridays. 
The sequencing lab run by Pekka (Charlie) and the Angels Heli, Susanna and Tiina 
thanked for their swift and accurate analyses and happy company. Niklas is thanked 
 92 
for his tennis lessons. I would like to thank past and present members of the 
department. Iiris, Olli, Iita, Heli, Mira, Anna, Anne, Kati, Maria, Jesper, Henna, 
Jani, Kaitsu, Juha I, Juha P, Nina, Tarja, Outi, Tintti, Annina, Juho, Juha S, Minna, 
Ritva, Arja, Päivi, Sisko, Jussi, Heidi, Elina, Tanja, Markus P, Markus, Ville H, 
Kaisu N, Kaisu L, Katri, Laura, Nora, Ville K, Tero H, Juri, Kaisa, Johanna S, 
Mervi, Janna, Minttu, Anu, William, Joe, Emma, Marika, Joni, Tiina P, Anne N and 
many others are thanked for cheerful company in the lab. Secretaries Sari Kivikko, 
Sari Mustala, Tuija Svahnbäck are thanked for the help whenever I needed. I wish to 
thank Jouni, Tuomo and Katja, Teemu, Kortsu, Junnu, Isto and Marika, Vesa and 
Tarja, Tomi, Janne, Jani, Olli, Kimmo, Terho and Jenni, Tauno and Seija for their 
friendship and activities in real life.  
I owe my gratitude to my parents Jorma and Pirkko and my sisters Riitta and Virpi, 
without their support and care this study would have been impossible. 
I owe my deepest gratitude to my wife Kirsi, her patience, love and care have been 
precious. 
I wish to thank the patients and families for participating in the study. 
This study has been financially supported by grants from the Finnish Cultural 
Foundation, Biomedicum Helsinki Foundation, the Sigrid Jusélius Foundation, 
Helsinki University Hospital Research Funding and the Center of Excellence in 
Disease Genetics of the Academy of Finland. 
Helsinki, 16th of November 2006 
Mikko Kuokkanen 
 93 
8 ELECTRONIC DATABASE INFORMATION 
Basic Local Alignment Search Tool, http://www.ncbi.nlm.nih.gov/blast/ 
Baylor College of Medicine, http://searchlauncher.bcm.tmc.edu/ 
Expressed Sequence Tags Database, http://www.ncbi.nlm.nih.gov/dbEST/ 
Finnish Disease Database, http://www.findis.org./ 
Fineli, Finnish Food Composition Database, http://www.fineli.fi/index.php?lang=en 
GenBank, http://www.ncbi.nlm.nih.gov/  
GENSCAN, http://genome.dkfz-heidelberg.de/cgi-bin/GENSCAN/genscan.cgi 
Genome Database, http://gdbwww.gdb.org/ 
Marshfield Medical Genetic Foundation, http://research.marshfieldclinic.org/ 
National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/ 
Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim/ 
Reference Sequence Database, http://www.ncbi.nlm.nih.gov/RefSeq/ 
SWISS-PROT, http://www.ebi.ac.uk/swissprot/  
University of California, Santa Cruz, http://genome.ucsc.edu/ 
 
 94 
9 REFERENCES 
 
Aaltonen J, Björses P, Sandkuijl L, Perheentupa J, Peltonen L (1994) An autosomal locus causing 
autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 
21. Nat Genet 8:83-7. 
Abbas H, Ahmad M (1983) Persistence of high intestinal lactase activity in Pakistan. Hum Genet 
64:277-8 
Ahmad M, Flatz G (1984) Prevalence of primary adult lactose malabsorption in Pakistan. Hum 
Hered 34:69-75 
Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P (2000) Androgen receptor and vitamin 
D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J 
Cancer 86:40-6 
Aittomäki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila 
EM, Lehvaslaiho H, Engel AR, et al. (1995) Mutation in the follicle-stimulating 
hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 
82:959-68. 
Alard P, Lantz O, Sebagh M, Calvo CF, Weill D, Chavanel G, Senik A, Charpentier B (1993) A 
versatile ELISA-PCR assay for mRNA quantitation from a few cells. Biotechniques 
15:730-7. 
Alwine JC, Kemp DJ, Stark GR (1977) Method for detection of specific RNAs in agarose gels by 
transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc Natl 
Acad Sci U S A 74:5350-4. 
Aminoff M, Carter JE, Chadwick RB, Johnson C, Grasbeck R, Abdelaal MA, Broch H, Jenner LB, 
Verroust PJ, Moestrup SK, de la Chapelle A, Krahe R (1999) Mutations in CUBN, 
encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary 
megaloblastic anaemia 1. Nat Genet 21:309-13. 
Aoki K (1986) A stochastic model of gene-culture coevolution suggested by the "culture historical 
hypothesis" for the evolution of adult lactose absorption in humans. Proc Natl Acad Sci 
U S A 83:2929-33 
Ardlie KG, Kruglyak L, Seielstad M (2002) Patterns of linkage disequilibrium in the human 
genome. Nat Rev Genet 3:299-309 
Armitage P, Berry G (1987) Statistical Methods in Medical Research. Blackwell Scientific 
Publications, Oxford 
Arola H (1994) Diagnosis of hypolactasia and lactose malabsorption. Scand J Gastroenterol Suppl 
202:26-35 
 95 
Arribas JC, Herrero AG, Martin-Lomas M, Canada FJ, He S, Withers SG (2000) Differential 
mechanism-based labeling and unequivocal activity assignment of the two active sites of 
intestinal lactase/phlorizin hydrolase. Eur J Biochem 267:6996-7005 
Auricchio S, Rubino A, Tosi R, Semenza G, Landolt M, Kistler HJ, Prader A (1963) Die 
quantitative Disaccharidasen-Aktivität des menschlichen Dunndarms und der erworbene 
Lactasemangel des Erwachsenen. Helv Med Acta 30:690-2. 
Avela K, Lipsanen-Nyman M, Idanheimo N, Seemanova E, Rosengren S, Mäkelä TP, Perheentupa 
J, Chapelle AD, Lehesjoki AE (2000) Gene encoding a new RING-B-box-Coiled-coil 
protein is mutated in mulibrey nanism. Nat Genet 25:298-301. 
Baserga SJ, Benz EJ (1988) Nonsense mutations in the human beta-globin gene affect mRNA 
metabolism. Proc Natl Acad Sci U S A. 85:2056-60 
Becker-Andre M, Hahlbrock K (1989) Absolute mRNA quantification using the polymerase chain 
reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). 
Nucleic Acids Res 17:9437-46. 
Beja-Pereira A, Luikart G, England PR, Bradley DG, Jann OC, Bertorelle G, Chamberlain AT, 
Nunes TP, Metodiev S, Ferrand N, Erhardt G (2003) Gene-culture coevolution between 
cattle milk protein genes and human lactase genes. Nat Genet 35:311-3 
Bersaglieri T, Sabeti PC, Patterson N, Vanderploeg T, Schaffner SF, Drake JA, Rhodes M, Reich 
DE, Hirschhorn JN (2004) Genetic signatures of strong recent positive selection at the 
lactase gene. Am J Hum Genet 74:1111-20 
Bertone ER, Hankinson SE, Newcomb PA, Rosner B, Willet WC, Stampfer MJ, Egan KM (2001) 
A population-based case-control study of carotenoid and vitamin A intake and ovarian 
cancer (United States). Cancer Causes Control 12:83-90 
Bidoli E, La Vecchia C, Talamini R, Negri E, Parpinel M, Conti E, Montella M, Carbone MA, 
Franceschi S (2001) Micronutrients and ovarian cancer: a case-control study in Italy. 
Ann Oncol 12:1589-93 
Bleeker FE, Hazen LG, Kohler A, Van Noorden CJ (2000) Direct comparison of the sensitivity of 
enzyme histochemical and immunohistochemical methods: cathepsin B expression in 
human colorectal mucosa. Acta Histochem 102:247-57. 
Bodlaj G, Stöcher M, Hufnagl P, Hubmann R, Biesenbach G, Stekel H, Berg J (2006) Genotyping 
of the lactase-phlorizin hydrolase -13910 polymorphism by LightCycler PCR and 
implications for the diagnosis of lactose intolerance. Clin Chem 52:148-51 
Boll W, Wagner P, Mantei N (1991) Structure of the chromosomal gene and cDNAs coding for 
lactase- phlorizin hydrolase in humans with adult-type hypolactasia or persistence of 
lactase. Am J Hum Genet 48:889-902. 
Borgström BA, Dahlqvist A, Lundh G, Sjövall J (1957) Studies of digestion and absorption in the 
human. J Clin Invest 36:1521-1536 
Borsani G, Bassi MT, Sperandeo MP, De Grandi A, Buoninconti A, Riboni M, Manzoni M, Incerti 
B, Pepe A, Andria G, Ballabio A, Sebastio G (1999) SLC7A7, encoding a putative 
 96 
permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat 
Genet 21:297-301. 
Bosse T, van Wering HM, Gielen M, Dowling LN, Fialkovich JJ, Piaseckyj CM, Gonzalez FJ, 
Akiyama TE, Montgomery RK, Grand RJ, Krasinski SD (2006) Hepatocyte nuclear 
factor-1alpha is required for expression but dispensable for histone acetylation of the 
lactase-phlorizin hydrolase gene in vivo. Am J Physiol Gastrointest Liver Physiol 
290:G1016-24 
Botstein D, White RL, Skolnick M, Davis RW (1980) Construction of a genetic linkage map in 
man using restriction fragment length polymorphisms. Am J Hum Genet 32:314-31. 
Braun A, Little DP, Köster H (1997) Detecting CFTR gene mutations by using primer oligo base 
extension and mass spectrometry. Clin Chem 43:1151-8 
Britton JA, Westhoff C, Howe GR, Gammon MD (2000) Lactose and benign ovarian tumours in a 
case-control study. Br J Cancer 83:1552-5 
Brown PO, Botstein D (1999) Exploring the new world of the genome with DNA microarrays. Nat 
Genet 21:33-7. 
Büning C, Ockenga J, Krüger S, Jurga J, Baier P, Dignass A, Vogel A, Strassburg C, Weltrich R, 
Genschel J, Lochs H, Schmidt H (2003) The C/C(-13910) and G/G(-22018) genotypes 
for adult-type hypolactasia are not associated with inflammatory bowel disease. Scand J 
Gastroenterol 38:538-42 
Carter MS, Doskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF (1995) A regulatory 
mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo 
is reversed by protein synthesis inhibitors in vitro. J Biol Chem. 270:28995-9003 
Cavalli-Sforza LL (1973) Analytic review: some current problems of human population genetics. 
Am J Hum Genet 25:82-104 
Cavalli-Sforza LL, Piazza A (1993) Human genomic diversity in Europe: a summary of recent 
research and prospects for the future. Eur J Hum Genet 1:3-18 
Cereghini S, Ott MO, Power S, Maury M (1992) Expression patterns of vHNF1 and HNF1 
homeoproteins in early postimplantation embryos suggest distinct and sequential 
developmental roles. Development 116:783-97 
Chawengsaksophak K, James R, Hammond VE, Kontgen F, Beck F (1997) Homeosis and 
intestinal tumours in Cdx2 mutant mice. Nature 386:84-7 
Chen YT, Mattison DR, Feigenbaum L, Fukui H, Schulman JD (1981) Reduction in oocyte 
number following prenatal exposure to a diet high in galactose. Science 214:1145-7 
Christie M, Oehler MK (2006) Molecular pathology of epithelial ovarian cancer. J Br Menopause 
Soc 12:57-63 
Coelho M, Luiselli D, Bertorelle G, Lopes AI, Seixas S, Destro-Bisol G, Rocha J (2005) 
Microsatellite variation and evolution of human lactase persistence. Hum Genet 
117:329-39 
 97 
Collins A, Frezal J, Teague J, Morton NE (1996) A metric map of humans: 23,500 loci in 850 
bands. Proc Natl Acad Sci U S A 93:14771-5. 
Collins FS (1992) Positional cloning: let's not call it reverse anymore. Nat Genet 1:3-6 
Collins FS (1995) Positional cloning moves from perditional to traditional. Nat Genet 9:347-50. 
Cook GC, Kajubi SK (1966) Tribal incidence of lactase deficiency in Uganda. Lancet 1:725-9. 
Cozen W, Peters R, Reichardt JK, Ng W, Felix JC, Wan P, Pike MC (2002) Galactose-1-
phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, 
and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes 
Control 13:113-20 
Cramer DW (1989) Lactase persistence and milk consumption as determinants of ovarian cancer 
risk. Am J Epidemiol 130:904-10 
Cramer DW, Greenberg ER, Titus-Ernstoff L, Liberman RF, Welch WR, Li E, Ng WG (2000) A 
case-control study of galactose consumption and metabolism in relation to ovarian 
cancer. Cancer Epidemiol Biomarkers Prev 9:95-101 
Cramer DW, Harlow BL, Willett WC, Welch WR, Bell DA, Scully RE, Ng WG, Knapp RC 
(1989) Galactose consumption and metabolism in relation to the risk of ovarian cancer. 
Lancet 2:66-71 
Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding 
pathogenesis. J Natl Cancer Inst 71:717-21 
Cuddenec Y, Delbruck H, Flatz G (1982) Distribution of the adult lactase phenotypes--lactose 
absorber and malabsorber--in a group of 131 army recruits. Gastroenterol Clin Biol 
6:776-9. 
Dahlqvist A (1984) Assay of intestinal disaccharidases. Scand J Clin Lab Invest 44:169-72 
Dahlqvist A, Hammond JB, Crane RK, Dumphy HJV, Littman A (1963) Intestinal lactase 
deficiency and lactose intolerance in adults. Gastroenterology 45:488-491 
Dahlqvist A, Lindquist B (1971) Lactose intolerance and protein malnutrition. Acta Paediatr Scand 
60:488-94. 
de la Chapelle A (1993) Disease gene mapping in isolated human populations: the example of 
Finland. J Med Genet 30:857-65 
de la Chapelle A, Hästbacka J, Lehesjoki AE, Sulisalo T, Kere J, Tahvanainen E, Sistonen P 
(1994) Kytkentä ja kytkentäepätasapaino suomalaisessa tautiperinnössä. Duodecim 
110:654-64 
de la Chapelle A, Wright FA (1998) Linkage disequilibrium mapping in isolated populations: the 
example of Finland revisited. Proc Natl Acad Sci U S A 95:12416-23 
Diesen C, Saarinen A, Pihko H, Rosenlew C, Cormand B, Dobyns WB, Dieguez J, Valanne L, 
Joensuu T, Lehesjoki AE (2004) POMGnT1 mutation and phenotypic spectrum in 
muscle-eye-brain disease. J Med Genet 41:e115 
 98 
Edwards JH (1980) Allelic association in man. In: Ericksson AW, Forsius HR, Nevanlinna HR, 
Workman PL, Norio R (eds) Population Structure and Genetic Disorders. Academic 
Press, New York, pp 239-255 
Elsas LJ, Dembure PP, Langley S, Paulk EM, Hjelm LN, Fridovich-Keil J (1994) A common 
mutation associated with the Duarte galactosemia allele. Am J Hum Genet 54:1030-6 
Enattah N, Pekkarinen T, Välimäki MJ, Löyttyniemi E, Järvelä I (2005a) Genetically defined 
adult-type hypolactasia and self-reported lactose intolerance as risk factors of 
osteoporosis in Finnish postmenopausal women. Eur J Clin Nutr 59:1105-11 
Enattah N, Välimäki VV, Välimäki MJ, Löyttyniemi E, Sahi T, Järvelä I (2004a) Molecularly 
defined lactose malabsorption, peak bone mass and bone turnover rate in young finnish 
men. Calcif Tissue Int 75:488-93 
Enattah NS, Forsblom C, Rasinperä H, Tuomi T, Groop PH, Järvelä I (2004b) The genetic variant 
of lactase persistence C (-13910) T as a risk factor for type I and II diabetes in the 
Finnish population. Eur J Clin Nutr 58:1319-22 
Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Järvelä I (2002) Identification of a 
variant associated with adult-type hypolactasia. Nat Genet 30:233-7. 
Enattah NS, Sulkava R, Halonen P, Kontula K, Järvelä I (2005b) Genetic variant of lactase-
persistent C/T-13910 is associated with bone fractures in very old age. J Am Geriatr Soc 
53:79-82 
Engle A, Muscat JE, Harris RE (1991) Nutritional risk factors and ovarian cancer. Nutr Cancer 
15:239-47 
Eriksson AW (1973) Genetic polymorphisms in Finno-Ugrian populations. Finns, Lapps and 
Maris. Isr J Med Sci 9:1156-70. 
Escher JC, de Koning ND, van Engen CG, Arora S, Buller HA, Montgomery RK, Grand RJ 
(1992) Molecular basis of lactase levels in adult humans. J Clin Invest 89:480-3. 
Fairfield KM, Hunter DJ, Colditz GA, Fuchs CS, Cramer DW, Speizer FE, Willett WC, 
Hankinson SE (2004) A prospective study of dietary lactose and ovarian cancer. Int J 
Cancer 110:271-7 
Fajardo O, Naim HY, Lacey SW (1994) The polymorphic expression of lactase in adults is 
regulated at the messenger RNA level. Gastroenterology 106:1233-41. 
Fang R, Olds LC, Santiago NA, Sibley E (2001) GATA family transcription factors activate 
lactase gene promoter in intestinal Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 
280:G58-67. 
Fang R, Santiago NA, Olds LC, Sibley E (2000) The homeodomain protein Cdx2 regulates lactase 
gene promoter activity during enterocyte differentiation. Gastroenterology 118:115-27. 
Fitzgerald K, Bazar L, Avigan MI (1998) GATA-6 stimulates a cell line-specific activation 
element in the human lactase promoter. Am J Physiol 274:G314-24. 
Flatz G (1987) Genetics of lactose digestion in humans. Adv Hum Genet 16:1-77 
 99 
Flatz G, Rotthauwe HW (1977) The human lactase polymorphism: physiology and genetics of 
lactose absorption and malabsorption. Prog Med Genet 2:205-49 
Flatz G, Saengudom C (1969) Lactose tolerance in Asians: a family study. Nature 224:915-6. 
Freeman TC, Collins AJ, Heavens RP, Tivey DR (1993) Genetic regulation of enterocyte function: 
a quantitative in situ hybridisation study of lactase-phlorizin hydrolase and Na(+)-
glucose cotransporter mRNAs in rabbit small intestine. Pflugers Arch 422:570-6 
Freiburghaus AU, Schmitz J, Schindler M, Rotthauwe HW, Kuitunen P, Launiala K, Hadorn B 
(1976) Protein patterns of brush-border fragments in congenital lactose malabsorption 
and in specific hypolactasia of the adult. N Engl J Med 294:1030-2 
Freund JN, Domon-Dell C, Kedinger M, Duluc I (1998) The Cdx-1 and Cdx-2 homeobox genes in 
the intestine. Biochem Cell Biol 76:957-69 
Freund JN, Jost B, Duluc I, Morel G (1995) Ultrastructural study of intestinal lactase gene 
expression. Biol Cell 83:211-7 
Frischmeyer PA, Dietz HC (1999) Nonsense-mediated mRNA decay in health and disease. Hum 
Mol Genet. 8:1893-900 
Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, Buring JE, et al. 
(2006) Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer 
Epidemiol Biomarkers Prev 15:364-72 
Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, Terada K, Reichardt 
JK, Ng WG (2002a) Association of galactose-1-phosphate uridyltransferase activity and 
N314D genotype with the risk of ovarian cancer. Am J Epidemiol 156:693-701 
Goodman MT, Wu AH, Tung KH, McDuffie K, Kolonel LN, Nomura AM, Terada K, Wilkens 
LR, Murphy S, Hankin JH (2002b) Association of dairy products, lactose, and calcium 
with the risk of ovarian cancer. Am J Epidemiol 156:148-57 
Gudmand-Höyer E, Dahlqvist A, Jarnum S (1969) Specific small-intestinal lactase deficiency in 
adults. Scand J Gastroenterol 4:377-86 
Gueguen L, Pointillart A (2000) The bioavailability of dietary calcium. J Am Coll Nutr 19:119S-136S 
Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina 
K, Wallace MR, Sakaguchi AY, et al. (1983) A polymorphic DNA marker genetically 
linked to Huntington's disease. Nature 306:234-8. 
Guz Y, Montminy MR, Stein R, Leonard J, Gamer LW, Wright CV, Teitelman G (1995) 
Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of 
pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during 
ontogeny. Development 121:11-8 
Hackman P, Vihola A, Haravuori H, Marchand S, Sarparanta J, De Seze J, Labeit S, Witt C, 
Peltonen L, Richard I, Udd B (2002) Tibial muscular dystrophy is a titinopathy caused 
by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J 
Hum Genet 71:492-500. 
 100 
Haenszel W, Kurihara M (1968) Studies of Japanese migrants. I. Mortality from cancer and other 
diseases among Japanese in the United States. J Natl Cancer Inst 40:43-68 
Haff LA, Smirnov IP (1997) Single-nucleotide polymorphism identification assays using a 
thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. 
Genome Res 7:378-88 
Hallman N, Hjelt L, Ahvenainen EK (1956) Nephrotic syndrome in newborns and young infants. 
Ann Paediatr Fenn 2:227-241 
Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, 
Speizer FE (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A 
prospective study. Jama 270:2813-8 
Harlow BL, Cramer DW, Geller J, Willett WC, Bell DA, Welch WR (1991) The influence of 
lactose consumption on the association of oral contraceptive use and ovarian cancer risk. 
Am J Epidemiol 134:445-53 
Harvey CB, Fox MF, Jeggo PA, Mantei N, Povey S, Swallow DM (1993) Regional localization of 
the lactase-phlorizin hydrolase gene, LCT, to chromosome 2q21. Ann Hum Genet 
57:179-85. 
Harvey CB, Hollox EJ, Poulter M, Wang Y, Rossi M, Auricchio S, Iqbal TH, Cooper BT, Barton 
R, Sarner M, Korpela R, Swallow DM (1998) Lactase haplotype frequencies in 
Caucasians: association with the lactase persistence/non-persistence polymorphism. Ann 
Hum Genet 62:215-23. 
Harvey CB, Pratt WS, Islam I, Whitehouse DB, Swallow DM (1995) DNA polymorphisms in the 
lactase gene. Linkage disequilibrium across the 70-kb region. Eur J Hum Genet 3:27-41 
Harvey CB, Wang Y, Darmoul D, Phillips A, Mantei N, Swallow DM (1996) Characterisation of a 
human homologue of a yeast cell division cycle gene, MCM6, located adjacent to the 5' 
end of the lactase gene on chromosome 2q21. FEBS Lett 398:135-40. 
Hearne CM, Ghosh S, Todd JA (1992) Microsatellites for linkage analysis of genetic traits. Trends 
Genet 8:288-94. 
Herrinton LJ, Weiss NS, Beresford SA, Stanford JL, Wolfla DM, Feng Z, Scott CR (1995) 
Lactose and galactose intake and metabolism in relation to the risk of epithelial ovarian 
cancer. Am J Epidemiol 141:407-16 
Heston LL, Gottesman II (1973) The evolution of lactose tolerance. In: Gottesman II, Heston LL 
(eds) Summary of the conference on lactose and milk intolerance. DHEW Publication 
No. (OCD), Washington D.C., pp 73-79 
Hiekkalinna T, Terwilliger JD, Sammalisto S, Peltonen L, Perola M (2005) AUTOGSCAN: 
powerful tools for automated genome-wide linkage and linkage disequilibrium analysis. 
Twin Res Hum Genet 8:16-21 
Hogenauer C, Hammer HF, Mellitzer K, Renner W, Krejs GJ, Toplak H (2005) Evaluation of a 
new DNA test compared with the lactose hydrogen breath test for the diagnosis of 
lactase non-persistence. Eur J Gastroenterol Hepatol 17:371-6 
 101 
Holland PM, Abramson RD, Watson R, Gelfand DH (1991) Detection of specific polymerase 
chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus 
DNA polymerase. Proc Natl Acad Sci U S A 88:7276-80. 
Hollox E (2005) Evolutionary genetics: genetics of lactase persistence--fresh lessons in the history 
of milk drinking. Eur J Hum Genet 13:267-9 
Hollox EJ, Poulter M, Wang Y, Krause A, Swallow DM (1999) Common polymorphism in a 
highly variable region upstream of the human lactase gene affects DNA-protein 
interactions. Eur J Hum Genet 7:791-800 
Hollox EJ, Poulter M, Zvarik M, Ferak V, Krause A, Jenkins T, Saha N, Kozlov AI, Swallow DM 
(2001) Lactase haplotype diversity in the Old World. Am J Hum Genet 68:160-172. 
Holzel A (1967) Sugar malabsorption due to deficiencies of disaccharidase activities and of 
monosaccharide transport. Arch Dis Child 42:341-52 
Holzel A, Schwarz V, Sutcliffe KW (1959) Defective lactose absorption causing malnutrition in 
infancy. Lancet i:1126-1128 
Huurre M (1992) Folio 153 Settlement. In: Atlas of Finland. National Board of Survey and 
Geographical Society of Finland. Map Centre, Helsinki, pp 2-5 
Hästbacka J, de la Chapelle A, Kaitila I, Sistonen P, Weaver A, Lander E (1992) Linkage 
disequilibrium mapping in isolated founder populations: diastrophic dysplasia in 
Finland. Nat Genet 2:204-11. 
Hästbacka J, de la Chapelle A, Mahtani MM, Clines G, Reeve-Daly MP, Daly M, Hamilton BA, 
Kusumi K, Trivedi B, Weaver A, et al. (1994) The diastrophic dysplasia gene encodes a 
novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium 
mapping. Cell 78:1073-87. 
Höglund P, Haila S, Socha J, Tomaszewski L, Saarialho-Kere U, Karjalainen-Lindsberg ML, 
Airola K, Holmberg C, de la Chapelle A, Kere J (1996) Mutations of the Down-
regulated in adenoma (DRA) gene cause congenital chloride diarrhoea. Nat Genet 
14:316-9. 
Ikonen E, Baumann M, Gron K, Syvänen AC, Enomaa N, Halila R, Aula P, Peltonen L (1991) 
Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the 
missense mutation causing the disease. Embo J 10:51-8. 
Isokoski M, Jussila J, Sarna S (1972) A simple screening method for lactose malabsorption. 
Gastroenterology 62:28-32 
Jacob R, Peters K, Naim HY (2002) The prosequence of human lactase-phlorizin hydrolase 
modulates the folding of the mature enzyme. J Biol Chem 277:8217-25 
Jacob R, Radebach I, Wüthrich M, Grünberg J, Sterchi EE, Naim HY (1996) Maturation of human 
intestinal lactase-phlorizin hydrolase: generation of the brush border form of the enzyme 
involves at least two proteolytic cleavage steps. Eur J Biochem 236:789-95. 
Jacob R, Weiner JR, Stadge S, Naim HY (2000) Additional N-glycosylation and its impact on the 
folding of intestinal lactase-phlorizin hydrolase. J Biol Chem 275:10630-7. 
 102 
Joensuu T, Hämäläinen R, Yuan B, Johnson C, Tegelberg S, Gasparini P, Zelante L, Pirvola U, 
Pakarinen L, Lehesjoki AE, de la Chapelle A, Sankila EM (2001) Mutations in a novel 
gene with transmembrane domains underlie Usher syndrome type 3. Am J Hum Genet 
69:673-84. 
Jokipii M (1992) Folio 153 Settlement. In: Atlas of Finland. National Board of Survey and 
Geographical Society of Finland. Map Centre, Helsinki, pp 5-9 
Jokipii M, Rikkinen K (1992) Folio 153 Settlement. In: Atlas of Finland. National Board of 
Survey and Geographical Society of Finland. Map Centre, Helsinki, pp 9-11 
Jussila J (1969) Diagnosis of lactose malabsorption by the lactose tolerance test with peroral 
ethanol administration. Scand J Gastroenterol 4:361-8 
Jussila J, Isokoski M, Launiala K (1970) Prevalence of lactose malabsorption in a Finnish rural 
population. Scand J Gastroenterol 5:49-56 
Jutikkala E, Pirinen K (1996) History of Finland. WSOY, Juva 
Järvelä I, Enattah NS, Kokkonen J, Varilo T, Savilahti E, Peltonen L (1998) Assignment of the 
locus for congenital lactase deficiency to 2q21, in the vicinity of but separate from the 
lactase-phlorizin hydrolase gene. Am J Hum Genet 63:1078-85. 
Karttunen L, Lönnqvist L, Godfrey M, Peltonen L, Syvänen AC (1996) An accurate method for 
comparing transcript levels of two alleles or highly homologous genes: application to 
fibrillin transcripts in Marfan patients' fibroblasts. Genome Res 6:392-403. 
Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R (1981) 
Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 
304:994-8 
Kestilä M, Lenkkeri U, Männikkö M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, 
Morita T, Nissinen M, Herva R, Kashtan CE, Peltonen L, Holmberg C, Olsen A, 
Tryggvason K (1998) Positionally cloned gene for a novel glomerular protein--nephrin--
is mutated in congenital nephrotic syndrome. Mol Cell 1:575-82. 
Keusch GT, Troncale FJ, Miller LH, Promadhat V, Anderson PR (1969a) Acquired lactose 
malabsorption in Thai children. Pediatrics 43:540-5. 
Keusch GT, Troncale FJ, Thavaramara B, Prinyanont P, Anderson PR, Bhamarapravathi N 
(1969b) Lactase deficiency in Thailand: effect of prolonged lactose feeding. Am J Clin 
Nutr 22:638-41 
Kiani F, Knutsen S, Singh P, Ursin G, Fraser G (2006) Dietary risk factors for ovarian cancer: the 
Adventist Health Study (United States). Cancer Causes Control 17:137-46 
Kittles RA, Perola M, Peltonen L, Bergen AW, Aragon RA, Virkkunen M, Linnoila M, Goldman 
D, Long JC (1998) Dual origins of Finns revealed by Y chromosome haplotype 
variation. Am J Hum Genet 62:1171-9. 
Klein RM (1989) Small intestinal cell proliferation during development. In: Lebenthal E (ed) 
Human Gastrointestinal Development. Raven Press, New York, pp 367-392. 
 103 
Kolehmainen J, Black GC, Saarinen A, Chandler K, Clayton-Smith J, Traskelin AL, Perveen R, 
Kivitie-Kallio S, Norio R, Warburg M, Fryns JP, de la Chapelle A, Lehesjoki AE (2003) 
Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a 
transmembrane protein with a presumed role in vesicle-mediated sorting and 
intracellular protein transport. Am J Hum Genet 72:1359-69 
Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, Sigurdardottir 
S, Barnard J, Hallbeck B, Masson G, Shlien A, Palsson ST, Frigge ML, Thorgeirsson 
TE, Gulcher JR, Stefansson K (2002) A high-resolution recombination map of the 
human genome. Nat Genet 31:241-7 
Krasinski SD, Estrada G, Yeh KY, Yeh M, Traber PG, Rings EH, Buller HA, Verhave M, 
Montgomery RK, Grand RJ (1994) Transcriptional regulation of intestinal hydrolase 
biosynthesis during postnatal development in rats. Am J Physiol 267:G584-94 
Krasinski SD, Upchurch BH, Irons SJ, June RM, Mishra K, Grand RJ, Verhave M (1997) Rat 
lactase-phlorizin hydrolase/human growth hormone transgene is expressed on small 
intestinal villi in transgenic mice. Gastroenterology 113:844-55 
Krasinski SD, Van Wering HM, Tannemaat MR, Grand RJ (2001) Differential activation of 
intestinal gene promoters: functional interactions between GATA-5 and HNF-1 alpha. 
Am J Physiol Gastrointest Liver Physiol 281:G69-84. 
Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Parametric and nonparametric linkage 
analysis: a unified multipoint approach. Am J Hum Genet 58:1347-63 
Kruse TA, Bolund L, Grzeschik KH, Ropers HH, Sjöström H, Norén O, Mantei N, Semenza G 
(1988) The human lactase-phlorizin hydrolase gene is located on chromosome 2. FEBS 
Lett 240:123-6. 
Kure S, Takayanagi M, Narisawa K, Tada K, Leisti J (1992) Identification of a common mutation 
in Finnish patients with nonketotic hyperglycinemia. J Clin Invest 90:160-4. 
Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, Sellers TA (1999) 
Prospective study of diet and ovarian cancer. Am J Epidemiol 149:21-31 
Kyttälä M, Tallila J, Salonen R, Kopra O, Kohlschmidt N, Paavola-Sakki P, Peltonen L, Kestilä M 
(2006) MKS1, encoding a component of the flagellar apparatus basal body proteome, is 
mutated in Meckel syndrome. Nat Genet 38:155-7 
Laan M, Pääbo S (1997) Demographic history and linkage disequilibrium in human populations. 
Nat Genet 17:435-8. 
Lacey SW, Naim HY, Magness RR, Gething MJ, Sambrook JF (1994) Expression of lactase-
phlorizin hydrolase in sheep is regulated at the RNA level. Biochem J 302 ( Pt 3):929-35 
Lahermo P, Sajantila A, Sistonen P, Lukka M, Aula P, Peltonen L, Savontaus ML (1996) The 
genetic relationship between the Finns and the Finnish Saami (Lapps): analysis of 
nuclear DNA and mtDNA. Am J Hum Genet 58:1309-22. 
Lander ES (1996) The new genomics: global views of biology. Science 274:536-9. 
 104 
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, et al. (2001) Initial 
sequencing and analysis of the human genome. Nature 409:860-921. 
Langley SD, Lai K, Dembure PP, Hjelm LN, Elsas LJ (1997) Molecular basis for Duarte and Los 
Angeles variant galactosemia. Am J Hum Genet 60:366-72 
Larsson SC, Bergkvist L, Wolk A (2004) Milk and lactose intakes and ovarian cancer risk in the 
Swedish Mammography Cohort. Am J Clin Nutr 80:1353-7 
Larsson SC, Orsini N, Wolk A (2006) Milk, milk products and lactose intake and ovarian cancer 
risk: a meta-analysis of epidemiological studies. Int J Cancer 118:431-41 
Lathrop GM, Lalouel JM (1984) Easy calculations of lod scores and genetic risks on small 
computers. Am J Hum Genet 36:460-5. 
Lathrop GM, Lalouel JM, Julier C, Ott J (1984) Strategies for multilocus linkage analysis in 
humans. Proc Natl Acad Sci U S A 81:3443-6. 
Launiala K, Kuitunen P, Visakorpi JK (1966) Disaccharidases and histology of duodenal mucosa 
in congenital lactose malabsorption. Acta Paediatr Scand 55:257-63. 
Lee SY, Wang Z, Lin CK, Contag CH, Olds LC, Cooper AD, Sibley E (2002) Regulation of 
intestine-specific spatiotemporal expression by the rat lactase promoter. J Biol Chem 
277:13099-105 
Leese HJ, Semenza G (1973) On the identity between the small intestinal enzymes phlorizin 
hydrolase and glycosylceramidase. J Biol Chem 248:8170-3 
Lehesjoki AE, Koskiniemi M, Norio R, Tirrito S, Sistonen P, Lander E, de la Chapelle A (1993) 
Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: 
linkage disequilibrium allows high resolution mapping. Hum Mol Genet 2:1229-34. 
Lehtivirta J, Seurujärvi-Kari I (1991) Saamelaiset. In: Laakso J (ed) Uralilaiset kansat: tietoa 
suomen sukukielistä ja niiden puhujista. WSOY, Helsinki, pp 123-155 
Leslie ND (2003) Insights into the pathogenesis of galactosemia. Annu Rev Nutr 23:59-80 
Lewinsky RH, Jensen TG, Moller J, Stensballe A, Olsen J, Troelsen JT (2005) T-13910 DNA 
variant associated with lactase persistence interacts with Oct-1 and stimulates lactase 
promoter activity in vitro. Hum Mol Genet 14:3945-53 
Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B (1990) 
Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 172:1865-7. 
Li WH, Sadler LA (1991) Low nucleotide diversity in man. Genetics 129:513-23. 
Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K (1995) Oligonucleotides with fluorescent dyes 
at opposite ends provide a quenched probe system useful for detecting PCR product and 
nucleic acid hybridization. PCR Methods Appl 4:357-62. 
Lloyd M, Mevissen G, Fischer M, Olsen W, Goodspeed D, Genini M, Boll W, Semenza G, Mantei 
N (1992) Regulation of intestinal lactase in adult hypolactasia. J Clin Invest 89:524-9. 
 105 
Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, 
Kobayashi M, Horton H, Brown EL (1996) Expression monitoring by hybridization to 
high-density oligonucleotide arrays. Nat Biotechnol 14:1675-80. 
Maiuri L, Rossi M, Raia V, Garipoli V, Hughes LA, Swallow D, Noren O, Sjostrom H, Auricchio 
S (1994) Mosaic regulation of lactase in human adult-type hypolactasia. 
Gastroenterology 107:54-60 
Malabanan A, Veronikis IE, Holick MF (1998) Redefining vitamin D insufficiency. Lancet 
351:805-6 
Mantei N, Villa M, Enzler T, Wacker H, Boll W, James P, Hunziker W, Semenza G (1988) 
Complete primary structure of human and rabbit lactase-phlorizin hydrolase: 
implications for biosynthesis, membrane anchoring and evolution of the enzyme. Embo 
J 7:2705-13. 
Maquat LE (2005) Nonsense-mediated mRNA decay in mammals. J Cell Sci 118:1773-6 
Markkanen M, Isaksson R, Norio R (1987) Erikoista suvussamme - Suomalainen tautiperintö 
lyhyesti. Duodecim 103:1434-1463 
Maury CP, Kere J, Tolvanen R, de la Chapelle A (1990) Finnish hereditary amyloidosis is caused 
by a single nucleotide substitution in the gelsolin gene. FEBS Lett 276:75-7. 
McCarty MF (2000) Parathyroid hormone may be a cancer promoter - an explanation for the 
decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med 
Hypotheses 54:475-82 
McCracken RD (1970) Adult lactose tolerance. Jama 213:2257-60. 
McCracken RD (1971) Origins and implications of the distribution of adult lactase deficiency in 
human populations. J Trop Pediatr Environ Child Health 17:7-10. 
Mee L, Honkala H, Kopra O, Vesa J, Finnila S, Visapaa I, Sang TK, Jackson GR, Salonen R, 
Kestila M, Peltonen L (2005) Hydrolethalus syndrome is caused by a missense mutation 
in a novel gene HYLS1. Hum Mol Genet 14:1475-88 
Meloni GF, Colombo C, La Vecchia C, Pacifico A, Tomasi P, Ogana A, Marinaro AM, Meloni T 
(2001) High prevalence of lactose absorbers in Northern Sardinian patients with type 1 
and type 2 diabetes mellitus. Am J Clin Nutr 73:582-5 
Meloni GF, Colombo C, La Vecchia C, Ruggiu G, Mannazzu MC, Ambrosini G, Cherchi PL 
(1999) Lactose absorption in patients with ovarian cancer. Am J Epidemiol 150:183-6 
Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC (2004) Nonsense surveillance 
regulates expression of diverse classes of mammalian transcripts and mutes genomic 
noise. Nat Genet. 2004 36:1073-8 
Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, Foszczynska-Kloda M, 
et al. (2003) Hereditary ovarian cancer in Poland. Int J Cancer 106:942-5 
Mettlin CJ, Piver MS (1990) A case-control study of milk-drinking and ovarian cancer risk. Am J 
Epidemiol 132:871-6 
 106 
Metz G, Blendis LM, Jenkins DJ (1976) Letter: H2 breath test for lactase deficiency. N Engl J 
Med 294:730 
Metz G, Jenkins DJ, Peters TJ, Newman A, Blendis LM (1975) Breath hydrogen as a diagnostic 
method for hypolactasia. Lancet 1:1155-7 
Miettinen S, Ahonen MH, Lou YR, Manninen T, Tuohimaa P, Syvälä H, Ylikomi T (2004) Role 
of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int 
J Cancer 108:367-73 
Mishkin B, Yalovsky M, Mishkin S (1997) Increased prevalence of lactose malabsorption in 
Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am 
J Gastroenterol 92:1148-53 
Mitchell GA, Brody LC, Sipilä I, Looney JE, Wong C, Engelhardt JF, Patel AS, Steel G, Obie C, 
Kaiser-Kupfer M, et al. (1989) At least two mutant alleles of ornithine delta-
aminotransferase cause gyrate atrophy of the choroid and retina in Finns. Proc Natl Acad 
Sci U S A 86:197-201. 
Mitchelmore C, Troelsen JT, Sjostrom H, Noren O (1998) The HOXC11 homeodomain protein 
interacts with the lactase-phlorizin hydrolase promoter and stimulates HNF1alpha-
dependent transcription. J Biol Chem 273:13297-306 
Mitchelmore C, Troelsen JT, Spodsberg N, Sjöström H, Norén O (2000) Interaction between the 
homeodomain proteins Cdx2 and HNF1alpha mediates expression of the lactase-
phlorizin hydrolase gene. Biochem J 346 Pt 2:529-35. 
Molkentin JD (2000) The zinc finger-containing transcription factors GATA-4, -5, and -6. 
Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 
275:38949-52 
Mommers M, Schouten LJ, Goldbohm RA, van den Brandt PA (2006) Dairy consumption and 
ovarian cancer risk in the Netherlands Cohort Study on Diet and Cancer. Br J Cancer 
94:165-70 
Montgomery RK, Buller HA, Rings EH, Grand RJ (1991) Lactose intolerance and the genetic 
regulation of intestinal lactase-phlorizin hydrolase. Faseb J 5:2824-32 
Morland SJ, Jiang X, Hitchcock A, Thomas EJ, Campbell IG (1998) Mutation of galactose-1-
phosphate uridyl transferase and its association with ovarian cancer and endometriosis. 
Int J Cancer 77:825-7 
Morton NE (1955) Sequential tests for the detection of linkage. Am J Hum Genet 7:277-318 
Mulcare CA, Weale ME, Jones AL, Connell B, Zeitlyn D, Tarekegn A, Swallow DM, Bradman N, 
Thomas MG (2004) The T allele of a single-nucleotide polymorphism 13.9 kb upstream 
of the lactase gene (LCT) (C-13.9kbT) does not predict or cause the lactase-persistence 
phenotype in Africans. Am J Hum Genet 74:1102-10 
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H (1986) Specific enzymatic amplification 
of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 
51:263-73. 
 107 
Myles S, Bouzekri N, Haverfield E, Cherkaoui M, Dugoujon JM, Ward R (2005) Genetic evidence 
in support of a shared Eurasian-North African dairying origin. Hum Genet 117:34-42 
Mäkelä-Bengs P, Järvinen N, Vuopala K, Suomalainen A, Ignatius J, Sipilä M, Herva R, Palotie 
A, Peltonen L (1998) Assignment of the disease locus for lethal congenital contracture 
syndrome to a restricted region of chromosome 9q34, by genome scan using five 
affected individuals. Am J Hum Genet 63:506-16. 
Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, Lalioti MD, 
Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S, Ito F, Shimizu N (1997) Positional 
cloning of the APECED gene. Nat Genet 17:393-8. 
Naim HY (1994) Processing and transport of human small intestinal lactase-phlorizin hydrolase 
(LPH). Role of N-linked oligosaccharide modification. FEBS Lett 342:302-7 
Naim HY (1995) The pro-region of human intestinal lactase-phlorizin hydrolase is enzymatically 
inactive towards lactose. Biol Chem Hoppe Seyler 376:255-8 
Naim HY (2001) Molecular and cellular aspects and regulation of intestinal lactase- phlorizin 
hydrolase. Histol Histopathol 16:553-61. 
Naim HY, Jacob R, Naim H, Sambrook JF, Gething MJ (1994) The pro region of human intestinal 
lactase-phlorizin hydrolase. J Biol Chem 269:26933-43 
Naim HY, Lacey SW, Sambrook JF, Gething MJ (1991) Expression of a full-length cDNA coding 
for human intestinal lactase- phlorizin hydrolase reveals an uncleaved, enzymatically 
active, and transport-competent protein. J Biol Chem 266:12313-20. 
Naim HY, Lentze MJ (1992) Impact of O-glycosylation on the function of human intestinal 
lactase-phlorizin hydrolase. Characterization of glycoforms varying in enzyme activity 
and localization of O-glycoside addition. J Biol Chem 267:25494-504 
Naim HY, Naim H (1996) Dimerization of lactase-phlorizin hydrolase occurs in the endoplasmic 
reticulum, involves the putative membrane spanning domain and is required for an 
efficient transport of the enzyme to the cell surface. Eur J Cell Biol 70:198-208. 
National Nutrition Council (1999) Finnish Nutrition Recommendations.32 
Neele AM, Einerhand AW, Dekker J, Buller HA, Freund JN, Verhave M, Grand RJ, Montgomery 
RK (1995) Verification of the lactase site of rat lactase-phlorizin hydrolase by site-
directed mutagenesis. Gastroenterology 109:1234-40 
Nikali K, Suomalainen A, Saharinen J, Kuokkanen M, Spelbrink JN, Lönnqvist T, Peltonen L 
(2005) Infantile onset spinocerebellar ataxia is caused by recessive mutations in 
mitochondrial proteins Twinkle and Twinky. Hum Mol Genet 14:2981-90 
Nikali K, Suomalainen A, Terwilliger J, Koskinen T, Weissenbach J, Peltonen L (1995) Random 
search for shared chromosomal regions in four affected individuals: the assignment of a 
new hereditary ataxia locus. Am J Hum Genet 56:1088-95. 
Nilsson TK, Johansson CA (2004) A novel method for diagnosis of adult hypolactasia by 
genotyping of the -13910 C/T polymorphism with Pyrosequencing technology. Scand J 
Gastroenterol 39:287-90 
 108 
Norat T, Riboli E (2003) Dairy products and colorectal cancer. A review of possible mechanisms 
and epidemiological evidence. Eur J Clin Nutr 57:1-17 
Norio R (1966) Heredity in the congenital nephrotic syndrome. A genetic study of 57 finnish 
families with a review of reported cases. Ann Paediatr Fenn 12:Suppl:1-94. 
Norio R (1981) Diseases of Finland and Scandinavia. In: Rothschild HR (ed) Biocultural aspects 
of disease. Academic Press, New York, pp 359-414 
Norio R (2000) Suomi-neidon geenit - tautiperinnön takana juurillemme johtamassa. Otava, Keuruu 
Norio R (2003a) Finnish Disease Heritage I: characteristics, causes, background. Hum Genet 
Norio R (2003b) Finnish Disease Heritage II: population prehistory and genetic roots of Finns. 
Hum Genet 
Norio R (2003c) The Finnish disease heritage III: the individual diseases. Hum Genet 
Norio R, Nevanlinna HR, Perheentupa J (1973) Hereditary diseases in Finland; rare flora in rare 
soul. Ann Clin Res 5:109-41. 
Nunez MG (1987) A Model for the early settlement of Finland. Fennoscandia archaeologica IV:3-18 
Oberholzer T, Mantei N, Semenza G (1993) The pro sequence of lactase-phlorizin hydrolase is 
required for the enzyme to reach the plasma membrane. An intramolecular chaperone? 
FEBS Lett 333:127-31 
Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrleitner-Pammer A, Berghold A, 
Goessler W, Stepan V, Dobnig H, Leb G, Renner W (2004) Genetic predisposition for 
adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone 
Miner Res 19:42-7 
O'Connell JR, Weeks DE (1998) PedCheck: a program for identification of genotype 
incompatibilities in linkage analysis. Am J Hum Genet 63:259-66 
Olatunbosun DA, Kwaku Adadevoh B (1971) Lactase deficiency in Nigerians. Am J Dig Dis 
16:909-14. 
Olds LC, Sibley E (2003) Lactase persistence DNA variant enhances lactase promoter activity in 
vitro: functional role as a cis regulatory element. Hum Mol Genet 12:2333-40 
Orkin SH (1998) Embryonic stem cells and transgenic mice in the study of hematopoiesis. Int J 
Dev Biol 42:927-34 
Ott J (1999) Analysis of Human Genetic Linkage. Johns Hopkins University Press, Baltimore 
Ott MO, Rey-Campos J, Cereghini S, Yaniv M (1991) vHNF1 is expressed in epithelial cells of 
distinct embryonic origin during development and precedes HNF1 expression. Mech 
Dev 36:47-58 
Paloneva J, Kestilä M, Wu J, Salminen A, Bohling T, Ruotsalainen V, Hakola P, Bakker AB, 
Phillips JH, Pekkarinen P, Lanier LL, Timonen T, Peltonen L (2000) Loss-of-function 
mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat 
Genet 25:357-61. 
 109 
Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, 
Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L (2002) Mutations in 
two genes encoding different subunits of a receptor signaling complex result in an 
identical disease phenotype. Am J Hum Genet 71:656-62. 
Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC (2004) A case-control study of diet and the 
risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13:1521-7 
Panzer P, Preuss U, Joberty G, Naim HY (1998) Protein domains implicated in intracellular 
transport and sorting of lactase-phlorizin hydrolase. J Biol Chem 273:13861-9 
Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschi S, Fedele L, La Vecchia C 
(2004) Risk factors for different histological types of ovarian cancer. Int J Gynecol 
Cancer 14:431-6 
Park RH, Duncan A, Russell RI (1990) Hypolactasia and Crohn's disease: a myth. Am J 
Gastroenterol 85:708-10 
Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. 
Int J Cancer 94:153-6 
Pastinen T, Kurg A, Metspalu A, Peltonen L, Syvänen AC (1997) Minisequencing: a specific tool 
for DNA analysis and diagnostics on oligonucleotide arrays. Genome Res 7:606-14. 
Pastinen T, Partanen J, Syvänen AC (1996) Multiplex, fluorescent, solid-phase minisequencing for 
efficient screening of DNA sequence variation. Clin Chem 42:1391-7. 
Pellegata NS, Dieguez-Lucena JL, Joensuu T, Lau S, Montgomery KT, Krahe R, Kivelä T, 
Kucherlapati R, Forsius H, de la Chapelle A (2000) Mutations in KERA, encoding 
keratocan, cause cornea plana. Nat Genet 25:91-5. 
Peltonen L, Jalanko A, Varilo T (1999) Molecular genetics of the Finnish disease heritage. Hum 
Mol Genet 8:1913-23 
Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez 
L, Faham M, Koskiniemi M, Warrington JA, Norio R, de la Chapelle A, Cox DR, Myers 
RM (1996) Mutations in the gene encoding cystatin B in progressive myoclonus 
epilepsy (EPM1). Science 271:1731-4. 
Phillips AD, Smith MW, Walker-Smith JA (1988) Selective alteration of brush-border hydrolases 
in intestinal diseases in childhood. Clin Sci (Lond) 74:193-200 
Poggi V, Sebastio G (1991) Molecular analysis of the lactase gene in the congenital lactase 
deficiency (abstract). Am J Hum Genet 49:105 
Pontoglio M (2000) Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose 
homeostasis. J Am Soc Nephrol 11 Suppl 16:S140-3 
Poulter M, Hollox E, Harvey CB, Mulcare C, Peuhkuri K, Kajander K, Sarner M, Korpela R, 
Swallow DM (2003) The causal element for the lactase persistence/non-persistence 
polymorphism is located in a 1 Mb region of linkage disequilibrium in Europeans. Ann 
Hum Genet 67:298-311 
 110 
Prentice A (2004) Diet, nutrition and the prevention of osteoporosis. Public Health Nutr 7:227-43 
Qin LQ, Xu JY, Wang PY, Hashi A, Hoshi K, Sato A (2005) Milk/dairy products consumption, 
galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. Eur 
J Cancer Prev 14:13-9 
Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, 
Mole S, Liu W, Soares MB, Bonaldo MF, Hirvasniemi A, de la Chapelle A, Gilliam TC, 
Lehesjoki AE (1999) The neuronal ceroid lipofuscinoses in human EPMR and mnd 
mutant mice are associated with mutations in CLN8. Nat Genet 23:233-6. 
Rasinperä H, Forsblom C, Enattah NS, Halonen P, Salo K, Victorzon M, Mecklin JP, Järvinen H, 
Enholm S, Sellick G, Alazzouzi H, Houlston R, Robinson J, Groop PH, Tomlinson I, 
Schwartz S, Jr., Aaltonen LA, Järvelä I (2005) The C/C-13910 genotype of adult-type 
hypolactasia is associated with an increased risk of colorectal cancer in the Finnish 
population. Gut 54:643-7 
Rasinperä H, Saarinen K, Pelkonen A, Järvelä I, Savilahti E, Kolho KL (2006) Molecularly 
defined adult-type hypolactasia in school-aged children with a previous history of cow's 
milk allergy. World J Gastroenterol 12:2264-8 
Rasinperä H, Savilahti E, Enattah NS, Kuokkanen M, Tötterman N, Lindahl H, Järvelä I, Kolho 
KL (2004) A genetic test which can be used to diagnose adult-type hypolactasia in 
children. Gut 53:1571-6 
Reichardt JK, Woo SL (1991) Molecular basis of galactosemia: mutations and polymorphisms in 
the gene encoding human galactose-1-phosphate uridylyltransferase. Proc Natl Acad Sci 
U S A 88:2633-7 
Remenyi A, Scholer HR, Wilmanns M (2004) Combinatorial control of gene expression. Nat 
Struct Mol Biol 11:812-5 
Ridanpää M, van Eenennaam H, Pelin K, Chadwick R, Johnson C, Yuan B, vanVenrooij W, Pruijn 
G, Salmela R, Rockas S, Mäkitie O, Kaitila I, de la Chapelle A (2001) Mutations in the 
RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair 
hypoplasia. Cell 104:195-203. 
Ridefelt P, Håkansson LD (2005) Lactose intolerance: lactose tolerance test versus genotyping. 
Scand J Gastroenterol 40:822-6 
Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the 
role of androgens and progesterone. J Natl Cancer Inst 90:1774-86 
Risch HA, Jain M, Marrett LD, Howe GR (1994) Dietary lactose intake, lactose intolerance, and 
the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes 
Control 5:540-8 
Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, Kosma VM 
(2001) Expression of transcription factor AP-2 in colorectal adenomas and 
adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin 
Pathol 54:533-8. 
 111 
Ross P, Hall L, Smirnov I, Haff L (1998) High level multiplex genotyping by MALDI-TOF mass 
spectrometry. Nat Biotechnol 16:1347-51 
Rossi M, Maiuri L, Fusco MI, Salvati VM, Fuccio A, Auricchio S, Mantei N, Zecca L, Gloor SM, 
Semenza G (1997) Lactase persistence versus decline in human adults: multifactorial 
events are involved in down-regulation after weaning. Gastroenterology 112:1506-14 
Runnebaum IB, Stickeler E (2001) Epidemiological and molecular aspects of ovarian cancer risk. J 
Cancer Res Clin Oncol 127:73-9 
Saarela T, Simila S, Koivisto M (1995) Hypercalcemia and nephrocalcinosis in patients with 
congenital lactase deficiency. J Pediatr 127:920-3 
Sahi T (1974) Lactose malabsorption in Finnish-speaking and Swedish-speaking populations in 
Finland. Scand J Gastroenterol 9:303-8 
Sahi T (1994a) Genetics and epidemiology of adult-type hypolactasia. Scand J Gastroenterol 
Suppl 202:7-20 
Sahi T (1994b) Hypolactasia and lactase persistence. Historical review and the terminology. Scand 
J Gastroenterol Suppl 202:1-6 
Sahi T, Isokoski M, Jussila J, Launiala K, Pyörälä K (1973) Recessive inheritance of adult-type 
lactose malabsorption. Lancet 2:823-6. 
Sahi T, Launiala K (1978) Manifestation and occurrence of selective adult-type lactose 
malabsorption in Finnish teenagers. A follow-up study. Am J Dig Dis 23:699-704. 
Sajantila A, Lahermo P, Anttinen T, Lukka M, Sistonen P, Savontaus ML, Aula P, Beckman L, 
Tranebjaerg L, Gedde-Dahl T, Issel-Tarver L, DiRienzo A, Pääbo S (1995) Genes and 
languages in Europe: an analysis of mitochondrial lineages. Genome Res 5:42-52. 
Sajantila A, Pääbo S (1995) Language replacement in Scandinavia. Nat Genet 11:359-60. 
Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, 
Hernandez-Avila M (2002) Nutritional determinants of epithelial ovarian cancer risk: a 
case-control study in Mexico. Oncology 63:151-7 
Salonen R, Somer M, Haltia M, Lorentz M, Norio R (1991) Progressive encephalopathy with 
edema, hypsarrhythmia, and optic atrophy (PEHO syndrome). Clin Genet 39:287-93. 
Sankila EM, Tolvanen R, van den Hurk JA, Cremers FP, de la Chapelle A (1992) Aberrant 
splicing of the CHM gene is a significant cause of choroideremia. Nat Genet 1:109-13. 
Savilahti E, Launiala K, Kuitunen P (1983) Congenital lactase deficiency. A clinical study on 16 
patients. Arch Dis Child 58:246-52. 
Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L (1998) CLN5, a 
novel gene encoding a putative transmembrane protein mutated in Finnish variant late 
infantile neuronal ceroid lipofuscinosis. Nat Genet 19:286-8. 
Schena M, Shalon D, Davis RW, Brown PO (1995) Quantitative monitoring of gene expression 
patterns with a complementary DNA microarray. Science 270:467-70. 
 112 
Schulz M, Lahmann PH, Riboli E, Boeing H (2004) Dietary determinants of epithelial ovarian 
cancer: a review of the epidemiologic literature. Nutr Cancer 50:120-40 
Schwartz MZ, Storozuk RB (1988) Influence of epidermal growth factor on intestinal function in 
the rat: comparison of systemic infusion versus luminal perfusion. Am J Surg 155:18-22 
Sebastio G, Villa M, Sartorio R, Guzzetta V, Poggi V, Auricchio S, Boll W, Mantei N, Semenza G 
(1989) Control of lactase in human adult-type hypolactasia and in weaning rabbits and 
rats. Am J Hum Genet 45:489-97. 
Siitonen HA, Kopra O, Kääriainen H, Haravuori H, Winter RM, Saamanen AM, Peltonen L, 
Kestilä M (2003) Molecular defect of RAPADILINO syndrome expands the phenotype 
spectrum of RECQL diseases. Hum Mol Genet 12:2837-44 
Simon TC, Roberts LJ, Gordon JI (1995) A 20-nucleotide element in the intestinal fatty acid 
binding protein gene modulates its cell lineage-specific, differentiation-dependent, and 
cephalocaudal patterns of expression in transgenic mice. Proc Natl Acad Sci U S A 
92:8685-9 
Simoons FJ (1969) Primary adult lactose intolerance and the milking habit: a problem in biological 
and cultural interrelations. I. Review of the medical research. Am J Dig Dis 14:819-36. 
Simoons FJ (1970) Primary adult lactose intolerance and the milking habit: a problem in biologic 
and cultural interrelations. II. A culture historical hypothesis. Am J Dig Dis 15:695-710. 
Simoons FJ (1978) The geographic hypothesis and lactose malabsorption. A weighing of the 
evidence. Am J Dig Dis 23:963-80. 
Skovbjerg H, Sjostrom H, Noren O (1981) Purification and characterisation of amphiphilic 
lactase/phlorizin hydrolase from human small intestine. Eur J Biochem 114:653-61 
Socha J, Ksiazyk J, Flatz G, Flatz SD (1984) Prevalence of primary adult lactose malabsorption in 
Poland. Ann Hum Biol 11:311-6 
Spodsberg N, Troelsen JT, Carlsson P, Enerbäck S, Sjöström H, Norén O (1999) Transcriptional 
regulation of pig lactase-phlorizin hydrolase: involvement of HNF-1 and FREACs. 
Gastroenterology 116:842-54. 
Stenman J, Finne P, Stahls A, Grenman R, Stenman UH, Palotie A, Orpana A (1999) Accurate 
determination of relative messenger RNA levels by RT-PCR. Nat Biotechnol 17:720-2. 
Sterchi EE, Mills PR, Fransen JA, Hauri HP, Lentze MJ, Naim HY, Ginsel L, Bond J (1990) 
Biogenesis of intestinal lactase-phlorizin hydrolase in adults with lactose intolerance. 
Evidence for reduced biosynthesis and slowed-down maturation in enterocytes. J Clin 
Invest 86:1329-37. 
Swallow DM (2006) DNA test for hypolactasia premature. Gut 55:131; author reply 131-2 
Swallow DM, Hollox EJ (2000) The genetic polymorphism of intestinal lactase activity in adult 
humans. In: Scriver CR, Beaudet AL, Sly SS, Valle D (eds) The Metabolic and 
Molecular Basis of Inherited Disease. McGraw-Hill, pp 1562-1651. 
 113 
Sykes DE, Weiser MM (1995) Rat intestinal crypt-cell replication factor with homology to early 
S- phase proteins required for cell division. Gene 163:243-7. 
Syvänen AC (1998) Solid-phase minisequencing as a tool to detect DNA polymorphism. Methods 
Mol Biol 98:291-8 
Syvänen AC, Aalto-Setälä K, Harju L, Kontula K, Söderlund H (1990) A primer-guided nucleotide 
incorporation assay in the genotyping of apolipoprotein E. Genomics 8:684-92. 
Syvänen AC, Ikonen E, Manninen T, Bengtström M, Söderlund H, Aula P, Peltonen L (1992a) 
Convenient and quantitative determination of the frequency of a mutant allele using 
solid-phase minisequencing: application to aspartylglucosaminuria in Finland. Genomics 
12:590-5. 
Syvänen AC, Sajantila A, Lukka M (1993) Identification of individuals by analysis of biallelic 
DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet 52:46-59. 
Syvänen AC, Söderlund H, Laaksonen E, Bengtström M, Turunen M, Palotie A (1992b) N-ras 
gene mutations in acute myeloid leukemia: accurate detection by solid-phase 
minisequencing. Int J Cancer 50:713-8. 
Takahashi K, Yamada H, Yanagida M (1994) Fission yeast minichromosome loss mutants mis 
cause lethal aneuploidy and replication abnormality. Mol Biol Cell 5:1145-58 
Takeuchi A, Okano T, Ishida Y, Kobayashi T (1995) Effects of dietary vitamin D intake on plasma 
levels of parathyroid hormone and vitamin D metabolites in healthy Japanese. Miner 
Electrolyte Metab 21:217-22 
Tambets K, Rootsi S, Kivisild T, Help H, Serk P, Loogvali EL, Tolk HV, et al. (2004) The western 
and eastern roots of the Saami--the story of genetic "outliers" told by mitochondrial 
DNA and Y chromosomes. Am J Hum Genet 74:661-82 
Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Köster H (1999) Chip-based genotyping by mass 
spectrometry. Proc Natl Acad Sci U S A 96:10016-20 
Terwilliger JD (1995) A powerful likelihood method for the analysis of linkage disequilibrium 
between trait loci and one or more polymorphic marker loci. Am J Hum Genet 56:777-87. 
Terwilliger JD, Zollner S, Laan M, Pääbo S (1998) Mapping genes through the use of linkage 
disequilibrium generated by genetic drift: 'drift mapping' in small populations with no 
demographic expansion. Hum Hered 48:138-54. 
The Finnish-German APECED Consortium (1997) An autoimmune disease, APECED, caused by 
mutations in a novel gene featuring two PHD-type zinc-finger domains. Autoimmune 
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. Nat Genet 17:399-403. 
The International Batten Disease Consortium (1995) Isolation of a novel gene underlying Batten 
disease, CLN3. Cell 82:949-57. 
The Retinoschisis Consortium (1998) Functional implications of the spectrum of mutations found 
in 234 cases with X-linked juvenile retinoschisis. Hum Mol Genet 7:1185-92. 
The World Dairy Situation (2003) Bulletin of the International Dairy Federation 384/2003.  
 114 
Torrents D, Mykkänen J, Pineda M, Feliubadalo L, Estevez R, de Cid R, Sanjurjo P, Zorzano A, 
Nunes V, Huoponen K, Reinikainen A, Simell O, Savontaus ML, Aula P, Palacin M 
(1999) Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein 
intolerance gene. Nat Genet 21:293-6. 
Torroni A, Bandelt HJ, D'Urbano L, Lahermo P, Moral P, Sellitto D, Rengo C, Forster P, 
Savontaus ML, Bonne-Tamir B, Scozzari R (1998) mtDNA analysis reveals a major late 
Paleolithic population expansion from southwestern to northeastern Europe. Am J Hum 
Genet 62:1137-52. 
Troelsen JT (2005) Adult-type hypolactasia and regulation of lactase expression. Biochim Biophys 
Acta 1723:19-32 
Troelsen JT, Mitchelmore C, Olsen J (2003a) An enhancer activates the pig lactase phlorizin 
hydrolase promoter in intestinal cells. Gene 305:101-11 
Troelsen JT, Mitchelmore C, Spodsberg N, Jensen AM, Norén O, Sjöström H (1997) Regulation 
of lactase-phlorizin hydrolase gene expression by the caudal- related homoeodomain 
protein Cdx-2. Biochem J 322:833-8. 
Troelsen JT, Olsen J, Moller J, Sjostrom H (2003b) An upstream polymorphism associated with 
lactase persistence has increased enhancer activity. Gastroenterology 125:1686-94 
Troelsen JT, Olsen J, Noren O, Sjostrom H (1992) A novel intestinal trans-factor (NF-LPH1) 
interacts with the lactase-phlorizin hydrolase promoter and co-varies with the enzymatic 
activity. J Biol Chem 267:20407-11 
Tzonou A, Hsieh CC, Polychronopoulou A, Kaprinis G, Toupadaki N, Trichopoulou A, 
Karakatsani A, Trichopoulos D (1993) Diet and ovarian cancer: a case-control study in 
Greece. Int J Cancer 55:411-4 
Wacker H, Keller P, Falchetto R, Legler G, Semenza G (1992) Location of the two catalytic sites 
in intestinal lactase-phlorizin hydrolase. Comparison with sucrase-isomaltase and with 
other glycosidases, the membrane anchor of lactase-phlorizin hydrolase. J Biol Chem 
267:18744-52 
Wagner E, Lykke-Andersen J (2002) mRNA surveillance: the perfect persist. J Cell Sci. 115:3033-8 
van Noorden CJ (2002) Direct comparison of enzyme histochemical and immunohistochemical 
methods to localize an enzyme. Mar Environ Res 54:575-7. 
van Wering HM, Bosse T, Musters A, de Jong E, de Jong N, Hogen Esch CE, Boudreau F, Swain 
GP, Dowling LN, Montgomery RK, Grand RJ, Krasinski SD (2004) Complex regulation 
of the lactase-phlorizin hydrolase promoter by GATA-4. Am J Physiol Gastrointest 
Liver Physiol 287:G899-909 
van Wering HM, Huibregtse IL, van der Zwan SM, de Bie MS, Dowling LN, Boudreau F, Rings 
EH, Grand RJ, Krasinski SD (2002a) Physical interaction between GATA-5 and 
hepatocyte nuclear factor-1alpha results in synergistic activation of the human lactase-
phlorizin hydrolase promoter. J Biol Chem 277:27659-67 
 115 
van Wering HM, Moyer L, Grand RJ, Krasinski SD (2002b) Novel interaction at the Cdx-2 
binding sites of the lactase-phlorizin hydrolase promoter. Biochem Biophys Res 
Commun 299:587-93 
Wang AM, Doyle MV, Mark DF (1989) Quantitation of mRNA by the polymerase chain reaction. 
Proc Natl Acad Sci U S A 86:9717-21. 
Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, et al. (1998a) Large-
scale identification, mapping, and genotyping of single- nucleotide polymorphisms in 
the human genome. Science 280:1077-82. 
Wang Y, Harvey CB, Hollox EJ, Phillips AD, Poulter M, Clay P, Walker-Smith JA, Swallow DM 
(1998b) The genetically programmed down-regulation of lactase in children. 
Gastroenterology 114:1230-6. 
Wang Y, Harvey CB, Pratt WS, Sams VR, Sarner M, Rossi M, Auricchio S, Swallow DM (1995) 
The lactase persistence/non-persistence polymorphism is controlled by a cis-acting 
element. Hum Mol Genet 4:657-62. 
Wang Z, Fang R, Olds LC, Sibley E (2004) Transcriptional regulation of the lactase-phlorizin 
hydrolase promoter by PDX-1. Am J Physiol Gastrointest Liver Physiol 287:G555-61 
Wang Z, Maravelias C, Sibley E (2006) Lactase gene promoter fragments mediate differential 
spatial and temporal expression patterns in transgenic mice. DNA Cell Biol 25:215-22 
Varilo T (1999) The age of the mutations in the Finnish disease heritage; a genealogical and 
linkage disequilibrium study. Thesis, University of Helsinki, Dep. of Medical Genetics 
and National Public Health Institute, Dep. of Human Molecular Genetics, Helsinki 
Varilo T, Nikali K, Suomalainen A, Lönnqvist T, Peltonen L (1996) Tracing an ancestral 
mutation: genealogical and haplotype analysis of the infantile onset spinocerebellar 
ataxia locus. Genome Res 6:870-5 
Webb PM, Bain CJ, Purdie DM, Harvey PW, Green A (1998) Milk consumption, galactose 
metabolism and ovarian cancer (Australia). Cancer Causes Control 9:637-44 
Weber H, Strandmann EP, Holewa B, Bartkowski S, Zapp D, Zoidl C, Ryffel GU (1996) 
Regulation and function of the tissue-specific transcription factor HNF1 alpha (LFB1) 
during Xenopus development. Int J Dev Biol 40:297-304 
Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, 
Kreienberg R, el-Naggar A, Press MF (1999) p53 mutations and expression in ovarian 
cancers: correlation with overall survival. Int J Gynecol Pathol 18:29-41 
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, et al. (2001) The 
sequence of the human genome. Science 291:1304-51. 
Verhave M, Krasinski SD, Christian SI, Van Schaik S, Van Den Brink GR, Doting EM, Maas SM, 
Wolthers KC, Grand RJ, Montgomery RK (2004) Regulatory regions in the rat lactase-
phlorizin hydrolase gene that control cell-specific expression. J Pediatr Gastroenterol 
Nutr 39:275-85 
 116 
Verheijen FW, Verbeek E, Aula N, Beerens CE, Havelaar AC, Joosse M, Peltonen L, Aula P, 
Galjaard H, van der Spek PJ, Mancini GM (1999) A new gene, encoding an anion 
transporter, is mutated in sialic acid storage diseases. Nat Genet 23:462-5. 
Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, Peltonen L 
(1995) Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal 
ceroid lipofuscinosis. Nature 376:584-7. 
Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: 
collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial 
ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136:1212-20 
Virtaneva K, D'Amato E, Miao J, Koskiniemi M, Norio R, Avanzini G, Franceschetti S, 
Michelucci R, Tassinari CA, Omer S, Pennacchio LA, Myers RM, Dieguez-Lucena JL, 
Krahe R, de la Chapelle A, Lehesjoki AE (1997) Unstable minisatellite expansion 
causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 15:393-6. 
Visapää I, Fellman V, Vesa J, Dasvarma A, Hutton JL, Kumar V, Payne GS, Makarow M, Van 
Coster R, Taylor RW, Turnbull DM, Suomalainen A, Peltonen L (2002) GRACILE 
syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation 
in BCS1L. Am J Hum Genet 71:863-76. 
Witte J, Lloyd M, Lorenzsonn V, Korsmo H, Olsen W (1990) The biosynthetic basis of adult 
lactase deficiency. J Clin Invest 86:1338-42. 
Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence 
monitoring of rapid cycle DNA amplification. Biotechniques 22:130-1, 134-8. 
von Heijne G (1986) A new method for predicting signal sequence cleavage sites. Nucleic Acids 
Res 14:4683-90. 
von Tirpitz C, Kohn C, Steinkamp M, Geerling I, Maier V, Moller P, Adler G, Reinshagen M 
(2002) Lactose intolerance in active Crohn's disease: clinical value of duodenal lactase 
analysis. J Clin Gastroenterol 34:49-53 
World Cancer Research Fund (1997) American Institute for Cancer Research. Ovary, food , 
nutrition and the prevention of cancer: a global perspective. Washington DC. American 
Institute for Cancer Research:288-293 
Vuopala K, Ignatius J, Herva R (1995) Lethal arthrogryposis with anterior horn cell disease. Hum 
Pathol 26:12-9. 
Wüthrich M, Grünberg J, Hahn D, Jacob R, Radebach I, Naim HY, Sterchi EE (1996) Proteolytic 
processing of human lactase-phlorizin hydrolase is a two- step event: identification of 
the cleavage sites. Arch Biochem Biophys 336:27-34. 
Xu YK, Ng WG, Kaufman FR, Lobo RA, Donnell GN (1989) Galactose metabolism in human 
ovarian tissue. Pediatr Res 25:151-5 
Yen ML, Yen BL, Bai CH, Lin RS (2003) Risk factors for ovarian cancer in Taiwan: a case-
control study in a low-incidence population. Gynecol Oncol 89:318-24 
 117 
Zabel MD, Wheeler W, Weis JJ, Weis JH (2002) Yin Yang 1, Oct1, and NFAT-4 form repeating, 
cyclosporin-sensitive regulatory modules within the murine CD21 intronic control 
region. J Immunol 168:3341-50 
Zecca L, Mesonero JE, Stutz A, Poiree JC, Giudicelli J, Cursio R, Gloor SM, Semenza G (1998) 
Intestinal lactase-phlorizin hydrolase (LPH): the two catalytic sites; the role of the 
pancreas in pro-LPH maturation. FEBS Lett 435:225-8 
Zheng L, Roeder RG, Luo Y (2003) S phase activation of the histone H2B promoter by OCA-S, a 
coactivator complex that contains GAPDH as a key component. Cell 114:255-66 
 
